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Abstract  
Background: After five years of median follow-up, the Tamoxifen Exemestane Adjuvant 
Multinational (TEAM) trial observed no difference in disease free survival between exemestane 
monotherapy and a sequential scheme of tamoxifen followed by exemestane in postmenopausal 
patients with early-stage, hormone receptor positive (HR+) breast cancer. As recurrence risk in HR+ 
breast cancer remains linear beyond five years after diagnosis, long-term follow-up outcomes of this 
trial were analysed.  
Methods: The TEAM trial, a multicenter open-label phase III randomised controlled trial, included 
postmenopausal patients with early stage HR+ positive breast cancer from nine countries between 
2001 and 2006. Patients were randomly allocated in a 1:1 ratio by a computer-generated random 
permuted block method to either five years of open-label exemestane monotherapy (25 mg daily) or 
a sequential scheme of tamoxifen (20 mg daily) followed by exemestane for a total duration of five 
years. Randomisation was performed centrally in each country. Long-term follow-up data for disease 
recurrence and survival was collected in six participating countries and analyzed by intention-to-
treat. The primary endpoint was disease free survival (DFS) at ten years of follow-up. The trial is 
registered with ClinicalTrials.gov, NCT00279448, NCT00032136; NTR 267; Ethics Commission Trial 
27/2001. 
Findings: 6120 patients were included in the current intention-to-treat analysis. Median follow-up 
was 9·8 years (interquartile range 8·0-10·3). During follow-up, 921 (30%) of 3075 patients in the 
exemestane arm and 929 (31%) of 3045 patients in the sequential arm experienced a DFS event. DFS 
at ten years was 67% (95% CI 65-69) for the exemestane arm and 67% (95% CI 65-69) for the 
sequential arm (hazard ratio (HR) 0·96, 95% CI 0·88-1·05, p=0·39).  
Interpretation: The long-term findings of the TEAM trial confirm that both exemestane alone and 
sequential therapy with upfront tamoxifen are equally effective as adjuvant endocrine therapy in 
postmenopausal HR+ early breast cancer patients. These results validate the opportunity to 
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individualize adjuvant endocrine strategy accordingly, based on patient preferences, comorbidities 
and tolerability.  
Funding: Unrestricted grant Pfizer, Dutch Cancer Foundation (UL 2010-4674).  
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Research in context  
Evidence before this study 
We performed a search in PubMed MEDLINE (OVID-version), Embase (OVID-version), and Cochrane, 
limited to articles published before March 1st 2017. For the search, we combined the terms ‘long-
term follow-up’, ‘aromatase inhibitors’, ‘tamoxifen’, ‘sequential therapy’, ‘postmenopausal women’, 
and ‘hormone receptor positive breast cancer’, also using various synonyms and related terms. This 
resulted in 104 papers, of which five were relevant results from randomised clinical trials. The 
majority of these trials studied long-term follow-up of other adjuvant endocrine therapy regimes, 
such as five years of tamoxifen versus anastrozole in the ATAC trial, or tamoxifen monotherapy 
versus sequential therapy in the IES trial. Furthermore, our search strategy identified a recent meta-
analysis performed by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), comparing all 
major regimes including an aromatase inhibitor (AI) with each other, a sequential scheme or with 
tamoxifen alone, for the longest follow-up available. In this meta-analysis, the comparison between 
AI monotherapy and tamoxifen followed by AI was limited to seven years of follow-up; hence, none 
of the included trials had ten-years data available. 
Added value of this study 
This study is the first trial to report on ten-year follow-up of randomizing patients between five years 
of AI monotherapy or sequential therapy with upfront tamoxifen followed by an AI. After ten years, 
no significant differences in either DFS or OS between both schedules were observed. However, we 
did observe a small difference in disease recurrence, in favour of patients treated with exemestane 
monotherapy (20% versus 22% with sequential scheme). 
Implications of all the available evidence 
For postmenopausal patients with early-stage, HR+ breast cancer five years of tamoxifen 
monotherapy, AI monotherapy, or sequential treatment with upfront tamoxifen are valid 
 Manuscript second revisions – Clean Copy – Plain Text 
 
5 
 
investigated treatment schedules to prevent relapse after surgery. Earlier, the EBCTCG meta-analysis 
showed that both the sequential strategy and AI monotherapy are superior to tamoxifen 
monotherapy after ten years of follow-up. The current analysis of the TEAM trial shows that at ten 
years of follow-up, both the sequential scheme with upfront tamoxifen and AI monotherapy are 
equal with regard to DFS and OS. Therefore, both strategies are equally effective treatment options 
for postmenopausal patients with HR+ early breast cancer. 
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Introduction 
For more than three decades, tamoxifen has been the hallmark for adjuvant treatment in women 
with hormone receptor positive (HR+) breast cancer, leading to a proportional risk reduction in 
recurrence of breast cancer and death by 40% and 26% respectively.1 Over the last ten years, 
aromatase inhibitors (AI), given either for five years or for two to three years after two to three 
years of tamoxifen, have shown superior efficacy over tamoxifen alone, further reducing the 
proportional risk of breast cancer recurrence by approximately 30% over five years of follow-up.2  
HR+ patients who remain disease free after five years of adjuvant endocrine treatment, still face a 
substantial risk of recurrence (11% and 20% ten and fifteen years after diagnosis, respectively3,4), 
indicating the importance of long-term follow-up for trials comparing adjuvant endocrine treatment 
strategies.  
The Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase III trial compared five years of 
exemestane with a sequential scheme of 2·5 years of tamoxifen followed by 2·5 years of 
exemestane. After five years of median follow-up, no significant difference for disease free survival 
(DFS), overall survival (OS) and relapse free survival (RFS) was observed between the two treatment 
strategies.5 The current analysis of the TEAM trial is the first study to present ten-year outcomes of 
the efficacy of five years of AI (exemestane) versus sequential therapy (tamoxifen followed by 
exemestane).  
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Methods 
Study design and participants  
The TEAM trial is a phase III open-label randomised controlled trial that enrolled postmenopausal 
women with histologically confirmed breast adenocarcinoma and locally assessed estrogen- (ER) 
and/or progesterone-receptor-positive (PgR) disease who had completed local treatment with 
curative intent between 2001 and 2006.5 There were no age-related restrictions for inclusion. Other 
eligibility criteria were an ECOG performance status of 0 or 1, adequate hematological parameters 
(PLT > 100x109/L, WBC > 3x 109/L), renal (creatinine <1.5 ULN) and liver function (ASAT or ALAT <2.5 
ULN). Exclusion criteria included: earlier adjuvant endocrine therapy or neo-adjuvant chemotherapy, 
uncontrolled cardiac disease, other malignancies or other serious illnesses interfering with subject 
compliance, adequate informed consent or study participation.  
Randomisation and masking 
Patients were randomly assigned in a 1:1 ratio centrally in each country by use of a computer-
generated random permuted block method with stratification per country. Treatment allocation was 
not masked to participants, those prescribing the medication, those assessing outcomes and 
analysing the data. Patients were enrolled by the local clinicians in the participating hospitals.  
Procedures 
Endocrine treatment was started within ten weeks after completion of surgery and end of 
chemotherapy if indicated, and was administered orally daily for five years in both treatment arms. 
Patients were initially assigned either to exemestane (25 mg once a day) for a duration of five years 
or tamoxifen (20 mg once a day, orally) for a duration of five years. After the publication of the IES 
trial,6 the protocol was amended. Patients assigned to tamoxifen were switched after 2·5 to three 
years to exemestane therapy for a total duration of five years of treatment. Dose reductions were 
not allowed. Patient visits were required every 3 months during the first year, and every 6 months 
 Manuscript second revisions – Clean Copy – Plain Text 
 
8 
 
during the remaining active treatment period. Study endpoints and adverse events were recorded 
during each visit during active treatment. Mammography was performed yearly, laboratory tests and 
other radiological evaluations were performed as determined by local guidelines.  
The original study was conducted in 566 hospitals in nine countries. For the current pre-planned long 
term follow-up analysis, we only included patients who were enrolled in countries where follow-up 
was collected for at least two additional years after the five years of endocrine therapy in the 
context of the study. For this reason, patients from Japan (n=184), France (n=1,230), and the United 
States (n=2,232) were excluded from analyses (Figure 1). Data were collected in the different 
countries and sent as a batch per country to Leiden, and thereafter merged into one database. 
Information on cause of death was gathered on the case report form and thereafter categorized into 
ten pre-specified groups. Classification of cause of death was verified by the TEAM central 
datacenter. Late side effects after five years of endocrine therapy in this current analysis were not 
recorded. Database cutoff was set at February 19, 2016.  
Outcomes 
The primary endpoint was disease free survival (DFS), defined as the time from randomisation to 
disease recurrence or death from any cause. Disease recurrence was defined as disease recurrence 
(locoregional or distant) or a new primary breast cancer. Ductal carcinoma in situ was not 
considered as recurrent disease. Secondary outcomes were overall survival (OS) defined as time 
from randomization to time of death due to any cause, recurrence free interval (RFI) defined as time 
from randomisation to recurrence or time of death due to breast cancer if no recurrence was 
reported before death and distant recurrence free interval (DRFI) defined as time from 
randomisation to distant recurrence or time of death due to breast cancer if no recurrence was 
reported before death. Patients with distant metastases at time of death were categorized as death 
due to breast cancer.  
Statistical analysis  
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All patients who were randomly assigned to treatment, except those who withdrew consent before 
start of treatment, were included in the intent-to-treat population. All analyses were performed in 
the intent-to-treat population. A power calculation was performed before study initiation for 
analyses after five years of follow-up, and has been described previously.5 All tests were two-sided 
and a p-value of less than or equal to 0·05 was considered statistically significant. Kaplan-Meier 
estimates of DFS and OS were calculated for each treatment group. DFS and OS were compared 
between treatment groups using log-rank tests and stratified by country and additional stratification 
factors within countries (nodal status (positive versus negative), PgR status (positive versus 
negative), adjuvant chemotherapy (yes versus no)). All hazard ratios (HRs) were calculated with a 
Cox regression analysis using the same stratification factors as the log-rank tests. Cumulative 
incidence of recurrence and subdistribution hazard ratios (sHRs) for RFI and DRFI were calculated 
using the Fine and Gray model for competing risks, taking other causes of death into account as 
competing events.7 Proportional differences were tested using Pearson’s χ2 test. All time-to-event 
curves were truncated after ten years of follow-up, while HRs and sHRs include all events until 
database cutoff.  
Additional analyses 
Predefined subgroup analyses were performed for DFS. Interaction between treatment and 
prognostic factors was tested for effect modification using the Cox proportional hazard model. A 
post-hoc analysis was performed to study the relation between treatment and breast cancer specific 
mortality (BCSM) and other cause mortality (OCM). Cumulative incidence of recurrence and sHRs 
were calculated using the Fine and Gray model for competing risks.  
An additional five year conditional survival analysis for DFS using the Cox proportional hazard model 
was performed as a post-hoc analysis to compare treatment groups for late disease recurrences, and 
subgroup analyses were performed to test interaction between treatment and prognostic factors for 
late recurrences. Furthermore, to estimate the influence of HER2 positive patients included in this 
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study population, analyses were repeated post-hoc after exclusion of the HER2 positive patients. 
Kaplan Meier estimates were calculated for ten year DFS for each treatment arm in the remaining 
population.  
For this long-term follow up analysis, patients from countries that did not collect long-term follow-
up data were excluded. To assess whether findings from this study could be generalized to the 
original population various additional post-hoc analyses were performed. First, baseline 
clinicopathological factors between the in- and excluded patients were compared. Second, DFS at 
five years after randomisation was compared between the in-and excluded patients. Third, 
treatment effect between the in- and excluded patients at five years was tested for interaction. Last, 
a sensitivity analysis was performed to compare treatment arms for DFS with complete follow up 
time for the original TEAM population. Patients from countries that did not collect outcomes after 
five years were censored.  
Statistical analyses were performed using R 3.3.0 version using the survival, prodlim and cmprsk 
packages. 
The study was conducted in compliance with the guidelines of the Declaration of Helsinki, 
International Conference on Harmonization and Good Clinical Practice. Appropriate approvals from 
the ethical committee were obtained. All patients provided written informed consent. This study is 
registered in France with ClinicalTrials.gov, NCT00279448; the Netherlands and Belgium with 
Netherlands Trial Register, NTR 267; the UK and Ireland with ClinicalTrials.gov, NCT00032136; and 
Germany with Ethics Commission Trial, 27/2001. Role of the funding source  
The TEAM trial was initially funded by an unrestricted grant from Pfizer. Collection of long term 
follow-up was funded by the Dutch Cancer Foundation (UL 2010-4674). Funding sources had no role 
in the study design, data collection, analysis, interpretation of the data, writing of the manuscript, or 
the decision to publish. Study investigators listed as authors were involved in data interpretation 
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writing the report and the decision to submit. The corresponding author had full access to all of the 
data and the final responsibility to submit for publication. All authors had access to the raw data. 
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Results 
In the original TEAM trial, 9766 patients were included in the intention-to-treat population between 
January 16th 2001 and January 31st 2006.5 Overall, 6120 (63%) patients from six countries were 
included in the current intention-to-treat population and analyzed for the primary and secondary 
outcomes (Figure 1). Median follow-up was 9·8 years (IQR 8·0-10·3) and median age at diagnosis was 
63·8 years (IQR 57·8-70·8). Baseline characteristics were similar between both treatment arms 
(Table 1).  
During the ten year study period, 921 (30%) of 3075 patients in the exemestane group and 929 
(31%) of 3045 patients in the sequential group experienced a DFS event (Table 2). The Kaplan-Meier-
estimated ten year DFS percentage was 67% (95% CI 65-69) for the exemestane arm and 67% (95% 
CI 65-69) for the sequential arm (HR 0·96, 95% CI 0·88-1·05, p=0·39, Figure 2A). Treatment effect was 
consistent between all subgroups and no significant interaction was observed between treatment 
and clinicopathological factors (Figure 3). Overall, hazard ratios were similar to those of the previous 
report after five years of median follow-up.5  
During follow-up, 733 (24%) of 3075 patients in the exemestane arm and 727 (24%) of 3045 patients 
in the sequential arm died (Table 3). Overall survival after ten years was 74% (95% CI 72-75)in the 
exemestane group and 73% (95% CI 72-75) in the sequential group (HR 0·98, 95% CI 0·89-1·09, 
p=0·74, Figure 2B). BC recurrence occurred in 567 (18%) of 3075 patients in the exemestane arm and 
623 (20%) of 3045 patients in the sequential arm during follow-up. Cumulative incidence for BC 
recurrences after ten years of follow up was slightly lower in the exemestane group (20%, 95% CI 19-
22) than in the sequential group (22%, 95% CI 20-24) (sHR for RFI 0·88, 95% CI 0·79-0·99, p=0·03, 
Figure 4A). Distant recurrences occurred in 468 (15%) of 3075 patients in the exemestane arm and 
497 (16%) of 3045 patients in the sequential arm. No difference in cumulative incidence for distant 
recurrence was observed for exemestane alone versus sequential therapy (16% (95% CI 15-18) 
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versus 18% (95% CI 16-19) respectively, sHR for DRFI 0·91, 95% CI 0·80-1·03, p=0·15, Figure 4B). 
Additional analyses  
In the exemestane arm, 377 (12%) of 3075 patients died due to breast cancer and in the sequential 
arm 419 (14%) of 3045 patients died due to breast cancer (Table 3). Cumulative incidence for BCSM 
after ten years of follow-up was 13·5% (95% CI 12·3-14·9) in the exemestane arm and 15·4% (95% CI 
13·0-16·9) in the sequential arm (sHR 0·88, 95% CI 0·77-1·01, p=0·07, Figure 5). Death due to other 
causes than BC occurred in 356 (12%) of 3075 patients in the exemestane arm and 308 (10%) of 
3045 patients in the sequential arm (Table 3). Cumulative incidence for OCM was 12·8% (95% CI 
11·5-14·2) in the exemestane arm and 11·3% (95% CI 10·0-12·6) in the sequential arm (sHR 1·14, 
95% CI 1·00-1·31, p=0·08, Figure 5). No significant differences for cause of death were observed 
between the treatment arms. The number and types of new primary non-breast cancers are shown 
in Table 4. Endometrial cancer occurred more frequently in the sequential arm than in the 
exemestane arm (23 (0·8%) of 3045 patients versus 7 (0·2%) of 3075 patients, respectively). Other 
second, non-breast cancers were not different between both treatment arms (Table 4).  
Five years after randomization, 2470 (80%) of 3075 patients in the exemestane arm and 2385 (78%) 
of 3045 patients in the sequential arm were alive and disease free. 431 (17%) of 2470 patients in the 
exemestane arm and 423 (18%) of 2385 patients in the sequential arm experienced a DFS event in 
the remaining follow up period. DFS at ten years was 80% (95% CI 78-82) in the exemestane arm and 
81% (95% 79-82) in the sequential arm (HR 0·98, 95% CI 0·86-1·13, p=0·82). This effect was 
consistent among all subgroups and no significant interaction was observed between treatment and 
clinicopathological factors (webappendix, page 1). 
For the repeated analysis excluding the HER2 positive patients, 560 HER2 positive patients (9 %) 
were excluded from the original trial population. In the remaining HER2 negative or HER2 unknown 
population, 812 (29%) of 2819 patients assigned to the exemestane arm and 814 (30%) of 2741 
patients assigned to the sequential arm experienced a DFS event. DFS at ten years was 68% (95% CI 
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66-70) for patients in the exemestane arm and 67% (95% CI 66-69) for patients in the sequential 
arm. This was not significantly different compared to the results of the total study population. 
Patients from countries that did not collect long-term follow-up had more favourable tumour 
characteristics at baseline (webappendix, page 2). DFS at five years for patients included in the long-
term follow-up analysis was lower than that of excluded patients (DFS 84%, 95% CI 83-84 and DFS 
90%, 95% CI 89-91, respectively). Treatment effect for DFS at five years was comparable between 
patients included in the long-term follow-up analysis and patients that were excluded (HR 0·96 (95% 
CI 0·88-1·06) and HR 1·01 (95% CI 0·84-1·22), respectively, p-value for interaction = 0·66). Treatment 
effect for the original TEAM population was comparable to the results of the long-term follow-up 
study (HR 0·97, 95% CI 0·90-1·06).  
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Discussion 
To our knowledge, this is the first trial reporting ten year outcomes of five years of AI monotherapy 
compared to five years sequential therapy with upfront tamoxifen, showing that after ten years of 
median follow-up both exemestane monotherapy and the sequential scheme are equally effective 
treatment strategies for postmenopausal patients with HR+ early breast cancer. No significant 
differences between the treatment arms were observed for DFS and OS, although a small benefit 
was observed for exemestane monotherapy with regard to cumulative incidence of recurrences. An 
additional analysis looking into cause of death suggests a lower breast cancer specific mortality but a 
higher other cause mortality for exemestane monotherapy compared to sequential therapy.  
The results from this ten year analysis of the TEAM trial are consistent with the long-term analysis of 
the BIG 1-98 trial. After a median follow-up of 8·0 years, this study reported no differences between 
letrozole and sequential therapy (tamoxifen followed by letrozole) for DFS (HR 1·07, 0·92-1·25) and 
OS (HR 1·10, 0·90-1·33).8 The TEAM results reported in this study represent a much larger patient 
cohort and a longer follow-up period, thereby strengthening the results reported from the BIG 1-98 
trial. Furthermore, our results are in line with findings from the EBCTCG meta-analysis, including all 
trials investigating the value of AI versus tamoxifen regimens in postmenopausal HR+ breast cancer 
patients. They observed a very small benefit regarding recurrences rates of AI monotherapy over the 
sequential scheme with upfront tamoxifen after a median follow-up period of seven years 
(recurrence rate 14·5% versus 13·8%), but observed no benefit with respect to OS in this same time 
period.2 In view of the current ten year results of the TEAM trial and data from the BIG 1-98 trial and 
EBCTCG meta-analysis, both the sequential scheme with upfront tamoxifen and AI monotherapy are 
equally effective strategies. 
When considering cause of death, results of the current analyses suggest that there might be a small 
benefit of exemestane therapy on breast cancer-specific mortality, although the percentage of 
distant metastasis was not significantly different (Figure 4B). Interestingly, this beneficial effect of 
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exemestane on breast cancer-specific mortality seems to be counterbalanced by an increase in non-
breast cancer related mortality leading to similar overall survival rates. In the TEAM trial report after 
five years of median follow-up, significantly more cardiovascular adverse events were observed in 
the patients receiving exemestane alone.5 After ten years of follow-up, death due to cardiac cause or 
vascular cause was higher in the exemestane arm (n=65) than in the sequential arm (n=47). In 
addition, more patients died due to a thromboembolic cause in the exemestane arm (n=11) than in 
the sequential arm (n=5) (Table 3). Unfortunately, this trial was not designed to show a significant 
difference in cause of death. A recently published meta-analysis showed a significantly higher risk for 
cardiovascular events for patients treated with AI monotherapy compared to upfront tamoxifen 
followed by an AI (RR 1·16, 95% CI 1·03-1·31). It has been suggested that the occurrence of more 
cardiovascular events in patients receiving an AI compared to patients receiving tamoxifen is most 
likely explained by the protective effect of tamoxifen on cardiovascular outcomes.9,10 The increased 
risk of death with an AI has also been observed in the ABCSG-12 trial, investigating zoledronic acid 
versus no zoledronic acid with adjuvant tamoxifen or anastrozol (in combination with LHRH 
analogues) in premenopausal BC patients. Anastrozol and tamoxifen (in combination with LHRH 
analogues) were equally effective for disease free survival after eight years of follow-up but a 
significantly worse overall survival for anastrozol was observed.11 Overall, these findings suggest that 
although AI might be more favorable for breast cancer related outcomes, it lacks the 
cardioprotective effect of tamoxifen, which might be preferred for patients with a relatively low risk 
breast cancer and high risk cardiovascular profile. Further long-term research is necessary to confirm 
these observations and to better define subgroups with high risk for cardiovascular diseases that 
might benefit from upfront tamoxifen. 
An important remaining question is whether it is possible to select some subgroups for which there 
is a more clear benefit for either upfront tamoxifen or AI use. In the BIG 1-98 trial, patients with a 
poor prognosis (using ER and PgR status, HER2 status, Ki-67 index and clinical prognostic factors) 
appeared to have more benefit regarding DFS from letrozole monotherapy compared to any other 
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treatment strategy.12 A meta-analysis, comparing tamoxifen and AI monotherapy (either for five or 
two to three years), suggested that HER2-negative tumors would benefit more from AI 
monotherapy.13 However, this study evaluated only the period in which the active treatment was 
different between both arms. Our analysis, covering 10 years of follow-up and comparing the 
sequential scheme with AI monotherapy in a large cohort, failed to identify any clinicopathological 
subgroup that would benefit more from either the sequential treatment or AI monotherapy. 
Therefore, the identification of a subgroup for which there is a more clear benefit of either therapy 
remains challenging. In the context of the TEAM pathology study, we plan to combine 
clinicopathological factors with biomarkers. This will hopefully identify biomarkers that will allow for 
better stratification.  
With no evident improvement in disease related outcomes and overall survival nor a clear benefit 
for a specific subgroup for either AI monotherapy or sequential therapy, the choice of therapy might 
depend on safety and tolerability not only during but also after completion of treatment. The TEAM 
five-year analysis showed that the use of tamoxifen is associated with an increase in gynaecological- 
and thromboembolic side effects, whereas exemestane was more often associated with 
musculoskeletal disorders like arthralgia, osteoporosis and subsequent fractures.5 In the current 
analyses, after ten years of median follow-up and five years after treatment completion, more 
endometrial cancers were still observed in the sequential than in the exemestane arm, although 
absolute numbers were low (23 versus 7, Table 4). Further analysis showed that median time to 
diagnosis of endometrial cancer was 7·0 years after randomization in this study for patients who 
received the sequential therapy. This suggests a long-term carry-over effect of tamoxifen use. 
Reassuringly, deaths due to endometrial cancer did not occur more frequently in one of the groups 
(Table 3). Unfortunately, no other long-term adverse events on the abovementioned items were 
collected in the context of the TEAM study. In the ATAC trial, fractures were more common during 
treatment in the anastrozole arm compared to the tamoxifen arm, but were similar after treatment 
completion at ten years of follow-up, suggesting no carry-over effect after treatment completion.14 
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Although some evidence from side studies of the TEAM trial and the BIG 1-98 trial suggest poorer 
cognitive functioning in patients receiving tamoxifen compared to patients using an AI,15,16 it remains 
unclear whether tamoxifen also affects long term cognitive functioning. Quality of life did not appear 
to be different between AIs and tamoxifen in several trials.17-19 However, no quality of life data from 
these trials are available after completion of therapy. It would be worthwhile to develop a 
cardiovascular risk and potentially other risk profiles, enabling to select the appropriate therapy 
regimen for a particular patient. 
Another relevant unanswered question is the optimal length of adjuvant endocrine therapy, which is 
currently being studied in several trials.20 Of note, 435 (16%) of the 2,753 Dutch patients in this 
analysis continued with letrozole beyond five years in the context of the prospective phase-III 
Investigation on the Duration of Extended Adjuvant Letrozole treatment (IDEAL) trial (randomization 
between 2·5 or five years of extended therapy with letrozole).21 TEAM trial patients that continued 
in the IDEAL trial were equally distributed among both treatment arms of the TEAM trial and were 
equally randomised for either 2·5 or five years of extended therapy in the IDEAL trial. Differences 
between the two treatment arms in the TEAM trial are therefore not likely explained by the 
extended therapy. However, extended therapy could have affected the ten year results at a similar 
rate for both arms and possibly have led to an underestimation of recurrence rates. Given the 
equivalence of sequential therapy (tamoxifen followed by AI) compared with AI therapy for the first 
five years of adjuvant endocrine therapy, it will be highly interesting whether upfront tamoxifen or 
AI monotherapy during five years has a differential benefit in patients who will receive extended 
endocrine therapy. 
During the inclusion period of the TEAM trial (study closure January 31, 2006), adjuvant trastuzumab 
was not yet administered as the first reports on the efficacy of adjuvant trastuzumab therapy only 
became available mid-2005.22,23 In the current patient cohort, only a minority of patients had HER2 
positive breast cancer (n=560, 9%). Our subgroup analysis did not show any difference in treatment 
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effect between patients with HER2-negative, HER2-positive or unknown HER2 status, and no 
significant interaction between subgroups was observed (Figure 3). Further, repeated analyses 
excluding the HER2 positive patients were consistent with the findings in the total cohort. Given 
these results, the findings of the total study cohort may be considered reliable estimates of outcome 
for HER2 negative/HR+ patients.  
Some countries that did not collect long-term follow-up (such as the United States and Japan) 
included relatively more low-risk patients in the TEAM trial (wepappendix, page 2). As a result, these 
patients had a significantly higher DFS at five years after randomization compared to patients 
included in the current long-term follow-up analysis. However, as subgroup analysis in this study 
showed that prognostic factors did not influence treatment effect (Figure 2), it is not expected to 
affect the findings of the current analyses. Moreover, no significant interaction for treatment was 
found between patients included in this long-term follow-up analysis and excluded patients . 
Therefore, we expect that results for treatment comparison in the current study cohort are 
representative for the original TEAM population. Furthermore, a sensitivity analysis that included 
both the included patients and excluded patients (with five years of follow-up) yielded consistent 
results. Despite the decreased number of patients included in the current analyses, the power to 
detect differences between treatment arms for the primary endpoint was sufficient as the number 
of events due to longer follow-up time increased compared to the five year evaluation of this study 
(current analysis: n=1850, Table 2; previous report: n=1428,5 respectively). 
There are some other limitations that we are aware of. Firstly, we did not collect long-term adverse 
events for the current analyses. Secondly, as mentioned previously, extended adjuvant therapy 
either inside or outside a study protocol could have possibly led to an underestimation of disease 
recurrence. Finally, we collected data on cause of death and although cause of death classification is 
more reliable in clinical trial settings, it could have been subject to misclassification.  
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In conclusion, both the sequential scheme with upfront tamoxifen and exemestane monotherapy for 
five years are equally effective adjuvant treatment options for postmenopausal, hormone-receptor-
positive breast cancer patients, with comparable survival rates after ten years of median follow-up. 
This allows the possibility for shared decision making between the clinician and patient, balancing 
individual patient characteristics and preferences, side effect profiles, and tolerability. Future studies 
will hopefully show which subgroup, if any, benefits more from either strategy, and whether 
extension of any of these strategies is worthwhile.  
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Tables  
Table 1. Baseline characteristics of patients in the intention to treat population 
  
Tamoxifen followed  
by exemestane (n=3045)  
Exemestane 
   
(n=3075) 
  N %  N % 
Age (years)           
 
< 50 102 3·3 
 
109 3·5 
 
50-59 948 31·1 
 
926 30·1 
 
60-69 1193 39·2 
 
1180 38·4 
 
≥ 70 802 26·3 
 
860 28·0 
Histological grade          
 
G1 (well) 301 9·9 
 
315 10·2 
 
G2 (moderate) 1569 51·5 
 
1599 52·0 
 
G3-G4 (poor) 930 30·5 
 
905 29·4 
 
Unknown 245 8·0 
 
256 8·3 
Tumour (T) stage          
 
T0,Tis 1 0·0 
 
1 0·0 
 
T1 1500 49·3 
 
1526 49·6 
 
T2 1321 43·4 
 
1363 44·3 
 
T3, T4 216 7·1 
 
175 5·7 
 
Tx, unknown 7 0·2 
 
10 0·3 
Nodal (N) stage          
 
N0 1295 42·5 
 
1308 42·5 
 
N1 1538 50·5 
 
1562 50·8 
 
N2-3 201 6·6 
 
195 6·3 
 
Unknown 11 0·4 
 
10 0·3 
Metastasis (M) stage           
 
M0 (no distant metastasis) 3041 99·9 
 
3069 99·8 
 
M1 (distant metastasis) 2 0·1 
 
5 0·2 
 
Not assessed  2 0·1 
 
1 0·0 
Estrogen-receptor status          
 
Positive 2970 97·5 
 
3014 98·0 
 
Negative 75 2·5 
 
58 1·9 
 
Unknown 0 0·0 
 
3 0·1 
Progesterone-receptor status           
 
Positive 2163 71·0 
 
2215 72·0 
 
Negative 535 17·6 
 
535 17·4 
 
Unknown 347 11·4 
 
325 10·6 
Most extensive surgery          
 
Mastectomy 1464 48·1 
 
1409 45·8 
 
Wide local excision 1577 51·8 
 
1663 54·1 
 
No resection 0 0·0 
 
1 0·0 
 
Unknown 4 0·1 
 
2 0·1 
Time from surgery to initiation of hormone treatment (months)      
 
< 3 1882 62·5 
 
1886 61·8 
 
3 to 6  628 20·8 
 
694 22·7 
 
≥ 6 502 16·7 
 
472 15·5 
 
Unknown 33 1·1 
 
23 0·7 
Adjuvant radiotherapy          
 
Yes 2053 67·4 
 
2114 68·7 
 
No 984 32·3 
 
950 30·9 
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Unknown 8 0·3 
 
11 0·4 
Adjuvant chemotherapy          
 
Yes 1112 36·5 
 
1141 37·1 
 
No  1933 63·5 
 
1934 62·9 
 
Unknown 0 0 
 
0 0 
Country           
 
Netherlands 1379 45·3 
 
1374 44·7 
 
Germany 723 23·7 
 
748 24·3 
 
United Kingdom and Ireland 639 21·0 
 
636 20·7 
 
Greece  100 3·3 
 
107 3·5 
  Belgium  204 6·7    210 6·8 
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Table 2. Disease-free survival events*  
  
Tamoxifen followed by  
exemestane (n=3045) 
Exemestane 
 (n=3075) 
    N % N % 
Total  929 30·5 921 30·0 
 
Locoregional recurrence only** 71 2·3 52 1·7 
 
Distant metastases 502 16·5 470 15·3 
 
New primary breast cancer*** 50 1·6 45 1·5 
 
Intercurrent deaths  306 10·0 354 11·5 
* only first events for DFS were recorded **Includes ipsilateral breast cancer. ***Without distant metastasis. 
 
Table 3. Causes of death  
  
Tamoxifen followed by 
exemestane (n=3045) 
Exemestane  
(n=3075) 
    N % N % 
Death due to breast cancer*  419 13·8 377 12·3 
Death due to other causes  308 10·1 356 11·6 
 
Second malignant disease 72 2·4 85 2·8 
 
Endometrial cancer 2 0·1 1 0·0 
 Cardiac related 45 1·5 61 2·0 
 Thromboembolism 5 0·2 11 0·4 
 Pulmonary related  18 0·6 20 0·7 
 Cerebral related 16 0·5 23 0·7 
 Vascular related 2 0·1 4 0·1 
 Other  91 3·0 95 3·1 
 Unknown reason 57 1·9 57 1·9 
*Death due to breast cancer was defined as death due to breast cancer as 
recorded or if distant metastasis were present at time of death  
      
Table 4. Non-breast cancers  
  
Tamoxifen followed by  
exemestane (n=3045) Exemestane (n=3075) 
    N % N % 
Non-breast cancers      
 
Colorectal  40 1·3 52 1·7 
 
Lung  32 1·1 37 1·2 
 
Endometrial  23 0·8 7 0·2 
 
Other  132 4·3 140 4·6 
One patient in the sequential arm developed two colorectal tumours; five patients 
in the sequential arm and six patients in the exemestane arm developed more than 
one non-breast cancer tumour.  
 
 
 
 Manuscript second revisions – Clean Copy – Plain Text 
 
27 
 
Figures 
Figure 1 
Caption: trial profile  
Figure 2  
Caption: Disease free survival (A) and overall survival (B)Figure 3:  
Caption: Subgroup analysis of disease free survival  
Legend: Numbers are number of events by numbers at risk at time of randomization (n/N(%)). The gray 
line represents a hazard ratio of 1·00, the black line is the overall hazard ratio of 0·96  
Figure 4:  
Caption: Cumulative incidence of recurrences (A) and distant recurrences (B) 
Figure 5:  
Caption: Stacked cumulative incidence of breast cancer specific mortality (BCSM) and other cause 
mortality (OCM) by treatment arm  
Legend: Cumulative incidence function for cause of death stacked on top of each other by the two 
treatment arms. Sum of the two functions represents all-cause mortality.  
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Supplementary Tables (provided as webappendix) 
Supplementary Table 1. Subgroup analysis of disease free survival for patients who 
remained disease free at five years after randomization 
  
n N HR (95% CI) 
Histological grade    
 G1 (well) 96 525 1·14 (0·76-1·71) 
  G2 (moderate) 415 2594 0·98 (0·81-1·19)  
  G3-G4 (poor) 278 1398 0·90 (0·72-1·15) 
  Gx/unknown 65 383 0·99 (0·72-1·92) 
Tumour size    
 T ≤2cm 347 2537 1·09 (0·88-1·34) 
 
T >2cm 504 2273 0·93 (0·81-1·27) 
Nodal status    
 negative 304 2167 1·01 (0·81-1·27) 
  positive 548 2676 0·96 (0·81-1·14) 
Progesterone receptor status     
 positive 611 3564 0·97 (0·83-1·14) 
 
negative 153 764 1·17 (0·85-1·61) 
 
not performed 90 527 0·81 (0·53-1·24) 
HER2    
 positive 87 408 1·01 (0·67-1·55) 
 negative 617 3087 0·96 (0·82-1·12) 
 not performed 150 1360 1·09 (0·79-1·50) 
Most extensive surgery    
 mastectomy 479 2128 0·91 (0·76-1·09) 
 
wide local excision 375 2724 1·12 (0·91-1·37) 
Radiotherapy    
 yes 542 3377 1·06 (0·90-1·26) 
 
no 311 1467 0·87 (0·70-1·10) 
Chemotherapy    
 
yes 261 1797 1·10 (0·86-1·40) 
 no 593 3058 0·93 (0·80-1·10) 
Age (years)    
 
<50 19 166 0·91 (0·37-2·25) 
 
50-59 200 1560 0·88 (0·67-1·17) 
 
60-69 278 1942 0·88 (0·67-1·17) 
 
≥70 357 1187 1·12 (0·69-1·11) 
Overall estimate 854 4855 0·98 (0·86-1·13) 
n: number of events, N: numbers at risk at time of randomization, hazard ratio (HR) and 
corresponding 95% confidence intervals (95% CI) for sequential therapy (reference) and 
exemestane monotherapy.  
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Supplementary Table 2. Baseline characteristics of patients in the original TEAM population, patients included for the current 
analysis and patients excluded for the current analysis  
  
Original TEAM 
population 
 
Included for ten 
year analysis 
 Excluded for ten 
year analysis  
 
  
(n=9766) 
 
(n=6120)  (n=3646)  
  N %  N %  N % P value*  
Age (years)               
 
< 50 331 3·4  211 3·4  120 3·3 0·44 
 
50-59 3017 30·9  1874 30·6  1143 31·3  
 
60-69 3731 38·2  2373 38·8  1358 37·2  
 
≥ 70 2687 27·5  1662 27·2  1025 28·1  
Histological grade          
 
G1 (well) 1677 17·2  616 10·1  1061 29·1 <0·001 
 
G2 (moderate) 4797 49·1  3168 51·8  1629 44·7  
 
G3-G4 (poor) 2438 25·0  1835 30·0  603 16·5  
 
Unknown 854 8·7  501 8·2  353 9·7  
Tumour (T) stage          
 
T0,Tis 6 0·1  2 0·0  4 0·1 <0·001 
 
T1 5690 58·3  3026 49·4  2664 73·1  
 
T2 3592 36·8  2684 43·9  908 24·9  
 
T3, T4 457 4·7  391 6·4  66 1·8  
 
Tx, unknown 21 0·2  17 0·3  4 0·1  
Nodal (N) stage          
 
N0 5112 52·3  2603 42·5  2509 68·8 <0·001 
 
N1 4110 42·1  3100 50·7  1010 27·7  
 
N2-3 478 4·9  396 6·5  82 2·2  
 
Unknown 66 0·7  21 0·3  45 1·2  
Metastasis (M) stage           
 
M0 (no distant metastasis) 9725 99·6  6110 99·8  3615 99·1 <0·001 
 
M1 (distant metastasis) 8 0·1  7 0·1  1 0·0  
 
Not assessed  33 0·3  3 0·0  30 0·8  
Estrogen-receptor status          
 
Positive 9586 98·2  5984 97·8  3602 98·8 0·001 
 
Negative 176 1·8  133 2·2  43 1·2  
 
Unknown 4 0·0  3 0·0  1 0·0  
Progesterone-receptor status           
 
Positive 7300 74·7  4378 71·5  2922 80·1 <0·001 
 
Negative 1725 17·7  1070 17·5  655 18·0  
 
Unknown 741 7·6  672 11·0  69 1·9  
Most extensive surgery          
 
Mastectomy 4333 44·4  2873 46·9  1460 40·0 <0·001 
 
Wide local excision 5423 55·5  3240 52·9  2183 59·9  
 
No resection 3 0·0  1 0·0  2 0·1  
 
Unknown 7 0·1  6 0·1  1 0·0  
Time from surgery to initiation of hormone treatment (months)           
 
< 3 5100 52·2  3768 61·6  1332 36·5 <0·001 
 
3 to 6  2661 27·2  1322 21·6  1339 36·7  
 
≥ 6 1912 19·6  974 15·9  938 25·7  
 
Unknown 93 1·0  56 0·9  37 1·0  
Adjuvant radiotherapy          
 
Yes 6697 68·6  4167 68·1  2530 69·4 <0·001 
 
No 2976 30·5  1934 31·6  1042 28·6  
 Manuscript second revisions – Clean Copy – Plain Text 
 
30 
 
 
 
 
 
 
Unknown 93 1·0  19 0·3  74 2·0  
Adjuvant chemotherapy          
 
Yes 3514 36·0  2253 36·8  1261 34·6 <0·001 
 
No  6252 64·0  3867 63·2  2385 65·4  
 
Unknown 0   0   0   
* P value corresponds to proportional distribution of patients included in the current analysis versus patient excluded in the 
current analysis 
9779 patients 
randomly assigned 
4904 assigned to 
exemestane 
4875 assigned to 
tamoxifen followed by 
exemestane  
4868 included in the 
intention-to-treat 
analysis at five years of 
follow-up 
4898 included in the 
intention-to-treat 
analysis at five years of 
follow-up 
3045 included in the 
intentio-to-treat 
analysis at ten years of 
follow-up  
3075 included in the 
intentio-to-treat 
analysis at ten years of 
follow-up  
7 withdrew consent 
 
1823 excluded due to 
lack of long-term 
follow-up data 
- Japan (n=93) 
- France (n=614) 
- United States 
(n=1116) 
 
6 withdrew consent 
1823 excluded due to 
lack of long-term 
follow-up data 
- Japan (n=91) 
- France (n=616) 
- United States 
(n=1116) 
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2 PROTOCOL SUMMARY 
 
Title   Tamoxifen and Exemestane Adjuvant Multicenter trial  
   TEAM trial 
 
Subtitle  An open label, randomized comparative Trial of 5 years adjuvant 
Exemestane treatment versus Tamoxifen for 2½-3 years followed by 2½-2 
years of Exemestane, for a total of 5 years as adjuvant treatment in 
Postmenopausal Women with Early Breast Cancer  
 
Study Design  Open label, randomized multicenter study, forming a part of a number of 
identical studies performed all over the world of which the results in terms 
of primary endpoints will be presented centrally. Subjects will be 
randomized 1:1 to receive either exemestane (25 mg once daily) for 5 
years or tamoxifen (20 mg once daily) for 2½-3 years followed by 2½-2 
years of exemestane (25 mg once daily). 
 
Subjects  Globally, the study will include approximately 8700 evaluable subjects 
from multiple multinational study sites.  
   Women with histologically or cytologically confirmed primary 
adenocarcinoma of the breast which have undergone curative intended 
surgery (R0) and who meet the following criteria will be enrolled in the 
study: 
- Postmenopausal status (as defined in the protocol) 
- Estrogen Receptor (ER) and/or Progesteron Receptor (PgR)   
 positive tumor 
- Any Tumor with a size > 3 cm, or  
     Any N+ or 
     Tumor size 1-3 cm, N0 and one of the following factors: 
      - MAI > 10 
      - Tumor gradation according to Bloom-Richardson: grade 3 
       - Any TNM stage Breast Cancer (BC) considered to receive  
       adjuvant hormonal therapy, as agreed by NABON and  
       NVMO (49, appendix VI) 
     - Adequate hematological-, renal- and hepatic function (defined as PLT > 
100x109/L, WBC > 3x 10 9/L, Creatinine< 1.5 UNL and SGOT (ASAT) 
or SGPT (ALAT)  < 2.5 UNL 
- Accessible for follow-up for the duration of the trial 
  - ECOG performance status 0 or 1 (appendix II)  
  - Written informed consent (according to ICH/GCP and local  
   IRB guidelines) 
 
Treatment  Patients will be randomized to receive exemestane 25 mg/day p.o. for 5 
years or tamoxifen 20 mg/day p.o. for 2½-3 years followed by 2½-2 years 
of exemestane 25 mg/day. 
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Primary   Relapse Free Survival (RFS) at 2¾ years  
Endpoint   
 
Key secondary  RFS at 5 years 
endpoint 
    
Other secondary  Overall survival (OS)   
Endpoints Incidence of second breast cancer (in contralateral breast) 
 Safety and long-term tolerability of the regimens 
    
 
Follow-up  According to center policy, but minimally: 
   Year 1:   every 3 months 
   Year 2, 3, 4, and 5: every 6 months 
   Year 6+:   annually  
 
 
Data to be Tumor Events:  local or distant relapse, contralateral breast 
recorded     cancer, deaths (breast cancer related  
       and others) 
 Second malignancies 
 Adverse events 
 Co-medication 
 
      
Participating  75 Dutch centers and other (inter)national  
Centers  Cooperative Groups (i.e. US Oncology) 
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3 ABBREVIATIONS AND DEFINITIONS OF TERMS 
 
ALAT   Alanineaminotransferase 
ASAT   Gutamaatoxaalacetaattransaminase 
BC   Breast Cancer 
BOOG   BOrstkanker Onderzoeks Groep Nederland (Dutch Breast Cancer  
              Trialists’ Group)  
CRF   Case Report Form 
DHT   Dihydroxytestosterone 
EBCTCG  Early Breast Cancer Trialists’ Collaborative Group 
EORTC  European Organization for Research and Treatment of Cancer 
ER   Estrogen Receptor 
FSH   Follicle Stimulating Hormone 
GCP   Good Clinical Practice 
Hb   Hemoglobin 
HR   Hazard Ratio 
HRT   Hormone Replacement Therapy 
IDMC   Independent Data Monitoring Committee 
IEC   Institutional Ethical Committee 
IRB   Institutional Review Board 
MAI   Mitotic Activity Index 
NCI-CTC  National Cancer Institute Common Toxicity Criteria 
NABON  NAtionaal BOrstkankeroverleg Nederland 
NVMO  Nederlandse Vereniging voor Medische Oncologie 
OS   Overall Survival 
PgR   Progesteron Receptor 
PLT   Platelets 
RBA   Relative Binding Affinity 
RFS   Relapse (Recurrence) Free Survival 
SAE   Serious Adverse Event  
SGOT   Serum Glutamic Oxaloacetic Transaminase 
SGPT   Serum Glutamic Pyruvic Transaminase 
TTP   Time To Progression 
UNL   Upper Normal Limit 
WBC    White Blood Cell Count 
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4 BACKGROUND AND INTRODUCTION 
 
4.1 Background Tamoxifen 
At the present time tamoxifen is still the standard hormonal treatment for post-menopausal 
women following  curative intended surgery (R0) for primary ER positive breast cancer.  The 
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) has summarized the available 
randomized trials, in women of all ages, as showing a 25% relative reduction in annual odds of 
relapse and 16% relative reduction in the annual odds of dying after a median follow-up of about 
10 years (1). 
The issue of the optimal duration of tamoxifen still remains to be solved. The results from the 
1995 EBCTCG overview show that 2 years of treatment was beneficial and that there was an 
additional benefit for continuing treatment to a total of 5 years, suggesting that in women with 
ER+ve/ER-unknown tumors the proportional average relative recurrence reductions (after about 
10 years of follow-up) compared with patients who received no tamoxifen were 21%  for 1 year 
of tamoxifen, 29% for 2 years of tamoxifen and 47% for 5 years of tamoxifen. The 
corresponding average relative reductions for mortality were 12%, 17%, and 26%, respectively 
(1). However, the interpretation of indirect evidence such as this must be done with caution, as 
comparison between trials may be confounded by factors like concomitant chemotherapy, patient 
selection and duration of follow-up. 
Several trials have been initiated to establish the tamoxifen duration question directly. Results 
from the first of these studies have been published. Early results from both the Swedish Breast 
Cancer Co-operative Group and the Cancer Research Campaign (CRC) Breast Cancer Trials 
Group, comparing 2 versus 5 years of tamoxifen, appear to suggest that patients treated for 5 
years have a better disease-free survival than those allocated to receive 2 years (2,3). For patients 
treated with 5 compared with 2 years of tamoxifen, the CRC trial reports a relative risk (hazard 
ratio) of recurrence/death of 0.81 (95%CI 0.69-0.98) [all ER unknown] and the Swedish trial 
similarly estimates the hazard ratio of recurrence/death as 0.82 (95%CI 0.71-0.96). Both trials 
suggest a relative reduction in the risk of recurrence/death of approximately 18% for 5 years 
compared with 2 years of tamoxifen, remarkably similar to that estimated indirectly from the 
overview. This translates to approximately a 4% difference in recurrence-free survival (RFS) 5 
years after randomization, although the size of the confidence intervals for each trial confirms 
that further information is needed before this estimate can be considered statistically reliable. 
Longer follow-up is also needed to provide a reliable analysis of overall survival. The results of 
both trials are, however, consistent with a modest reduction in risk of death following 5 years 
compared with 2 years of tamoxifen. 
Four trials that were designed to investigate duration of tamoxifen beyond 5 years have now 
reported early results (4,5,6,7). However, the results thus far are controversial and do not support 
prolongation of tamoxifen beyond 5 years. The NSABP B14 trial (5) shows a significant better 
relapse free survival and overall survival for the 5 years treatment in node-negative patients. The 
Scottish trial also claims better outcome for the 5 years treatment in a population of node-
positive and node-negative patients (4). Finally, in contrast to both studies previously mentioned, 
the only randomized study that shows benefit for 10 years tamoxifen is a relatively small ECOG 
trial (6). Longer follow-up in a larger patient group is necessary to provide a reliable answer as to 
whether to continue tamoxifen treatment for more than 5 years (8). Further trials are still ongoing 
which will, in due course, provide definitive information as to the optimal duration of tamoxifen. 
At that time the balance between therapeutic effect and increase in risk of endometrial cancer 
will be determined. Therefore, based on the current evidence, 5 years of tamoxifen is considered 
as the best standard adjuvant endocrine treatment for postmenopausal patients. 
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In order to achieve improved results, several groups have initiated studies to determine the effect 
of the addition of cytotoxic chemotherapy in the setting of postmenopausal patients. Two trials 
seem representative to summarize the results: (a) The IBCSG randomized patients to receive 
chemotherapy plus tamoxifen compared with tamoxifen alone; this trial resulted in a marginal 
benefit for those women receiving cytotoxic chemotherapy (an average of an extra 6 months free 
from recurrence), but this appeared to be outweighed by the decrease in quality of life as 
estimated by TWIST (9). (b) The ICCG have compared the use of epirubicin in addition to 
tamoxifen with tamoxifen alone; this resulted in a significant improvement in RFS (p=0.023) 
(10). In both studies survival was not significantly improved by the addition of chemotherapy. 
However, based on these results, chemotherapy combined with tamoxifen has been incorporated 
in the Dutch National Guidelines (49, appendix VI). Therefore, (planned) chemotherapy will not 
be an exclusion criterion for this trial. Patients will be stratified for (planned) chemotherapy and 
type of chemotherapy (if applicable). 
 
4.2 Background Exemestane 
Another form of endocrine therapy, with similar tolerability compared to tamoxifen, has been 
developed which appears to benefit patients with advanced breast cancer who have responded 
and/or stabilized to tamoxifen and who developed progression later on. This class of compounds 
is called aromatase inhibitors. 
Aromatase inhibitors act systemically to inhibit estrogen synthesis in tissues. These compounds 
prevent estrogen biosynthesis by inhibiting the enzyme aromatase, which catalyses the 
conversion of adrenal- and ovarian androgens to estrogens. There has therefore been interest in 
developing these compounds as potential therapies for hormone responsive breast cancer in 
postmenopausal women. 
Aminoglutethimide was the first generation aromatase inhibitor. Although effective as an 
adjuvant therapy in breast cancer (11), it was poorly tolerated and was replaced by the well-
tolerated second-generation aromatase inhibitor 4-OH-androstenedione (formestane).  This 
compound, however, only suppresses plasma estradiol to 1/3 of baseline levels and requires 
parenteral administration (12,13). 
Some years later, third generation aromatase inhibitors were developed. They fall into two 
principal categories, i.e.: (a) non-steroidal, exemplified by fadrozole, vorozole, letrozole and 
anastrozole and (b) steroidal, exemplified by exemestane (14-23). 
Exemestane is a very potent, orally active, selective and long lasting steroidal, irreversible 
inactivator of aromatase. In in vitro studies exemestane appeared to be 2.8 and 156 times more 
potent than the steroidal formestane and the non-steroidal aminoglutethimide (AG), respectively, 
in inhibiting human placental aromatase. In vivo studies of aromatase inactivation indicate that 
exemestane, by the oral route, is several times more potent than formestane (24,25). 
 
Exemestane has no noteworthy binding to estrogen-, progesterone-, glucocorticoid- or 
mineralocorticoid receptors and only a very low binding to the androgen receptor (relative 
binding affinity, RBA, 0.2% from that of dihydrotestosterone, DHT) (26). However, its 
metabolite FCE 25071 (17-hydro-exemestane) was found to have a binding affinity to the 
androgen receptor (100-fold higher than that of exemestane (RBA 27% from and 0.28% that of 
DHT, respectively) (P&U, data on file).  
 
Early hormonal studies in breast cancer patients using an estrogen assay, later on found to suffer 
from non-specific interactions of exemestane metabolites (Celite-RIA), indicated for exemestane 
a maximal inhibition of estrogens up to 30% of baseline levels starting from doses of 2.5-5 mg 
daily (19-21). However, more recent results obtained, using a very specific and sensitive 
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analytical method (HPLC - RIA), indicate that exemestane suppresses plasma estrogens down to 
6-11% of pre-treatment levels (18, 22), thus showing an activity comparable to that observed 
with non steroidal aromatase inhibitors of third generation such as letrozole, and significantly 
more pronounced than that of formestane.   
 
Recent in vitro and clinical data on intratumoral and peripheral aromatase inhibition indicate that 
the drug is a potent inhibitor of the enzyme.  In vitro, exemestane inhibits the aromatase enzyme 
in human placenta, in adipose breast tissue and in tumor tissue, at concentrations of 1000nM, to 
5%, 13% and 15% of the baseline values, respectively. In patients, the drug inhibits peripheral 
aromatisation down to 2.2% of the baseline, after 8 weeks of treatment with 25mg daily (P&U, 
data on file), which is considered to be the standard dose. These results are in line or superior to 
the ones obtained with other, non-steroidal, aromatase inhibitors, such as anastrozole or 
letrozole, and are consistent with the efficacy data so far obtained in phase I and phase II studies.   
  
4.2.1 Exemestane trial results 
Phase I studies 
In total 137 patients have been treated with exemestane at various daily doses (up to 600 mg), 
and no MTD was determined, whereas 25 objective responses have been observed (18%). 
 
Phase II studies  
Four multicenter, multinational phase II trials in second- (tamoxifen failures) or third line 
treatment (tamoxifen- and megestrol acetate or tamoxifen- and AG failures) have been 
completed enrolling 437 patients  (P&U, data on file).  
 
In total 265 patients were accrued in the two studies (US and European) carried out at the 
standard dose of 25 mg daily in patients with advanced breast cancer, primarily refractory to 
tamoxifen or progressing after initial response to tamoxifen, and in patients relapsing during or 
within 12 months of discontinuing adjuvant tamoxifen. Of these, 262 are currently available for 
response evaluation. Overall, the objective response rate (CR plus PR) was 23%; including 
patients with long term stabilization of disease ( >24 weeks), 45% of the patients benefited from 
therapy (P&U, data on file). In the European study, the median duration of objective response 
was 68 weeks, of overall response (CR, PR or disease stabilization > 24 weeks) 59 weeks and the 
median time to progression (TTP) was 29 weeks; the corresponding figures in the US study were 
49, 43 and 24 weeks, respectively (P&U, data on file).  
 
Considering the response rate to exemestane observed in patients failing tamoxifen (21%), this is 
in the same range as reported in the recent phase III studies for letrozole (29) or vorozole (30), 
but higher than that recorded with anastrozole 1 mg daily (27), or formestane (28). 
 
In a US study assessing the efficacy of exemestane (25 mg daily) as 3rd-line treatment after 
failure of both tamoxifen and megestrol acetate, 91 patients were evaluable for response 
assessment (50). Response to treatment was observed in 13% of patients with an additional 18% 
obtaining stable disease >24 weeks. The median duration of objective response, overall response 
and TTP are currently 27, 34, and 9 weeks, respectively (50). 
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In total 78 patients were treated in a study assessing the efficacy of exemestane (200 mg daily 
dose) as 3rd-line treatment of patients progressing on AG given at a daily dose of >500 mg for at 
least 8 weeks (22,23) and all of them are currently available for response evaluation. They 
include 33 patients unresponsive to AG, 39 patients who had progressed after an initial response 
to AG, and 6 patients for whom response to prior therapy was either not available or not 
evaluable. Overall, the objective response rate was 26% (12% in patients refractory to AG and 
33% in the responsive ones). Disease stabilization (>24 weeks) was achieved in an additional 
13% of patients  (15% of those refractory to AG and 13% of those responsive percentage of 
patients benefiting from therapy thus being 39% in this study. The median duration of objective 
response (CR+PR), overall response (CR, PR or disease stabilization >24 weeks) and time to 
progression (TTP) were 59, 48, and 21 weeks, respectively. These results are very promising 
considering the fact that the patient population consisted of patients previously treated with at 
least two hormonal agents and that 55% of them had received in addition at least one line of 
chemotherapy. Furthermore, this study confirms previous observations of lack of cross-resistance 
when steroidal aromatase inhibitors are given after non-steroidal aromatase inhibitors (27, 28, 
51). 
 
Randomized Phase II and III studies 
Exemestane (25 mg daily) was evaluated in a phase III, randomized, double-blind, multicenter, 
multinational comparative study of postmenopausal women with advanced breast cancer who 
had disease progression after hormonal treatment with antiestrogens (primarily TAM) for 
metastatic disease or as adjuvant therapy. Subjects were required to have measurable metastases 
or lytic bone disease due to breast cancer, reasonable performance, ER/PgR receptor status 
positive or unknown, and near-normal organ function.  Subjects may also have received prior 
cytotoxic therapy, either as adjuvant treatment or for metastatic disease.  In this study (94 OEXE 
018), 769 subjects were randomized to receive exemestane 25 mg once daily (N = 366) or 
megestrol acetate 40 mg four times daily (N = 403). Intent-to-treat results for randomized 
subjects from the study are summarized in Table 1 (46). 
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Table 1.  Efficacy Results from a Phase III Study of Postmenopausal Women with Advanced Breast Cancer Whose 
Disease Had Progressed after Antiestrogen Therapy 
 
Response Characteristics 
Exemestane 
(N=366) 
Megestrol acetate 
(N=403) 
 
p-value 
Objective Response Rate = CR + PR (%) 
 95% Confidence Interval 
15.0 
(11.5-19.1) 
12.4 
(9.4-16.0) 
 
Overall Success = CR + PR + SD  24 Weeks (%) 
 95% Confidence Interval 
37.4 
(32.3-42.6) 
34.6 
(29.9-39.6) 
 
CR (%) 2.2 1.2  
PR (%) 12.8 11.2  
SD (%) 40.7 41.9  
SD  24 Weeks (%) 21.3 21.1  
PD (%) 35.0 36.2  
Other (%)* 9.3 9.4  
Median Duration of Response (weeks) 76.1 71.0  
Median Duration of Overall Success (weeks) 60.1 49.1 0.025 
Median Duration of SD  24 Weeks (weeks) 48.0 46.6  
Median TTP (weeks) 
     Hazard Ratio (Exemestane-MA) 0.84 
20.3 16.6 0.037 
Median TTF (weeks) 16.3 15.7 0.042 
Median Overall Survival (weeks) Not reached 123.4 0.039 
75% Survival (weeks)† 
 95% Confidence Interval 
74.6 
(59.1-91.0) 
55.0 
(46.1-70.3) 
 
*Includes subjects who were not treated or not evaluable 
†25th percentile 
Abbreviations:  CR = complete response, PD = progressive disease, PR = partial response, SD = stable disease (no 
change), TTP = time to tumor progression, TTF = time to treatment failure 
 
Comparison of exemestane vs. tamoxifen as 1st-line hormonal therapy in advanced breast cancer 
therapy is ongoing. Results from a randomized phase II trial comparing exemestane versus 
tamoxifen are promising and show high activity and low toxicity for exemestane (48). Recently, 
superior results were reported of exemestane compared with tamoxifen as first line hormonal 
treatment in a phase III trial of the EORTC Breast Group (52). This superiority consisted of a 
significant higher response rate, time to progression and less thrombo embolic events. 
A large adjuvant study has recently been completed comparing 5 years treatment with tamoxifen 
with sequential treatment of tamoxifen and exemestane for 5 years (53). The published data 
demonstrated that there is a significant clinical benefit produced by switching patients to 
exemestane after 23 years of tamoxifen therapy, compared to keeping patients on 5 years of 
tamoxifen (3). Switching to exemestane significantly improved disease-free survival and resulted 
in significantly fewer second breast cancers (P=0.04) with a more favorable safety profile. At 
three years there was an absolute difference in disease-free survival of 4.7% with a 32% 
reduction in risk of recurrence for women switched to exemestane. However at a median follow-
up of 30.6 months, overall survival was not different in patients switched to exemestane, 
compared to those patients who remained on tamoxifen for a total of 5 years.  
 
 
4.3 Safety  
4.3.1 Exemestane 
An overall safety analysis has been performed on 744 postmenopausal breast cancer patients 
treated in the exemestane clinical program (phase I and II studies) with fixed doses ranging from 
0.5 to 600mg daily, for a median time of 4 months. Approximately 20% of them received the 
drug for 1 year or longer (up to 3.5 years). In total 555 patients received the dose of 25 mg, 
which is considered the standard dose. 
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When events are considered in this safety analysis, that either are drug-related or from 
indeterminate cause, the overall frequency at the standard dose of 25mg was 49%. Reported 
events were mainly mild to moderate in severity using the CTC criteria. The most frequent 
adverse events reported were hot flushes (16%), nausea (12%), fatigue (7%) and dizziness (6%). 
More detailed data are shown below: 
 
Table 2. Adverse events, either drug-related or of indeterminate cause, in postmenopausal breast 
cancer patients treated with exemestane in a daily dose of 25 mg. 
 
Adverse Event 25mg(555 pts) 
 
% n 
Any Event 49 274 
   
Hot flushes 16 88 
Nausea 12 65 
Dizziness 6 36 
Increased Sweating 5 30 
Fatigue 7 37 
Headache 5 29 
Asthenia 1 6 
Insomnia 3 18 
Alopecia 2 14 
Pain 3 15 
Skin Rash 3 18 
Anorexia 3 15 
Edema-peripheral/leg  2 9 
Abdominal Pain 2 14 
Vomiting 2 13 
Constipation 2 9 
Dyspepsia 2 9 
Hypertricosis 1 5 
Paresthesia <1 4 
Dysphonia <1 2 
Acne <1 4 
 
Severe adverse events that were drug-related or from indeterminate cause were reported in only 
3% of the overall patient population considered, but increased to 7% in patients treated with the 
200mg dose. 
 
Treatment discontinuation due to adverse drug reactions occurred in 1.5% of the patients. Of the 
555 patients treated with the 25mg daily dose, 1% discontinued treatment for drug-related 
adverse reactions and only in two cases for grade 3 adverse reactions (allergic skin reaction in 
one case and grade 3 nausea in another). The other 4 patients discontinued treatment for grade 2 
nausea (two cases, with concurrent grade 2 depression in one of them), grade 2 dizziness and 
weakness in one case and elevated liver function test in the last one. 
 
Laboratory tests performed during clinical trials in patients with advanced disease did not 
indicate major side effects, apart from liver test alterations and decrease in lymphocyte count. 
Grade 2-3 liver function tests abnormalities led to drug discontinuation in one case (0.2%).  
 
When compared to other treatments in comparative trials, the toxicity of exemestane seems to be 
mild. When compared to megestrol acetate, side effects appear to be comparable or favorable for 
exemestane. Preliminary results indicate the same when compared with tamoxifen. (48). 
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4.3.2 Tamoxifen 
Secondary cancers: 
The effect of tamoxifen on endometrial tissue has been investigated for many years. Results and 
conclusions however, remain controversial. Effects that appear to be associated with tamoxifen 
treatment are: uterine fibroids, endometrial polyps, endometriosis and endometrial hyperplasia 
(36-41). 
Besides this, several reports associate tamoxifen treatment with increased risk for endometrial 
cancer (42-44). Moreover, in a very recent article from the Dutch Comprehensive Cancer 
Centres’ Alert Group, published in The Lancet (45), it has been reported that the risk of 
endometrial cancer increased with longer duration of tamoxifen use (p< 0.001), with relative 
risks of 2.0 (1.2 – 3.2) for 2-5 years and 6.9  (2.4 – 19.4) for at least 5 years compared to non-
users. Moreover, long-term tamoxifen users have a worse prognosis of endometrial cancers, 
which seems to be due to less favorable histology and higher stage. However, the benefit of 
tamoxifen on breast cancer survival far outweighs the increased mortality from endometrial 
cancer. 
 
Other adverse events: 
In table 3 the adverse events are shown that were reported in the placebo-controlled NSABP B-
14 trial. In this study, pre- and postmenopausal patients with primary breast cancer and 
histologically negative axillary nodes whose tumor estrogen receptors were positive (≥ 10 fmol) 
were re-randomized (in case they were still free of breast cancer recurrence after 5 years of 
tamoxifen adjuvant treatment) to either an additional 5 years of tamoxifen or 5 years placebo in a 
double-blind fashion.  Hot flashes, vaginal discharge, and irregular menses were more frequent 
in women who were treated with tamoxifen, whereas fluid retention and weight gain were 
similar in the placebo and tamoxifen–treated groups. Thromboembolic phenomena were higher 
in the tamoxifen-treated group (1.2% vs. 0.4%), and 2 patients in the tamoxifen-treated group 
died of pulmonary emboli. A minority of patients may suffer severe symptoms, but these will 
diminish with time. Finally, less than 5% of women stop tamoxifen because of side effects (5). 
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Table 3. Percentage of Women Who Reported an Adverse Side Effect in the NSABP-14  
5-Year Tamoxifen Trial (20 mg Daily) Vs Placebo 
 
Both pre- and postmenopausal women participated in the study. These are the only side effects 
noted by the nearly 3,000 women involved in the trial. It should be recognized that all side 
effects were not experienced by all women. 
 
 
Adverse Effects 
 
Tamoxifen (n = 1424) 
 
Placebo (n = 1420) 
Hot flashes 63,9% 47,6% 
Weight gain (> 5%) 38,1% 40,1% 
Fluid retention 32,4% 29,7% 
Vaginal discharge 29,6% 15,2% 
Nausea 25,7% 23,9% 
Irregular menses 24,6% 18,8% 
Weight loss (> 5%) 22,6% 18,0% 
Skin changes 18,7% 15,3% 
Increased blood urea nitrogen (BUN) 18,1% 20,2% 
Diarrhea 11,2% 14,0% 
Increased serum glutamic-oxaloacetic 
transaminase (SGOT) 
4,8% 2,8% 
Increased alkaline phosphatase 3,0% 4,6% 
Vomiting 2,1% 1,7% 
Increased bilirubin 1,8% 1,2% 
Increased creatinine 1,7% 1,0% 
Thrombocytopenia* 1,5% 1,2% 
Leukopenia** 0,4% 1,1% 
Thrombotic events    
 Deep vein thrombosis 0,8% 0,3% 
 Pulmonary embolism 0,4% 0,1% 
 Superficial phlebitis 0,3% 0.0% 
   
 
* Defined as a platelet count of < 100,000/mm3 
** Defined as a white blood cell count of < 3,000/mm3 
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4.3.3 Exemestane versus Tamoxifen 
The only information about adverse events in a randomized study comparing exemestane and 
tamoxifen comes from a randomized phase II trial conducted by the EORTC Breast Cancer 
Cooperative Group (EORTC protocol 10951) in postmenopausal patients with metastatic breast 
cancer who received exemestane or tamoxifen as first line hormonal treatment. Table 4 shows 
the results. 
  
Table 4. Percentage of women who reported grade 2 and 3 NCIC-CTC toxicities in EORTC 
protocol 10951 
 
Grade 2 and 3 NCI-CTC Toxicities 
 % of Patients 
 Exemestane (n=37) Tamoxifen (n=39) 
Anorexia _ 5.1 
Dyspnea / Cough 16.2 12.8 
Edema 2.7 7.7 
Fatigue 5.4 12.8 
Diarrhea / Constipation 5.4 5.1 
Hot Flashes 2.7 15.4 
Infection 5.4 5.1 
Nausea 2.7 7.7 
Pain, bone 5.4 15.3 
Sweating _ 10.3 
Skin 8.1 _ 
Weight gain / loss 5.4 / 2.7 5.1 / 0 
 
The results have been presented at ASCO, 2000 by Paridaens (48). The phase II study will be 
extended to a phase III study. 
 
5 STUDY RATIONALE 
 
The good antitumor activity and safety profile of exemestane, as demonstrated in the phase II 
and III studies in postmenopausal women with metastatic breast cancer (discussed in chapter 4) 
provide a good rationale to investigate the efficacy and safety of adjuvant exemestane in a 
prospective, randomized study versus the current standard tamoxifen, in postmenopausal women 
with ER positive early breast cancer. Besides efficacy end-points (RFS, OS), safety and long-
term tolerability (second malignancies) are important research objectives in such a trial. 
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6 TRIAL OBJECTIVES AND ENDPOINTS 
 
6.1 Primary objective 
To determine whether up-front adjuvant treatment with exemestane compared with adjuvant 
tamoxifen improves the relapse-free survival (RFS) of postmenopausal, receptor positive, early 
breast cancer patients following 2¾ (2½ -3) years of treatment.  
 
6.2 Key secondary objective 
5-years RFS as a point estimate obtained from the Kaplan-Meier survival estimates of the two 
treatment arms. The difference in 5-years RFS between the treatment arms will be reported, 
along with its standard error (SE) and an associated 95%-confidence interval. 
 
6.3 Other secondary objectives 
Overall survival, the relative safety profiles, and the incidence of new primary breast cancers of 
the postmenopausal women treated with 5 years of exemestane versus tamoxifen therapy for 2½ 
-3 years followed by 2½ -2 years of exemestane (a total of 5 years). 
 
6.4 Endpoints 
Primary endpoint of this study will be relapse-free survival (RFS) at 2¾. Key secondary 
endpoint will be relapse-free survival (RFS at 5 years. Other secondary endpoints will determine 
overall survival, the incidence of contralateral breast cancer, safety and long-term tolerability of 
both hormonal regimens. 
  
Relapse is defined as the appearance of loco-regional recurrence or distant metastases at any site. 
Time to first locoregional recurrence, contralateral breast cancer and time to first distant 
recurrence will be recorded on separate parts of the CRF. In the event of relapse, all patients will 
be followed for progression and survival, irrespective whether their recurrence is loco-regional, 
consists of a second (breast) primary, or is in a distant site. These above sites will be registered, 
whereas recurrence in a supraclavicular node will be registered as a separate item. Date of 
suspicion of relapse, as confirmed by the investigator, as well as action taken to confirm relapse, 
will be recorded on the CRF. 
 
Events that should be recorded are: 
 
1. Ipsilateral breast-, chest wall-, or axillary nodal relapse (loco-regional)  
2. Contralateral breast cancer 
3. Supraclavicular nodal relapse  
4. Distant relapse  
5. Death and cause of death (breast cancer / other) 
6. Other second malignancies 
7. (Serious) Adverse Events 
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7 STUDY DESIGN 
 
This is a multi-center open-label, randomized, parallel group, comparative clinical trial. The trial 
is conducted by the Dutch TEAM Study Group under the auspices of NABON-BOOG (Dutch 
Breast Cancer Trialists’ Group). A Steering Committee has been appointed, consisting of one 
medical oncologist and one surgical oncologist from each of the 9 Dutch Comprehensive Cancer 
Centres, acting as regional study coordinators. This Steering Committee is responsible for a good 
conduct of the trial.  
 
Treatment 
Eligible subjects must be randomized and started on adjuvant hormonal treatment within ten 
weeks after completion of surgery, and/or chemotherapy (primary treatment). 
Subjects will be randomized 1:1 to receive either exemestane, 25 mg once daily for 5 years or 
tamoxifen 20 mg once daily for 2½-3 years followed by 2½ -2 years of exemestane 25 mg once 
daily, for a total of 5 years. Both study drugs are registered for breast cancer and will be 
prescribed by the investigator. 
 
Evaluation schedule 
After randomization, patients will visit the hospital every 3 months during the first year. 
Thereafter, during year 2, 3, 4 and 5 after randomization, patients will be seen by the physician 
every 6 months. 
At each visit, complaints and adverse effects will be recorded, physical examination will be 
performed, and concomitant medication will be registered. Yearly, a mammography will be 
performed. Furthermore, blood chemistry and hematology will be assessed according to local 
policy. For an exact overview of the follow-up schedule, please see the trial flowchart on page 
27.  
For patients who relapse during the 5 years adjuvant treatment and who are still 
considered to be suitable for hormonal therapy, it is strongly recommended to switch to the 
medication of the other trial arm.  Results of this “cross-over” (response rate, duration of 
response and time to progression) will be registered. 
 
Registration of relapse 
In case of any relapse, the adjuvant treatment has to be stopped, and this is registered as an event. 
Any malignant contralateral breast cancer will be registered as a second primary, and relapse 
with supraclavicular disease will be registered as distant relapse, unless otherwise specifically 
indicated. 
 
‘Breast cancer’ deaths will be all deaths with breast cancer specified as a cause of death and 
deaths from any cause following a distant relapse. 
  
All patients will be evaluated for endpoints in the treatment arm to which they were randomized, 
irrespective of the treatment they actually received. No patient will be removed from the 
analyses, irrespective of whether she is found to have violated an eligibility criterion after 
randomization or to have been withdrawn from trial medication prematurely. Thus, analysis will 
be by “intention to treat” including all patients randomized. 
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Premature discontinuation 
Patients will be withdrawn from the trial if, in the opinion of the investigator, it is medically 
necessary, or if it is the wish of the patient. If a patient does not return for a scheduled visit, 
every effort should be made to contact the patient. In any circumstance, every effort should be 
made to document the patient’s outcome. Particularly, if a patient requests withdrawal from the 
trial, the patient must be asked whether she accepts that her clinical data will continue to be used 
for trial purposes (particularly details of disease-related events and follow-up).   
Patients will discontinue study treatment in the case of any relapse. Treatment after relapse is at 
the discretion of the investigator, taking into consideration the recommendation under 
“Evaluation Schedule” concerning the crossover design. Other reasons for a patient to 
discontinue treatment will be the occurrence of a serious adverse event (SAE), withdrawal of 
consent or experience of unacceptable toxicity. There will be no dose modification and the 
patient will be discontinued from treatment should any unacceptable event occur. An ‘Off 
Treatment’ form must be completed, and the Central Data Center must be informed if treatment 
is discontinued prematurely for any reason. All patients will continue to be followed-up, 
irrespective of whether they have discontinued treatment prematurely or not. 
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8 SELECTION OF SUBJECTS 
 
8.1 Inclusion criteria 
The study population consists of postmenopausal women diagnosed with resectable breast 
cancer, meeting all of the following eligibility criteria: 
 
- Histologically/cytologically confirmed adenocarcinoma of the breast, followed by  
 intended curative surgery (R0) and if indicated, also radiotherapy  
- Any Tumor with a size > 3 cm, or  
 Any N+ or 
 Tumor size 1-3 cm, N0 and one of the following factors: 
- MAI > 10 
- Tumor grading according to Bloom-Richardson: grade 3  
- Any TNM stage BC considered to receive adjuvant hormonal therapy, as 
agreed by NABON-NVMO  (49, appendix VI) 
 
- ER and/or PgR receptor status positive (as defined by local hospital criteria) 
 
- Post-menopausal defined as: 
 -  Age  50 and amenorrhea for > 1 year 
 -  Bilateral surgical oophorectomy (and no HRT) (any age is acceptable) 
- Age < 50 with natural amenorrhea > 1 year at breast cancer diagnosis 
      (and uterus in situ) 
 
In case of doubt about subject’s menopausal status, FSH assessments have to be 
performed to define the menopausal status (FSH should be in the postmenopausal range 
according to values of the local institution) 
 
- Adequate hematological-, renal- and hepatic function (defined as 
PLT > 100x109/L, WBC > 3x 10 9/L, Creatinine< 1.5 UNL and SGOT (ASAT) or SGPT 
(ALAT)  < 2.5 UNL) 
-      Accessible for follow-up for the duration of the trial 
 
-      ECOG performance status 0 or1 (appendix II) 
 
- Written informed consent (according to ICH/GCP and local IRB guidelines) 
 
- Baseline clinical laboratory tests are done within 4 weeks prior to randomization 
 
- Adjuvant hormonal treatment is started within 10 weeks after completion of surgery (date 
of tumor removal or re-excision) or date of last adjuvant chemotherapy 
 
 
 23(74)
TEAM-trial                                           Final protocol, including amendment 1 & 2                       November 10, 2004 
 
8.2 Exclusion criteria 
Those patients who did not undergo intended curative primary treatment or who fulfilled one of 
the following criteria: 
- Inflammatory breast cancer 
- Positive supraclavicular nodes 
- Ulceration/infiltration of local skin metastasis  
 
- Both ER negative and PgR negative primary tumor 
 
- Evidence of distant metastases (M1) 
 
- Patients who have received previous hormonal treatment as adjuvant treatment for breast 
cancer  
 
- Uncontrolled cardiac disease including unstable angina, CHF or arrhythmia requiring 
medical therapy or with a history of myocardial infarction within the past 3 months or 
any other serious concomitant disease. 
 
- Psychiatric disorders preventing proper informed consent 
 
- Tumor with a size < 1cm and N0 
 
- Tumor size 1-3 cm, N0 without additional risk factors 
 
- Concomitant malignancies except for adequately treated carcinoma in situ of the uterine 
cervix or basal squamous cell carcinoma of the skin, unless agreed by the Steering 
Committee. Subjects with other malignancies must be disease-free for at least 5 years. 
Patients with a history of breast cancer should be excluded. 
 
- Concurrent participation in another clinical study that may interfere with the results of the 
trial involving investigational agents within thirty days of treatment from this study, 
unless this is agreed by both the Steering Committee and the Coordinating Investigator of 
the study involved. 
 
- Other serious illnesses that may interfere with subject compliance, adequate informed 
consent or determination of causality of adverse events. 
 
- Hormone replacement therapy for treatment of menopausal symptoms that was not 
stopped at least 4 weeks prior to randomization 
 
- Patients who were treated with neo-adjuvant chemotherapy 
 
- Patients with a bilateral tumor 
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9 TRIAL ADMINISTRATION, DATA MANAGEMENT & 
MONITORING 
 
9.1 Data Management 
The Data Center Heelkunde from the department of Surgery of the Leids Universitair Medisch 
Centrum (LUMC) in Leiden will be the Central Data Center for the Dutch Team Study Group.  
The Central Data Center will be responsible for randomization of patients, supply of Case 
Record Forms (CRF’s), receipt of CRF pages, generation of edits/queries, creation of Clean File 
and submission of clean CRF data to the Central Data Base in Canada. 
Also, the Central Data Center can perform audits in participating institutions, whenever the 
Steering Committee considers this to be necessary. 
 
Randomization 
Randomization can be done by telephone or by fax. During the randomization procedure all 
eligibility criteria will be checked. At the end of the procedure the treatment will be randomly 
allocated to the patients. A sequential identification number will also be given. This number and 
the allocated medication have to be recorded on the randomization form, along with the 
randomization date. The randomization form must be signed by the investigator (in case of faxed 
randomization, the confirmation of the data manager will also have to be signed by the 
investigator) and be filed with the Case Report Forms. 
  
Data Flow 
The CRF’s must be completed and signed by the investigator or one of his/her authorized staff 
members as soon as the requested information is available. CRF’s will contain common 
information, but this information will be kept to a minimum. The time between the patient’s visit 
and completion/shipment of CRF pages should be kept to a reasonable minimum. In all cases it 
remains the responsibility of the investigator to check that original case report forms are sent to 
the Central Data Center and to verify that they are completed and filled out correctly. 
The CRF will have the form of a booklet that can be kept in the patient's records and can serve as 
source document. After completion (within 1 month after the visit), the pages must be sent by 
mail to the Central Data Center. Afterwards, the CRF must be restored in the patients' records. 
All sections are to be completed on the forms before faxing it to the Central Data Center. If 
information is not known, this must be clearly indicated.  
 
To enable peer review, and/or audits from Health Authorities/NABON-BOOG, the investigator 
must agree to keep records, including the identity of all participating subjects (sufficient 
information to link records, e.g. CRF’s and hospital records), all original signed Informed 
Consent Forms, copies of all CRF’s and detailed records of drug disposition. To comply with 
international regulations, the records should be retained by the Investigator for 15 years, 
including assessments like CT scans. 
 
9.2 Monitoring 
A pre-study and/or site initiation visit to determine the qualifications of the Investigator(s), to 
inspect the clinical laboratory facilities, and to fully inform the Investigator of his/her 
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responsibilities and the procedures for assuring adequate and correct documentation may be 
conducted on behalf of the Dutch Team Study Group, if deemed necessary. 
Monitoring of the individual centers will take place on a regular pre-determined basis, but 
monitoring will be confined to a minimum. The decision to perform monitoring visits lies with 
the Steering Committee of the Dutch TEAM Study Group, who may also decide who will 
perform the monitoring visits.  
Data to be verified will include informed consent, eligibility adverse events and outcome. Any 
major problems identified during monitoring will be reported to the Steering Committee. 
All records will be maintained in accordance with local regulations and in a manner that ensures 
security and confidentiality. 
 
The Investigator must assure that the subjects' anonymity will be maintained on all documents 
submitted to the Dutch TEAM Study Group.  Each subject will be identified in the Case Report 
Form (CRF) by a subject identification number, initials and date of birth. The subject 
identification number will consist of site number and randomization number. 
A case report form (CRF) is required and should be completed for each included subject. The 
completed original CRF's are the sole property of the Dutch Team Study Group and should not 
be made available in any form to third parties, except for authorized representatives of 
appropriate Health/Regulatory Authorities, without written permission from the Dutch TEAM 
Study Group. 
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10 ASSESSMENTS AND FOLLOW UP SCHEDULE 
 
10.1 Pre-randomization (within 4 weeks of randomization and start of hormonal 
therapy) 
 To be recorded: 
 Medical history 
 Metastatic screen: Additional tests/investigations, if clinically indicated, are at the 
investigator’s discretion. 
 Hematology (Hb, WBC, platelets) & Biochemistry (Creatinine, ASAT or ALAT, 
Calcium, Protein, Alkaline Phosphatase and Glucose) 
 Demography (date of birth) 
 Concomitant medication (description of other medication prescribed for more than     
7 days and taken within one month of randomization). 
 Type of menopause (see eligibility criteria) 
 Clinical examination 
 Mammography (pre-surgery) 
 
10.2 On Study  
 To be recorded: 
 Trial Events (End-points): see Chapter 6 
 Concomitant medication 
 
Evaluation schedule 
After randomization, patients will visit the center every 3 months for the first year. Thereafter, 
during year 2, 3, 4 and 5 after randomization, patients will visit the center every 6 months. 
During the visits, physical examination will be performed, concomitant medication will be 
registered and adverse events (if any) will be recorded. Yearly, a mammography will be 
performed. Furthermore, blood chemistry and hematology will be assessed, according to local 
policy. 
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TRIAL FLOWCHART 
Year 1 2 3 4 5 Follow-up 5 
Visit 0 
 
1 
 
2 
 
3 4 5 6 7 8 9 10 11 12  
Month 0 3 6 9 12 18 24 30 36 42 48 54 60  
 
              
Medical History X              
Initial Data  1 X              
Clinical examination  X X X X X X X X X X X X X X  
Hematology/Biochem  2 X              
Events (if present)  X X X X X X X X X X X X X 
Co-medication  3 X X X X X X X X X X X X X X 6 
Adverse events  4 X X X X X X X X X X X X X X 7 
Mammography     X    X  X  X  X  X X 
 
Notes: 
1.   Type of primary surgery, tumor pathology and characteristics, pre- existing medical 
conditions  
  
2.  Hb, WBC, PLT, ASAT/ALAT, creatinine, Alkaline Phosphatase, Calcium, Protein and 
Glucose 
 
3.  Any medication prescribed and used for more than 7 consecutive days 
 
4.  As described in the chapter “Adverse Events” 
 
5.  Yearly, according to the Dutch National Guidelines 
 
6.  Not mandatory 
 
7.  Only if they occur within 30 days after last dose of study drug (see also 11.2) 
 
10.3 Follow-up  
Follow-up after relapse should be according to the schedule in the Trial Flowchart, unless 
otherwise clinically indicated. 
All patients should have long-term follow-up, irrespective of whether they have been withdrawn 
from treatment prematurely. The anticipated follow-up frequency is once every year, unless 
otherwise clinically indicated. 
To be recorded:  
- Trial Events (End-points): see Chapter 6 
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11 ADVERSE EVENTS 
 
11.1 Adverse Event Definition 
11.1.1. An adverse event is defined as any untoward medical occurrence in a subject to whom a 
drug has been administered; the event does not need to have a causal relationship to the study 
drug(s). All such medical occurrences from the first dose of study medication to 30 days after the 
last dose of study drug(s) are reported as adverse events and must be recorded on the CRF. 
 
In addition, any known untoward event that occurs subsequent to the adverse event reporting 
period that the Investigator assesses as possibly related to the study drug(s) should also be 
considered an adverse event. 
 
11.1.2 A pre-existing condition should not be reported as an adverse event unless the condition 
worsens or episodes increase in frequency during the adverse event reporting period. 
 
11.1.3 Symptoms of the targeted cancer should not be reported as adverse events. 
 
11.1.4 A serious adverse event (SAE) is one that is fatal or life- threatening (i.e., results in an 
immediate risk of death); is permanently or substantially disabling; requires or prolongs 
hospitalization (only if related to an unexpected complication); or is a congenital anomaly, a new 
cancer or medication overdose.  This category also includes any other event the Investigator 
judges to be serious or which would suggest a significant hazard, contra-indication, side effect or 
precaution. 
 
11.1.5 An unexpected event is one that is not listed as a known toxicity of the investigational 
drug in the protocol, the consent form, the package insert, or the Investigator’s brochure. 
 
11.2 Adverse Event Recording 
Toxicity’s will be reviewed using the National Cancer Institute Common Toxicity Criteria (NCI 
CTC version 2.0) (Appendix I).  Any toxicity’s incurred but not categorized by the NCI CTC 
should be graded by the physician and be recorded using a scale of (1) mild, (2) moderate, or (3) 
severe, on the Case Report Form (CRF), as defined in Appendix IV. 
 
All adverse events will be recorded on the CRF through 30 days following last treatment dose on 
study or until the start of other anti-cancer treatment, whichever occurs first.  Additionally, all 
adverse events deemed possibly related to the study products (exemestane or tamoxifen) will be 
followed until resolution (or the Investigator assesses them to be chronic or stable) or initiation 
of other anti-cancer therapy, whichever occurs first.   
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11.3 Serious Adverse Event Recording 
All serious adverse events occurring during the treatment period and within 30 days of the last 
treatment dose on study must be reported. Any SAE possibly or probably related to the study 
treatment should be reported by fax to the Central Data Center in The Netherlands within 24 
hours of the initial observation of the event. Details should be documented on a specified 
Serious Adverse Event Form. 
The Serious Adverse Event Form must be completed and returned to the Central Data Center 
within 5 calendar days of the initial observation of the event. The SAE form should be signed by 
the investigator  
 
PLEASE SEND THE ORIGINAL REPORT TO: 
 
Central Data Center Dutch Team Study Group 
Leids Universitair Medisch Centrum (LUMC) 
Department of Surgery K-6-R 
P.O. Box 9600 
2300 RC  LEIDEN 
The Netherlands 
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12 DETERMINATION OF EFFICACY 
 
Patients on both treatment arms are followed at specified intervals and evaluated for evidence of 
relapse. Required evaluations at each time point are specified in this protocol (Section 10.2).   
 
12.1 Relapse Free Survival 
Relapse free survival is defined as the time from first drug administration to the earliest recorded 
documentation of relapse, or death due to any cause in the absence of previous documentation of 
relapse. Patients without relapse may be withdrawn from treatment for a variety of reasons (page 
21), and their relapse time will be censored. Where available, patients withdrawn because of a 
specific event will be censored at the date of the specific event or the date of recorded 
confirmation of event. If such a date is not appropriate or available, the patient will be censored 
at date of last follow-up.  
 
12.2 Overall Survival 
Overall survival is defined as the time from first drug administration to date of death. In the 
absence of confirmation of death, survival time will be censored to last date of follow-up. 
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13 STATISTICAL CONSIDERATIONS 
 
13.1 Organization of the TEAM Trial 
The TEAM Trial is organized as a single trial consisting of 8 separate managed country specific 
trials with 10 participating countries. Each country has its own protocol, CRF, and database. The 
trials are very similar to each other in design, with efforts made to ensure that data are 
compatible. The countries have their own side studies that they are running with questions, 
which they will be able to answer with their own patients. For the primary analysis of RFS, the 
overall results will be pooled. Each country specific trial has a Principal Investigator and a 
Country Trial Committee. 
 
The overall trial is managed by a Steering Committee consisting of all of the Principal 
Investigators, a statistician from the Central Data Centre, and representatives from the 
sponsoring company. There is an Independent Data Monitoring Committee consisting of a 
biostatistician and 4 oncologists, 2 each from Europe and North America who meet regularly to 
evaluate the progress of the trial and make recommendations on whether to continue. There is 
also a sub-committee of the Steering Committee called the Data Management Committee, which 
consists of 4 of the Principal Investigators, the biostatistician from the Central Data Center and 
representatives of the sponsoring company. 
 
The Central Data Center is located at the Leiden University Medical Center in the Netherlands. 
Data from all the countries are collected in the central database regularly to prepare for DMC 
meetings and to monitor the progress of the trial.  
 
13.2 Hypothesis 
13.2.1 Hypothesis and Sample Size calculation for 3 years analysis 
 
Patients in the tamoxifen arm switch to exemestane after 2¾ years  (range from 2½ -3 years) of 
treatment with tamoxifen. Analysis of the comparison between tamoxifen and exemestane in 
RFS will be the first primary analysis of this protocol. For this analysis, patients in the switch 
arm will be censored at the time of switch; patients in the upfront exemestane arm will be 
censored at 2¾ years, halfway between 2½ and 3 years.  
The ATAC paper (by Aman U. Buzdar) provided updated information comparing tamoxifen and 
anastrozole (Clinical Cancer research, Vol. 10, 2004). The 3-yr DFS rate was estimated 
approximately 0.9 for the tamoxifen arm. If we still assume the HR of RFS to be 1.28 between 
the two treatment groups (tamoxifen arm / exemestane arm), at least 720 events are required to 
detect the statistical significance in RFS with the significant level of 0.05 (2-sided) and 90% of 
power. Assume that patients were uniformly entered into the study in 3 years and 3-yr RFS rate 
is 0.9 for the tamoxifen arm, 8740 evaluable patients are required in order to observe 720 
events. It is estimated that 720 events will be observed at 2¾ years after the last patient is 
randomized. 
 
Timing of the first primary analysis on RFS: approximately 2¾ years after the last patient has 
been enrolled. 
 
Based on this, the following hypotheses are stated: 
 
A: under the null-hypothesis (H0) if there is no difference between the two treatments, assuming 
the 3 years RFS is 90%, then: treatment arm A (tamoxifen) and treatment arm B (exemestane) 
will show a 3 years RFS of 90%.  
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B: under the alternative hypothesis (H1) that the HR is 1.28 for the first 2¾ years   
Based on these assumptions and considering a significance level () of 0.05, a power (1-) of 
0.90 and a two-sided test, approximately 8740 randomized patients will be required. 
 
The Data Management Committee for the trial will monitor the event rate and may consider 
whether there is a need to use a tighter hazard ratio. Any decision to work with a smaller hazard 
ratio will mean more events will need to be observed and the trial duration will be longer. 
 
13.2.2 Rationale for 5 years analysis 
It is expected that the hazard ratio (HR) of the switch-arm with respect to the exemestane arm is 
considerably different before (HR=1.28) and after switch (lower). This makes the Cox 
proportional hazards assumption (namely, a constant HR over the whole five years) a priori 
unlikely to be true and hence standard survival analysis like the Cox regression model and the 
log-rank test, and standard sample size calculations, based on a single hazard ratio, invalid. 
Moreover, it is very hard to pose hypotheses concerning the anticipated difference in RFS 
between the two treatment arms at 5 years. Given these two considerations, we choose a non-
hypothesis driven analysis at 5 years, with the second primary endpoint being 5-years RFS as a 
point estimate obtained from the Kaplan-Meier survival estimates of the two treatment arms. The 
difference in 5-years RFS between the treatment arms will be reported, along with its standard 
error (SE) and an associated 95%-confidence interval. 
At the first primary analysis at 2½ -3 years, it will be computed (given the accrual of the already 
included patients) how much additional follow-up (with a maximum of 5 years after the last 
patient has been enrolled) is required to be able to estimate the difference in 5-years RFS 
between the treatment arms with a pre-specified precision, a standard error of at most 0.01. As 
the standard error of 3-years RFS at the first primary analysis, given the hypothesized hazard 
rates, is approximately 0.006, this should be feasible.  
 
13.3 Patient enrolment 
The trial will remain open to accrual in all countries until 8700 core patients are accrued. After 
this target has been reached, some countries may continue accrual until side studies have reached 
their accrual targets. Patients enrolled after the core accrual is completed will be included in the 
final analysis. 
 
13.4 Stratification 
At randomization, patients will be stratified by center and by treatment with 
chemotherapy (yes/no) and time period between surgery and start of hormonal therapy, if 
applicable. 
 
13.5 Rationale for Type of Analysis and Trial Organization 
This country specific study is designed to be a part of a larger group of studies that will be 
pooled in order to test RFS and OS. A total of 720 events are needed in order to test for a 
reduction in the RFS between the two treatment arms when the true hazard ratio is 1.28 (3 years 
relapse free survival of 90%) 
 
The rationale for testing using multiple studies and testing using a pooled analysis as opposed to 
conducting one large multi-national study is that many additional questions of interest that do not 
require such a large sample size can be answered. The reporting of one study’s main objective 
will not be delayed while waiting for the other studies to finish and therefore, not delaying the 
release of important clinical results. In addition, the CRF’s will be more manageable and data 
clean up will be simplified.  
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The data from all the trials will be collected in a central database located at the Leiden University 
Medical Center, Netherlands periodically throughout the trial. Interim analyses and the final 
analysis for the combined trial will be conducted in this central location.  
There are six major areas in which a meta-analysis might lead to misinterpretation: study design, 
combinability, heterogeneity of studies, statistical analysis, sensitivity analysis, and control of 
bias. The confidence one places in the results of any such meta-analysis is limited by the 
combinability of the studies; that is inherent differences in design, sample, and endpoints. Thus, 
the greater the similarity of the studies with regard to those points, the greater the confidence one 
may have in the results of a meta-analysis.   
The TEAM Trial, of which this trial is a part, is different from trials usually analyzed with meta-
analytic methods. The data in this trial can be pooled because the studies will all be similar in 
patient population, design, duration, endpoints, and will use similar forms for data collection.  
Care will be taken to test for heterogeneity of studies and to incorporate any such heterogeneity 
into the statistical analysis.  As this is a pre-specified pooling it will not be subject to the usual 
issues facing a meta-analysis such as publication bias (the phenomenon in which studies with 
positive results are more likely to be published than studies with negative results), which is often 
the largest bias of meta-analysis results. 
 
13.6 Efficacy Analysis 
13.6.1 Primary Efficacy Analysis 
The primary efficacy endpoint will be the cumulative probability of being relapse-free at 2¾ 
years post-treatment start (before tamoxifen arm switching to exemestane), as estimated from the 
Kaplan-Meier curves for each treatment arm. The difference in RFS will be assessed using the 
log-rank test at the 0.05 significance level.  
 
13.6.2 Key Secondary Efficacy Analysis 
The key secondary efficacy endpoint will be relapse-free survival at 5 years post-treatment start 
as a point estimate obtained from the Kaplan-Meier survival estimates of the two treatment arms. 
The difference in 5-years RFS between the treatment arms will be reported, along with its 
standard error (SE) and an associated 95%-confidence interval. 
 
The difference in this cumulative probability will be assessed using the log-rank test for Kaplan-
Meier curves at the p = 0,05 significance level. Ninety-five percent confidence intervals on the 
treatment estimates and the hazard ratio will be computered. Cox regression models will be used 
to explore the influence of stratification and prognostic factors on relapse-free survival. Each 
factor will be evaluated for inclusion in the multivariate model, and only factors significant at the 
10% level will be considered. 
 
13.6.3 Other Secondary Efficacy Analyses 
Other secondary efficacy endpoints will be assessed as above.  
 
13.6.4 Safety Analysis 
Safety analyses will include all randomized subjects who received at least one dose of study 
medication. Adverse events will be recorded and graded according to the CTC classification 
system.   
 
The frequency and percentage of patients experiencing a specific adverse event will be tabulated 
by treatment group.  Adverse events will be summarized by worst CTC grade and reported 
relationship with study group.  In the case that the adverse events or event frequencies are judged 
to be clinically important, a Chi-square test will be used to analyze the difference between the 
treatment groups. 
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14 INDEPENDENT DATA MONITORING COMMITTEE 
 
An Independent Data Monitoring Committee (IDMC) will be established which will be 
independent of the trial organizers. 
Interim analysis of side effects, tolerability, relapse -free and overall survival for all randomized 
patients will be performed at 2 years after the start of the study. All these analyses will be 
supplied in strict confidence by the trial organization to the IDMC together with any other 
analyses that the IDMC may request. 
 
The IDMC reserves the right to release any data on outcome or side-effects through the chairman 
of the Steering Committee to participating investigators if it determines at any stage that the 
combined evidence from this and other studies justifies it. This includes the circulation of the 
toxicity data if the IDMC believes that this may lead to an improvement in patient care. 
 
15 STOPPING RULES / DISCONTINUATION CRITERIA 
 
The Dutch TEAM Study Group reserves the right to discontinue the study prior to inclusion of 
the intended number of subjects, but intends only to exercise this right for valid scientific or 
administrative reasons.  After such a decision, the investigator must contact all participating 
subjects within four weeks. Study materials must be collected and case report forms completed 
to the extent possible. 
 
16 ETHICAL REQUIREMENTS 
 
16.1 Ethical Conduct of the Study  
The Investigator will ensure that the study is performed in accordance with the recommendations 
guiding physicians in biomedical research involving human subjects adopted by the 18th World 
Medical Assembly, Helsinki, Finland, 1964 and later revisions (see Appendix III) or the laws 
and regulations of the country, whichever provide greater protection for the subject. 
It is the responsibility of the investigator to obtain approval of the trial protocol and any 
subsequent amendment from the IRB/IEC. All correspondence with the IRB/IEC should be filed 
by the Investigator. Copies of the IRB/IEC approval should be forwarded to the Central Data 
Center of the Dutch Team Study Group. 
 
It is the responsibility of the investigator to give each patient (or the patient’s legally authorized 
representative), prior to inclusion in the trial, full and adequate verbal and written information 
regarding the objective and procedures of the trial and the possible risks involved. The patients 
must be informed about their right to withdraw from the trial and the possible risk involved. 
Written patient information (included as appendix to the protocol) must be given to each patient 
before enrolment. The written patient information enclosed is a sample, but may only be changed 
on request of the Medical Ethical Committee. I it is the responsibility of the investigator to 
obtain signed informed consent from all patients prior to inclusion in the trial. 
 
A copy of the patient information sheet is included in Appendix V. All amendments and 
translations to the patient information sheet must be agreed by the TEAM Study Group, prior to 
trial commencement. 
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Patient identification data (initials and hospital number) will be required at randomization to 
assist with long-term follow-up. TEAM Study Group will preserve the confidentiality of patients 
taking part in this study.  
16.2 Changes to the Final Study Protocol 
Any variation in procedure from that specified in the final Study Protocol may lead to the results 
of the trial being questioned and in some cases rejected.  Any proposed protocol change must 
therefore be discussed with and approved by the TEAM Study Group and is submitted for Ethics 
Committee/Institutional Review Board and Health Authority (when applicable) approval or 
notification, in accordance with local regulatory requirements.  Any protocol change should be 
documented in a Protocol Amendment.  Changes not pre-approved by the Team Study Group 
may be considered as protocol deviations. 
 
17 PUBLICATION POLICY 
 
The results of the pooled analysis will be published in the name of the TEAM Trial in a peer-
reviewed journal on behalf of all collaborators. All presentations and publications, including 
abstracts, relating to the main trial must be authorized by the TEAM Steering Committee. The 
individual countries will be allowed to publish their efficacy results, however, the publication of 
efficacy results from the pooled analysis will take precedence over efficacy result publications of 
individual countries, unless the Steering Committee decides otherwise.  
 
Individual countries will be encouraged to publish the results of their side studies as soon as the 
data are mature. The Principal Investigator and Country Trial Committee will have the 
responsibility to make decisions about publications of these results and authorship. 
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APPENDIX I Common Toxicity Criteria (CTC, version 2.0) 
 
Grade 
Toxicity 0 1 2 3 4 
ALLERGY/IMMUNOLOGY 
Allergic reaction/ 
hypersensitivity  
(including drug fever) 
None transient rash, drug 
fever < 38°C 
(<100.4°F) 
Urticaria, drug 
fever  38°C 
(100.4°F), and/or 
asymptomatic 
bronchospasm 
symptomatic 
bronchospasm, 
requiring parenteral 
medication(s), with or 
without urticaria; 
allergy-related 
edema/angioedema 
Anaphylaxis 
Note: Isolated urticaria, in the absence of other manifestations of an allergic or hypersensitivity reaction, is graded in the 
DERMATOLOGY/SKIN category. 
Allergic rhinitis  
(including sneezing, nasal 
stuffiness, postnasal drip) 
None mild, not requiring 
treatment 
Moderate, requiring 
treatment 
- - 
Autoimmune reaction None serologic or other 
evidence of 
autoimmune 
reaction but patient 
is asymptomatic 
(e.g., vitiligo), all 
organ function is 
normal and no 
treatment is 
required 
Evidence of 
autoimmune 
reaction involving a 
non-essential organ 
or function (e.g., 
hypothyroidism), 
requiring treatment 
other than 
immunosuppressive 
drugs 
reversible autoimmune 
reaction involving 
function of a major 
organ or other toxicity 
(e.g., transient colitis or 
anemia), requiring 
short-term 
immunosuppressive 
treatment 
autoimmune 
reaction 
causing major 
grade 4 organ 
dysfunction; 
progressive and 
irreversible 
reaction; long-
term 
administration 
of high-dose 
immuno-
suppressive 
therapy 
required 
Also consider Hypothyroidism, Colitis, Hemoglobin, Hemolysis. 
Serum sickness None - - Present - 
Urticaria is graded in the DERMATOLOGY/SKIN category if it occurs as an isolated symptom. If it occurs with other manifestations of 
allergic or hypersensitivity reaction, grade as Allergic reaction/hypersensitivity above. 
Vasculitis None mild, not requiring 
treatment 
symptomatic, 
requiring 
medication 
requiring steroids ischemic 
changes or 
requiring 
amputation 
Allergy/Immunology-
Other 
(Specify, __________) 
None Mild moderate Severe life-threatening 
or disabling 
AUDITORY/HEARING 
Conductive hearing loss is graded as Middle ear/hearing in the AUDITORY/HEARING category. 
Earache is graded in the PAIN category. 
External auditory canal Normal external otitis with 
erythema or dry 
desquamation 
external otitis with 
moist desquamation 
external otitis with 
discharge, mastoiditis 
necrosis of the 
canal soft 
tissue or bone 
Note: Changes associated with radiation to external ear (pinnae) are graded under Radiation dermatitis in the DERMATOLOGY/SKIN 
category. 
Inner ear/hearing Normal hearing loss on 
audiometry only 
tinnitus or hearing 
loss, not requiring 
hearing aid or 
treatment 
tinnitus or hearing loss, 
correctable with hearing 
aid or treatment 
severe 
unilateral or 
bilateral 
hearing loss 
(deafness), not 
correctable 
Middle ear/hearing Normal serous otitis 
without subjective 
decrease in hearing 
serous otitis or 
infection requiring 
medical 
intervention; 
subjective decrease 
in hearing; rupture 
of tympanic 
membrane with 
discharge 
otitis with discharge, 
mastoiditis or 
conductive hearing loss 
necrosis of the 
canal soft 
tissue or bone 
Auditory/Hearing-Other 
(Specify, __________) 
Normal Mild moderate Severe life-threatening 
or disabling 
BLOOD/BONE MARROW 
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Grade 
Toxicity 0 1 2 3 4 
Bone marrow cellularity normal for age mildly 
hypocellular or 
25% reduction 
from normal 
cellularity for age 
moderately 
hypocellular or >25 
-  50% reduction 
from normal 
cellularity for age 
or >2 but <4 weeks 
to recovery of 
normal bone 
marrow cellularity 
severely hypocellular or 
>50 -  75% reduction 
in cellularity for age or 
4 - 6 weeks to recovery 
of normal bone marrow 
cellularity 
aplasia or >6 
weeks to 
recovery of 
normal bone 
marrow 
cellularity 
Normal ranges:      
children ( 18 years) 90% cellularity 
average 
    
younger adults (19-59) 60-70% cellularity 
average 
    
older adults ( 60 years) 50% cellularity 
average 
    
Note: Grade Bone marrow cellularity only for changes related to treatment not disease. 
CD4 count WNL < LLN - 500/mm3 200 - < 500/mm3 50 - < 200/mm3 < 50/mm3 
Haptoglobin Normal Decreased - Absent - 
Hemoglobin (Hgb) WNL < LLN - 10.0 g/dl 
< LLN - 100 g/L 
< LLN - 6.2 
mmol/L 
8.0 - < 10.0 g/dl 
80 - < 100 g/L 
4.9 - < 6.2 mmol/L 
6.5 - < 8.0 g/dl 
65 - 80 g/L 
4.0 - < 4.9 mmol/L 
< 6.5 g/dl 
< 65 g/L 
< 4.0 mmol/L 
Note: The following criteria may be used for leukemia studies or bone marrow infiltrative/myelophthisic process if the protocol so specifies. 
For leukemia studies or 
bone marrow infiltrative/ 
myelophthisic processes 
WNL 10 - <25% 
decrease from 
pretreatment 
25 - <50% decrease 
from pretreatment 
50 - <75% decrease 
from pretreatment 
75% decrease 
from 
pretreatment 
Hemolysis (e.g., immune 
hemolytic anemia, drug-
related hemolysis, other) 
None only laboratory 
evidence of 
hemolysis [e.g., 
direct antiglobulin 
test (DAT, 
Coombs’) 
schistocytes] 
evidence of red cell 
destruction and  
2gm decrease in 
hemoglobin, no 
transfusion 
requiring transfusion 
and/or medical 
intervention (e.g., 
steroids) 
catastrophic 
consequences 
of hemolysis 
(e.g., renal 
failure, 
hypotension, 
bronchospasm, 
emergency 
splenectomy) 
Also consider Haptoglobin, Hgb. 
Leukocytes (total WBC) WNL < LLN - 3.0 x 109 
/L 
< LLN - 3000/mm3 
2.0 - < 3.0 x 109 
/L 
2000 - < 
3000/mm3 
1.0 - < 2.0 x 109 /L 
1000 - < 2000/mm3 
< 1.0 x 109 /L 
< 1000/mm3 
For BMT studies: WNL 2.0 - <3.0 X 
109/L 
2000 - 
<3000/mm3 
1.0 - <2.0 x 109 /L 
1000 - <2000/mm3 
0.5 - <1.0 x 109 /L 
500 - <1000/mm3 
<0.5 x 109 /L 
<500/mm3 
Note: The following criteria using age, race and sex normal values may be used for pediatric studies if the protocol so specifies. 
  75 - <100% LLN 50 - <75% LLN 25 - 50% LLN <25% LLN 
Lymphopenia WNL <LLN - 1.0 x 109 
/L 
<LLN - 1000/mm3 
0.5 - <1.0 x 109 /L
500 - <1000/mm3 
<0.5 x 109 /L 
<500/mm3 
- 
Note: The following criteria using age, race, and sex normal values may be used for pediatric studies if the protocol so specifies. 
  75-<100%LLN 50-<75%LLN 25-<50%LLN <25%LLN 
Neutrophils/granulocytes 
(ANC/AGC) 
WNL 1.5 - <2.0 x 109 
/L 
1500 - 
<2000/mm3 
1.0 - <1.5 x 109 /L
1000 - <1500/mm3 
0.5 - <1.0 x 109 /L 
500 - <1000/mm3 
< 0.5 x 109 /L 
< 500/mm3 
For BMT: WNL 1.0 - <1.5 x 109 
/L 
1000 - 
<1500/mm3 
0.5 - <1.0 x 109 /L
500 - <1000/mm3 
0.1 - <0.5 x 109 /L 
100 - <500/mm3 
<0.1 x 109 /L 
<100/mm3 
Note: The following criteria may be used for leukemia studies or bone marrow infiltrative/myelophthisic process if the protocol so specifies. 
For leukemia studies or 
bone marrow infiltrative/ 
myelophthisic process 
WNL 10 - <25% 
decrease from 
baseline 
25 - <50% decrease 
from baseline 
50 - <75% decrease 
from baseline 
75% decrease 
from baseline 
Platelets WNL < LLN - <75.0 x 
109 /L 
< LLN - 
75000/mm3 
50.0 - < 75.0 x 109 
/L 
50000 - < 
75000/mm3 
10.0 - < 50.0 x 109 /L 
10000 - < 50000/mm3 
< 10.0 x 109 /L
< 10000/mm3 
For BMT: WNL 50.0 - <75.0 x 109 
/L 
50000 - 
<75000/mm3  
20.0 - <50.0 x 109 
/L 
20000 - 
<50000/mm3 
10.0 - <20.0 x 109 /L 
10000 - <20000/mm3 
<10.0 x 109 /L 
<10000/mm3 
Note: The following criteria may be used for leukemia studies or bone marrow infiltrative/myelophthisic process if the protocol so specifies. 
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Grade 
Toxicity 0 1 2 3 4 
For leukemia studies or 
bone marrow infiltrative/ 
myelophthisic process 
WNL 10 - <25% 
decrease from 
baseline 
25 - <50% decrease 
from baseline 
50 - <75% decrease 
from baseline 
75% decrease 
from baseline 
Transfusion: Platelets None - - Yes platelet 
transfusions 
and other 
measures 
required to 
improve 
platelet 
increment; 
platelet 
transfusion 
refractoriness 
associated with 
life-threatening 
bleeding. (e.g., 
HLA or cross 
matched 
platelet 
transfusions) 
For BMT: None 1 platelet 
transfusion in 24 
hours 
2 platelet 
transfusions in 24 
hours 
3 platelet transfusions 
in 24 hours 
platelet 
transfusions 
and other 
measures 
required to 
improve 
platelet 
increment; 
platelet 
transfusion 
refractoriness 
associated with 
life-threatening 
bleeding. (e.g., 
HLA or cross 
matched 
platelet 
transfusions) 
Also consider Platelets. 
Transfusion: pRBCs None - - Yes - 
For BMT: None 2 u pRBC 
(15cc/kg) in 24 
hours elective or 
planned 
 
 
3 u pRBC (>15 
30cc/kg) in 24 
hours elective or 
planned 
4 u pRBC (>30cc/kg) 
in 24 hours 
hemorrhage or 
hemolysis 
associated with 
life-threatening 
anemia; 
medical 
intervention 
required to 
improve 
hemoglobin 
Also consider Hemoglobin. 
Blood/Bone Marrow-
Other 
(Specify, __________) 
None Mild moderate Severe life-threatening 
or disabling 
CARDIOVASCULAR (ARRHYTHMIA) 
Conduction abnormality/ 
Atrioventricular heart 
block 
None asymptomatic, not 
requiring treatment 
(e.g., Mobitz type I 
second-degree AV 
block, 
Wenckebach) 
symptomatic, but 
not requiring 
treatment 
symptomatic and 
requiring treatment 
(e.g., Mobitz type II 
second-degree AV 
block, third-degree AV 
block) 
life-threatening 
(e.g., 
arrhythmia 
associated with 
CHF, 
hypotension, 
syncope, 
shock) 
Nodal/junctional 
arrhythmia/dysrhythmia 
None asymptomatic, not 
requiring treatment 
symptomatic, but 
not requiring 
treatment 
symptomatic and 
requiring treatment 
life-threatening 
(e.g., 
arrhythmia 
associated with 
CHF, 
hypotension, 
syncope, 
shock) 
Palpitations None Present - - - 
Note: Grade palpitations only in the absence of a documented arrhythmia. 
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Grade 
Toxicity 0 1 2 3 4 
Prolonged QTc interval 
(QTc > 0.48 seconds) 
None asymptomatic, not 
requiring treatment 
symptomatic, but 
not requiring 
treatment 
symptomatic and 
requiring treatment 
life-threatening 
(e.g., 
arrhythmia 
associated with 
CHF, 
hypotension, 
syncope, 
shock) 
Sinus bradycardia None asymptomatic, not 
requiring treatment 
symptomatic, but 
not requiring 
treatment 
symptomatic and 
requiring treatment 
life-threatening 
(e.g., 
arrhythmia 
associated with 
CHF, 
hypotension, 
syncope, 
shock) 
Sinus tachycardia None asymptomatic, not 
requiring treatment 
symptomatic, but 
not requiring 
treatment 
symptomatic and 
requiring treatment of 
underlying cause 
- 
Supraventricular 
arrhythmias (SVT/atrial 
fibrillation/ flutter) 
None asymptomatic, not 
requiring treatment 
symptomatic, but 
not requiring 
treatment 
symptomatic and 
requiring treatment 
life-threatening 
(e.g., 
arrhythmia 
associated with 
CHF, 
hypotension, 
syncope, 
shock) 
Syncope (fainting) is graded in the NEUROLOGY category. 
Vasovagal episode None - present without loss 
of consciousness 
present with loss of 
consciousness 
- 
Ventricular arrhythmia 
(PVCs/bigeminy/trigemin
y/ 
ventricular tachycardia) 
None asymptomatic, not 
requiring treatment 
symptomatic, but 
not requiring 
treatment 
symptomatic and 
requiring treatment 
life-threatening 
(e.g., 
arrhythmia 
associated with 
CHF, 
hypotension, 
syncope, 
shock) 
Cardiovascular/ 
Arrhythmia-Other  
(Specify, ___________) 
None asymptomatic, not 
requiring treatment 
symptomatic, but 
not requiring 
treatment 
symptomatic, and 
requiring treatment of 
underlying cause 
life-threatening 
(e.g., 
arrhythmia 
associated with 
CHF, 
hypotension, 
syncope, 
shock) 
CARDIOVASCULAR (GENERAL) 
Acute vascular leak 
syndrome 
Absent - symptomatic, but 
not requiring fluid 
support 
respiratory compromise 
or requiring fluids 
life-
threatening; 
requiring 
pressor support 
and/or 
ventilatory 
support 
Cardiac- 
ischemia/infarction 
None non-specific T-
wave flattening or 
changes 
asymptomatic, ST- 
and T- wave 
changes suggesting 
ischemia 
angina without evidence 
of infarction 
acute 
myocardial 
infarction 
Cardiac left ventricular 
function 
Normal asymptomatic 
decline of resting 
ejection fraction of 
 10% but < 20% 
of baseline value; 
shortening fraction 
 24% but < 30% 
asymptomatic but 
resting ejection 
fraction below LLN 
for laboratory or 
decline of resting 
ejection fraction  
20% of baseline 
value; < 24% 
shortening fraction 
CHF responsive to 
treatment 
severe or 
refractory CHF 
or requiring 
intubation 
CNS cerebrovascular ischemia is graded in the NEUROLOGY category. 
Cardiac troponin I (cTnI) Normal - - levels consistent with 
unstable angina as 
defined by the 
manufacturer 
levels 
consistent with 
myocardial 
infarction as 
defined by the 
manufacturer 
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Grade 
Toxicity 0 1 2 3 4 
Cardiac troponin T (cTnT) Normal  0.03 - < 0.05 
ng/ml 
 0.05 - < 0.1 ng/ml  0.1 - < 0.2 ng/ml  0.2 ng/ml 
Edema None asymptomatic, not 
requiring therapy 
symptomatic, 
requiring therapy 
symptomatic edema 
limiting function and 
unresponsive to therapy 
or requiring drug 
discontinuation 
anasarca 
(severe 
generalized 
edema) 
Hypertension None asymptomatic, 
transient increase 
by >20 mmHg 
(diastolic) or to > 
150/100* if 
previously WNL; 
not requiring 
treatment 
recurrent or 
persistent or 
symptomatic 
increase by > 20 
mmHg (diastolic) 
or to > 150/100* if 
previously WNL; 
not requiring 
treatment 
requiring therapy or 
more intensive therapy 
than previously 
hypertensive 
crisis 
*Note: For pediatric patients, use age and sex appropriate normal values > 95th percentile ULN. 
Hypotension None changes, but not 
requiring therapy 
(including transient 
orthostatic 
hypotension) 
requiring brief fluid 
replacement or 
other therapy but 
not hospitalization; 
no physiologic 
consequences 
requiring therapy and 
sustained medical 
attention, but resolves 
without persisting 
physiologic 
consequences 
shock 
(associated 
with acidemia 
and impairing 
vital organ 
function due to 
tissue 
hypoperfusion) 
Also consider Syncope (fainting). 
Note: Angina or MI is graded as Cardiac- ischemia/infarction in the CARDIOVASCULAR (GENERAL) category. 
For pediatric patients, systolic BP 65 mmHg or less in infants up to 1 year old and 70 mmHg or less in children older than 1 year of age, use 
two successive or three measurements in 24 hours. 
Myocarditis None - - CHF responsive to 
treatment 
severe or 
refractory CHF 
Operative injury of 
vein/artery 
None primary suture 
repair for injury, 
but not requiring 
transfusion 
primary suture 
repair for injury, 
requiring 
transfusion 
vascular occlusion 
requiring surgery or 
bypass for injury 
myocardial 
infarction; 
resection of 
organ (e.g., 
bowel, limb) 
Pericardial effusion/ 
pericarditis 
None asymptomatic 
effusion, not 
requiring treatment 
pericarditis (rub, 
ECG changes, 
and/or chest pain) 
physiologic 
consequences resulting 
from symptoms 
tamponade 
(drainage or 
pericardial 
window 
required) 
Peripheral arterial 
ischemia 
None - brief episode of 
ischemia managed 
non-surgically and 
without permanent 
deficit 
requiring surgical 
intervention 
life-threatening 
or with 
permanent 
functional 
deficit (e.g., 
amputation) 
Phlebitis (superficial) None - present - - 
Note: Injection site reaction is graded in the DERMATOLOGY/SKIN category. 
 Thrombosis/embolism is graded in the CARDIOVASCULAR (GENERAL) category. 
Syncope (fainting) is graded in the NEUROLOGY category. 
Thrombosis/embolism None - deep vein 
thrombosis, not 
requiring 
anticoagulant 
deep vein thrombosis, 
requiring anticoagulant 
therapy 
embolic event 
including 
pulmonary 
embolism 
Vein/artery operative injury is graded as Operative injury of vein/artery in the CARDIOVASCULAR (GENERAL) category. 
Visceral arterial ischemia 
(non-myocardial) 
None - brief episode of 
ischemia managed 
non-surgically and 
without permanent 
deficit 
requiring surgical 
intervention 
life-threatening 
or with 
permanent 
functional 
deficit (e.g., 
resection of 
ileum) 
Cardiovascular/ 
General-Other  
(Specify, 
______________) 
None Mild moderate Severe life-threatening 
or disabling 
COAGULATION 
Note: See the HEMORRHAGE category for grading the severity of bleeding events. 
DIC  
(disseminated 
intravascular coagulation) 
Absent - - laboratory findings 
present with no 
bleeding 
laboratory 
findings and 
bleeding 
Also grade Platelets. 
Note: Must have increased fibrin split products or D-dimer in order to grade as DIC. 
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Grade 
Toxicity 0 1 2 3 4 
Fibrinogen WNL 0.75 - <1.0 x 
LLN 
0.5 - <0.75 x LLN 0.25 - <0.5 x LLN <0.25 x LLN 
Note: The following criteria may be used for leukemia studies or bone marrow infiltrative/myelophthisic process if the protocol so specifies. 
For leukemia studies: WNL <20% decrease 
from pretreatment 
value or LLN 
20 - <40% 
decrease from 
pretreatment value 
or LLN 
40 - <70% decrease 
from pretreatment value 
or LLN 
<50 mg% 
Partial thromboplastin 
time (PTT) 
WNL > ULN -  1.5 x 
ULN 
> 1.5 -  2 x ULN >2 x ULN - 
Phelbitis is graded in the CARDIOVASCULAR (GENERAL) category. 
Prothrombin time (PT) WNL > ULN -  1.5 x 
ULN 
> 1.5 -  2 x ULN >2 x ULN - 
Thrombosis/embolism is graded in the CARDIOVASCULAR (GENERAL) category. 
Thrombotic 
microangiopathy (e.g., 
thrombotic 
thrombocytopenic 
purpura/TTP or hemolytic 
uremic syndrome/HUS) 
Absent - - laboratory findings 
present without clinical 
consequences 
laboratory 
findings and 
clinical 
consequences, 
(e.g., CNS 
hemorrhage/ 
bleeding or 
thrombosis/ 
embolism or 
renal failure) 
requiring 
therapeutic 
intervention 
For BMT: - evidence of RBC 
destruction 
(schistocytosis) 
without clinical 
consequences 
evidence of RBC 
destruction with 
elevated creatinine 
(3 x ULN) 
evidence of RBC 
destruction with 
creatinine (>3 x ULN) 
not requiring dialysis 
evidence of 
RBC 
destruction 
with renal 
failure 
requiring 
dialysis and/or 
encephalopathy 
Also consider Hemoglobin (Hgb), Platelets, Creatinine. 
Note: Must have microangiopathic changes on blood smear (e.g., schistocytes, helmet cells, red cell fragments). 
Coagulation-Other 
(Specify, __________) 
None Mild moderate Severe life-threatening 
or disabling 
CONSTITUTIONAL SYMPTOMS 
Fatigue 
(lethargy, malaise, 
asthenia) 
None increased fatigue 
over baseline, but 
not altering normal 
activities 
moderate (e.g., 
decrease in 
performance status 
by 1 ECOG level or 
20% Karnofsky or 
Lansky) or causing 
difficulty 
performing some 
activities 
severe (e.g., decrease in 
performance status by 
2 ECOG levels or 40% 
Karnofsky or Lansky) or 
loss of ability to 
perform some activities 
bedridden or 
disabling 
Note: See Appendix III for performance status scales. 
Fever (in the absence of 
neutropenia, where 
neutropenia is defined as 
AGC < 1.0 x 109/L) 
None 38.0 - 39.0°C 
(100.4 - 102.2°F) 
39.1 - 40.0°C 
(102.3 - 104.0°F ) 
> 40.0°C (>104.0°F ) 
for < 24hrs 
> 40.0°C 
(>104.0°F ) for 
> 24hrs 
Also consider Allergic reaction/hypersensitivity. 
Note: The temperature measurements listed above are oral or tympanic. 
Hot flashes/flushes are graded in the ENDOCRINE category. 
Rigors, chills None mild, requiring 
symptomatic 
treatment (e.g., 
blanket) or non-
narcotic 
medication 
severe and/or 
prolonged, 
requiring narcotic 
medication 
not responsive to 
narcotic medication 
- 
Sweating  
(diaphoresis) 
Normal mild and 
occasional 
frequent or 
drenching 
- - 
Weight gain < 5% 5 - <10% 10 - <20%  20% - 
Also consider Ascites, Edema, Pleural effusion. 
Weight gain - veno-
occlusive disease (VOD) 
     
Note: The following criteria is to be used ONLY for weight gain associated with Veno-Occlusive Disease. 
 <2% 2 - <5% 5 - <10%  10% or as ascities 10% or fluid 
retention 
resulting in 
pulmonary 
failure 
 46(74)
TEAM-trial                                           Final protocol, including amendment 1 & 2                       November 10, 2004 
 
Grade 
Toxicity 0 1 2 3 4 
Weight loss < 5% 5 - <10% 10 - <20% 20% - 
Also consider Vomiting, Dehydration, Diarrhea. 
Constitutional Symptoms-
Other 
(Specify, __________) 
None Mild moderate Severe life-threatening 
or disabling 
DERMATOLOGY/SKIN 
Alopecia Normal mild hair loss pronounced hair 
loss 
- - 
Bruising  
(in absence of grade 3 or 4 
thrombocytopenia) 
None localized or in 
dependent area 
generalized - - 
Note: Bruising resulting from grade 3 or 4 thrombocytopenia is graded as Petechiae/purpura and Hemorrhage/bleeding with grade 3 or 4 
thrombocytopenia in the HEMORRHAGE category, not in the DERMATOLOGY/SKIN category. 
Dermatitis, focal 
(associated with high-dose 
chemotherapy and bone 
marrow transplant) 
None faint erythema or 
dry desquamation 
moderate to brisk 
erythema or a 
patchy moist 
desquamation, 
mostly confined to 
skin folds and 
creases; moderate 
edema 
confluent moist 
desquamation, 1.5 cm 
diameter, not confined 
to skin folds; pitting 
edema 
skin necrosis or 
ulceration of 
full thickness 
dermis; may 
include 
spontaneous 
bleeding not 
induced by 
minor trauma 
or abrasion 
Dry skin Normal controlled with 
emollients 
not controlled with 
emollients 
- - 
Erythema multiforme 
(e.g., Stevens-Johnson 
syndrome, toxic epidermal 
necrolysis) 
Absent - scattered, but not 
generalized 
eruption 
severe or requiring IV 
fluids (e.g., generalized 
rash or painful 
stomatitis) 
life-threatening 
(e.g., 
exfoliative or 
ulcerating 
dermatitis or 
requiring 
enteral or 
parenteral 
nutritional 
support) 
Flushing Absent Present - - - 
Hand-foot skin reaction None skin changes or 
dermatitis without 
pain (e.g., 
erythema, peeling) 
skin changes with 
pain, not interfering 
with function 
skin changes with pain, 
interfering with function 
- 
Injection site reaction None pain or itching or 
erythema 
pain or swelling, 
with inflammation 
or phlebitis 
ulceration or necrosis 
that is severe or 
prolonged, or requiring 
surgery 
- 
Nail changes Normal discoloration or 
ridging 
(koilonychia) or 
pitting 
partial or complete 
loss of nail(s) or 
pain in nailbeds 
- - 
Petechiae is graded in the HEMORRHAGE category. 
Photosensitivity None painless erythema painful erythema erythema with 
desquamation 
- 
Pigmentation changes 
(e.g., vitiligo) 
None localized 
pigmentation 
changes 
generalized 
pigmentation 
changes 
- - 
Pruritus None mild or localized, 
relieved 
spontaneously or 
by local measures 
intense or 
widespread, 
relieved 
spontaneously or by 
systemic measures 
intense or widespread 
and poorly controlled 
despite treatment 
- 
Purpura is graded in the HEMORRHAGE category. 
Radiation dermatitis None faint erythema or 
dry desquamation 
moderate to brisk 
erythema or a 
patchy moist 
desquamation, 
mostly confined to 
skin folds and 
creases; moderate 
edema 
confluent moist 
desquamation, 1.5 cm 
diameter, not confined 
to skin folds; pitting 
edema 
skin necrosis or 
ulceration of 
full thickness 
dermis; may 
include 
bleeding not 
induced by 
minor trauma 
or abrasion 
Note: Pain associated with radiation dermatitis is graded separately in the PAIN category as Pain due to radiation. 
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Grade 
Toxicity 0 1 2 3 4 
Radiation recall reaction 
(reaction following 
chemotherapy in the 
absence of additional 
radiation therapy that 
occurs in a previous 
radiation port) 
None faint erythema or 
dry desquamation 
moderate to brisk 
erythema or a 
patchy moist 
desquamation, 
mostly confined to 
skin folds and 
creases; moderate 
edema 
confluent moist 
desquamation, 1.5 cm 
diameter, not confined 
to skin folds; pitting 
edema 
skin necrosis or 
ulceration of 
full thickness 
dermis; may 
include 
bleeding not 
induced by 
minor trauma 
or abrasion 
Rash/desquamation None macular or papular 
eruption or 
erythema without 
associated 
symptoms 
macular or papular 
eruption or 
erythema with 
pruritus or other 
associated 
symptoms covering 
<50% of body 
surface or localized 
desquamation or 
other lesions 
covering <50% of 
body surface area 
symptomatic 
generalized 
erythroderma or 
macular, papular or 
vesicular eruption or 
desquamation covering 
50% of body surface 
area 
generalized 
exfoliative 
dermatitis or 
ulcerative 
dermatitis 
For BMT: None macular or papular 
eruption or 
erythema covering 
<25% of body 
surface area 
without associated 
symptoms 
macular or papular 
eruption or 
erythema with 
pruritis or other 
associated 
symptoms covering 
25 - <50% of body 
surface or localized 
desquamation or 
other lesions 
covering 25 - 
<50% of body 
surface area 
symptomatic 
generalized 
erythroderma or 
symptomatic macular, 
papular or vesicular 
eruption, with bullous 
formation, or 
desquamation covering 
50% of body surface 
area  
generalized 
exfoliative 
dermatitis or 
ulcerative 
dermatitis or 
bullous 
formation 
Also consider Allergic reaction/hypersensitivity. 
Note: Erythema multiforme (Stevens-Johnson syndrome) is graded separately as Erythema multiforme. 
Urticaria  
(hives, welts, wheals) 
None requiring no 
medication 
requiring PO or 
topical treatment or 
IV medication or 
steroids for <24 
hours 
requiring IV medication 
or steroids for 24 
hours 
- 
Wound- infectious None Cellulitis superficial infection infection requiring IV 
antibiotics 
necrotizing 
fascitis 
Wound- non-infectious None incisional 
separation 
incisional hernia fascial disruption 
without evisceration 
fascial 
disruption with 
evisceration 
Dermatology/Skin-Other 
(Specify, ________) 
None Mild moderate Severe life-threatening 
or disabling 
ENDOCRINE 
Cushingoid appearance 
(e.g., moon face with or 
without buffalo hump, 
centripetal obesity, 
cutaneous striae) 
Absent - present - - 
Also consider Hyperglycemia, Hypokalemia. 
Feminization of male Absent - - Present - 
Gynecomastia None Mild pronounced or 
painful 
pronounced or painful 
and requiring surgery 
- 
Hot flashes/flushes None mild or no more 
than 1 per day 
moderate and 
greater than 1 per 
day 
- - 
Hypothyroidism absent asymptomatic,TSH 
elevated, no 
therapy given 
symptomatic or 
thyroid replacement 
treatment given 
patient hospitalized for 
manifestations of 
hypothyroidism 
myxedema 
coma 
Masculinization of female absent - - Present - 
SIADH (syndrome of 
inappropriate antidiuretic 
hormone) 
absent - - Present - 
Endocrine-Other  
(Specify, __________) 
none Mild moderate Severe life-threatening 
or disabling 
GASTROINTESTINAL 
Amylase is graded in the METABOLIC/LABORATORY category. 
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Grade 
Toxicity 0 1 2 3 4 
Anorexia none loss of appetite oral intake 
significantly 
decreased 
requiring IV fluids requiring 
feeding tube or 
parenteral 
nutrition 
Ascites (non-malignant) none Asymptomatic symptomatic, 
requiring diuretics 
symptomatic, requiring 
therapeutic paracentesis 
life-threatening 
physiologic 
consequences 
Colitis none - abdominal pain 
with mucus and/or 
blood in stool 
abdominal pain, fever, 
change in bowel habits 
with ileus or peritoneal 
signs, and radiographic 
or biopsy 
documentation 
perforation or 
requiring 
surgery or toxic 
megacolon 
Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, 
Melena/GI bleeding, Rectal bleeding/hematochezia, Hypotension. 
Constipation none requiring stool 
softener or dietary 
modification 
requiring laxatives obstipation requiring 
manual evacuation or 
enema 
obstruction or 
toxic 
megacolon 
Dehydration none dry mucous 
membranes and/or 
diminished skin 
turgor 
requiring IV fluid 
replacement (brief) 
requiring IV fluid 
replacement (sustained) 
physiologic 
consequences 
requiring 
intensive care; 
hemodynamic 
collapse 
Also consider Hypotension, Diarrhea, Vomiting, Stomatitis/pharyngitis (oral/pharyngeal mucositis). 
Diarrhea 
Patients without 
colostomy: 
none increase of < 4 
stools/day over 
pre-treatment 
increase of 4-6 
stools/day, or 
nocturnal stools 
increase of 7 
stools/day or 
incontinence; or need 
for parenteral support 
for dehydration 
physiologic 
consequences 
requiring 
intensive care; 
or 
hemodynamic 
collapse 
Patients with a colostomy: none mild increase in 
loose, watery 
colostomy output 
compared with 
pretreatment 
moderate increase 
in loose, watery 
colostomy output 
compared with 
pretreatment, but 
not interfering with 
normal activity 
severe increase in loose, 
watery colostomy 
output compared with 
pretreatment, interfering 
with normal activity 
physiologic 
consequences, 
requiring 
intensive care; 
or 
hemodynamic 
collapse 
For BMT none >500 - 1000ml of 
diarrhea/day 
>1000 - 1500ml of 
diarrhea/day 
>1500ml of 
diarrhea/day 
severe 
abdominal pain 
with or without 
ileus 
For Pediatric BMT:  >5 - 10 ml/kg of 
diarrhea/day 
>10 - 15 ml/kg of 
diarrhea/day 
>15 ml/kg of 
diarrhea/day 
- 
Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, Pain, 
Dehydration, Hypotension. 
Duodenal ulcer (requires 
radiographic or 
endoscopic 
documentation) 
none - requiring medical 
management or 
non-surgical 
treatment 
uncontrolled by 
outpatient medical 
management; requiring 
hospitalization 
perforation or 
bleeding, 
requiring 
emergency 
surgery 
Dyspepsia/heartburn none Mild moderate Severe - 
Dysphagia, esophagitis, 
odynophagia (painful 
swallowing) 
none mild dysphagia, 
but can eat regular 
diet 
dysphagia, 
requiring 
predominantly 
pureed, soft, or 
liquid diet 
dysphagia, requiring IV 
hydration 
complete 
obstruction 
(cannot 
swallow saliva) 
requiring 
enteral or 
parenteral 
nutritional 
support, or 
perforation 
Note: If toxicity is radiation-related, grade either under Dysphagia- esophageal related to radiation or Dysphagia- pharyngeal related to 
radiation. 
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Grade 
Toxicity 0 1 2 3 4 
Dysphagia- esophageal 
related to radiation 
none mild dysphagia, 
but can eat regular 
diet 
dysphagia, 
requiring 
predominantly 
liquid, pureed or 
soft diet 
dysphagia requiring 
feeding tube, IV 
hydration or 
hyperalimentation 
complete 
obstruction 
(cannot 
swallow 
saliva); 
ulceration with 
bleeding not 
induced by 
minor trauma 
or abrasion or 
perforation 
Also consider Pain due to radiation, Mucositis due to radiation. 
Note: Fistula is graded separately as Fistula- esophageal. 
Dysphagia - pharyngeal 
related to radiation 
none mild dysphagia, 
but can eat regular 
diet 
dysphagia, 
requiring 
predominantly 
pureed, soft, or 
liquid diet 
dysphagia, requiring 
feeding tube, IV 
hydration or 
hyperalimentation 
complete 
obstruction 
(cannot 
swallow 
saliva); 
ulceration with 
bleeding not 
induced by 
minor trauma 
or abrasion or 
perforation 
Also consider Pain due to radiation, Mucositis due to radiation. 
Note: Fistula is graded separately as Fistula- pharyngeal. 
Fistula- esophageal none - - Present requiring 
surgery 
Fistula- intestinal none - - Present requiring 
surgery 
Fistula- pharyngeal none - - Present requiring 
surgery 
Fistula- rectal/anal none - - Present requiring 
surgery 
Flatulence none Mild moderate - - 
Gastric ulcer  
(requires radiographic or 
endoscopic 
documentation) 
none - requiring medical 
management or 
non-surgical 
treatment 
bleeding without 
perforation, 
uncontrolled by 
outpatient medical 
management; requiring 
hospitalization or 
surgery 
perforation or 
bleeding, 
requiring 
emergency 
surgery 
Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia. 
Gastritis none - requiring medical 
management or 
non-surgical 
treatment 
uncontrolled by out-
patient medical 
management; requiring 
hospitalization or 
surgery 
life-threatening 
bleeding, 
requiring 
emergency 
surgery 
Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia. 
Hematemesis is graded in the HEMORRHAGE category. 
Hematochezia is graded in the HEMORRHAGE category as Rectal bleeding/hematochezia. 
Ileus (or 
neuroconstipation) 
none - intermittent, not 
requiring 
intervention 
requiring non-surgical 
intervention 
requiring 
surgery 
Mouth dryness normal Mild moderate - - 
Mucositis      
Note: Mucositis not due to radiation is graded in the GASTROINTESTINAL category for specific sites: Colitis, Esophagitis, Gastritis, 
Stomatitis/pharyngitis (oral/pharyngeal mucositis), and Typhlitis; or the RENAL/GENITOURINARY category for Vaginititis. 
Radiation-related mucositis is graded as Mucositis due to radiation. 
Mucositis due to radiation none erythema of the 
mucosa 
patchy 
pseudomembranous 
reaction (patches 
generally  1.5 cm 
in diameter and 
non-contiguous) 
confluent 
pseudomembranous 
reaction (contiguous 
patches generally > 1.5 
cm in diameter) 
necrosis or 
deep 
ulceration; may 
include 
bleeding not 
induced by 
minor trauma 
or abrasion 
Also consider Pain due to radiation. 
Note: Grade radiation mucositis of the larynx here. 
Dysphagia related to radiation is also graded as either Dysphagia- esophageal related to radiation or Dysphagia- pharyngeal related to 
radiation, depending on the site of treatment. 
Nausea none able to eat oral intake 
significantly 
decreased 
no significant intake, 
requiring IV fluids 
- 
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Grade 
Toxicity 0 1 2 3 4 
Pancreatitis none - - abdominal pain with 
pancreatic enzyme 
elevation 
complicated by 
shock (acute 
circulatory 
failure) 
Also consider Hypotension. 
Note: Asymptomatic amylase and Amylase are graded in the METABOLIC/LABORATORY category. 
Pharyngitis is graded in the GASTROINTESTINAL category as Stomatitis/pharyngitis (oral/pharyngeal mucositis). 
Proctitis none increased stool 
frequency, 
occasional blood-
streaked stools, or 
rectal discomfort 
(including 
hemorrhoids), not 
requiring 
medication 
increased stool 
frequency, 
bleeding, mucus 
discharge, or rectal 
discomfort 
requiring 
medication; anal 
fissure 
increased stool 
frequency/diarrhea, 
requiring parenteral 
support; rectal bleeding, 
requiring transfusion; or 
persistent mucus 
discharge, necessitating 
pads 
perforation, 
bleeding or 
necrosis or 
other life-
threatening 
complication 
requiring 
surgical 
intervention 
(e.g., 
colostomy) 
Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, and 
Pain due to radiation. 
Note: Fistula is graded separately as Fistula- rectal/anal. 
Proctitis occurring more than 90 days after the start of radiation therapy is graded in the RTOG/EORTC Late Radiation Morbidity Scoring 
Scheme. (See Appendix IV) 
Salivary gland changes none slightly thickened 
saliva/may have 
slightly altered 
taste (e.g., 
metallic); 
additional fluids 
may be required 
thick, ropy, sticky 
saliva; markedly 
altered taste; 
alteration in diet 
required 
- acute salivary 
gland necrosis 
Sense of smell normal slightly altered markedly altered - - 
      
Stomatitis/pharyngitis 
(oral/pharyngeal 
mucositis) 
none painless ulcers, 
erythema, or mild 
soreness in the 
absence of lesions 
painful erythema, 
edema, or ulcers, 
but can eat or 
swallow 
painful erythema, 
edema, or ulcers 
requiring IV hydration 
severe 
ulceration or 
requires 
parenteral or 
enteral 
nutritional 
support or 
prophylatic 
intubation 
For BMT: none painless ulcers, 
erythema, or mild 
soreness in the 
absence of lesions 
painful erythema, 
edema or ulcers but 
can swallow 
painful erythema, 
edema, or ulcers 
preventing swallowing 
or requiring hydration 
or parenteral (or enteral) 
nutritional support 
severe 
ulceration 
requiring 
prophylactic 
intubation or 
resulting in 
documented 
aspiration 
pneumonia 
Note: Radiation-related mucositis is graded as Mucositis due to radiation. 
Taste disturbance 
(dysgeusia) 
normal slightly altered markedly altered - - 
Typhlitis  
(inflammation of the 
cecum) 
none - - abdominal pain, 
diarrhea, fever, or 
radiographic 
documentation 
perforation, 
bleeding or 
necrosis or 
other life-
threatening 
complication 
requiring 
surgical 
intervention 
(e.g., 
colostomy) 
Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, 
Hypotension, Febrile/neutropenia. 
Vomiting none 1 episode in 24 
hours over 
pretreatment 
2-5 episodes in 24 
hours over 
pretreatment 
6 episodes in 24 hours 
over pretreatment; or 
need for IV fluids 
Requiring 
parenteral 
nutrition; or 
physiologic 
consequences 
requiring 
intensive care; 
hemodynamic 
collapse 
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Grade 
Toxicity 0 1 2 3 4 
Also consider Dehydration. 
Weight gain is graded in the CONSTITUTIONAL SYMPTOMS category. 
Weight loss is graded in the CONSTITUTIONAL SYMPTOMS category. 
Gastrointestinal-Other 
(Specify, __________) 
none Mild moderate Severe life-threatening 
or disabling 
HEMORRHAGE 
Note: Transfusion in this section refers to pRBC infusion. 
For any bleeding with grade 3 or 4 platelets (< 50,000), always grade Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia. Also 
consider platelets, transfusion- pRBCS, and transfusion-platelets in addition to the grade that incorporates the site or type of bleeding. 
If the site or type of hemorrhage/bleeding is listed, also use the grading that incorporates the site of bleeding: CNS hemorrhage/bleeding, 
Hematuria, Hematemesis, Hemoptysis, Hemorrhage/bleeding with surgery, Melena/lower GI bleeding, Petechiae/purpura 
(Hemorrhage/bleeding into skin), Rectal bleeding/hematochezia, Vaginal bleeding. 
If the platelet count is 50,000 and the site or type of bleeding is listed, grade the specific site. If the site or type is not listed and the platelet 
count is 50,000, grade Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia and specify the site or type in the OTHER category. 
Hemorrhage/bleeding 
with grade 3 or 4 
thrombocytopenia 
none mild without 
transfusion 
 requiring transfusion catastrophic 
bleeding, 
requiring major 
non-elective 
intervention 
Also consider Platelets, Hemoglobin, Transfusion-platelet, Transfusion-pRBCs. 
Note: This toxicity must be graded for any bleeding with grade 3 or 4 thrombocytopenia. Also grade the site or type of 
hemorrhage/bleeding. If the site is not listed, grade as Other in the HEMORRHAGE category. 
Hemorrhage/bleeding 
without grade 3 or 4 
thrombocytopenia 
none mild without 
transfusion 
 requiring transfusion catastrophic 
bleeding 
requiring major 
non-elective 
intervention 
Also consider Platelets, Hemoglobin, Transfusion-platelet, Transfusion-pRBCs. 
Note: Bleeding in the absence of grade 3 or 4 thrombocytopenia is graded here only if the specific site or type of bleeding is not listed 
elsewhere in the HEMORRHAGE category. Also grade as Other in the HEMORRHAGE category. 
CNS hemorrhage/bleeding none - - bleeding noted on CT or 
other scan with no 
clinical consequences 
hemorrhagic 
stroke or 
hemorrhagic 
vascular event 
(CVA) with 
neurologic 
signs and 
symptoms 
Epistaxis none mild without 
transfusion 
- requiring transfusion catastrophic 
bleeding, 
requiring major 
non-elective 
intervention 
Hematemesis none mild without 
transfusion 
- requiring transfusion catastrophic 
bleeding, 
requiring major 
non-elective 
intervention 
Hematuria  
(in the absence of vaginal 
bleeding) 
none microscopic only intermittent gross 
bleeding, no clots 
persistent gross 
bleeding or clots; may 
require catheterization 
or instrumentation, or 
transfusion 
open surgery or 
necrosis or 
deep bladder 
ulceration 
Hemoptysis none mild without 
transfusion 
- requiring transfusion catastrophic 
bleeding, 
requiring major 
non-elective 
intervention 
Hemorrhage/bleeding 
associated with surgery 
none mild without 
transfusion 
- requiring transfusion catastrophic 
bleeding, 
requiring major 
non-elective 
intervention 
Note: Expected blood loss at the time of surgery is not graded as a toxicity. 
Melena/GI bleeding none mild without 
transfusion 
- requiring transfusion catastrophic 
bleeding, 
requiring major 
non-elective 
intervention 
Petechiae/purpura 
(hemorrhage/bleeding into 
skin or mucosa) 
none rare petechiae of 
skin 
petechiae or 
purpura in 
dependent areas of 
skin 
generalized petechiae or 
purpura of skin or 
petechiae of any 
mucosal site 
- 
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Grade 
Toxicity 0 1 2 3 4 
Rectal bleeding/ 
hematochezia 
none mild without 
transfusion or 
medication 
persistent, requiring 
medication (e.g., 
steroid 
suppositories) 
and/or break from 
radiation treatment 
requiring transfusion catastrophic 
bleeding, 
requiring major 
non-elective 
intervention 
Vaginal bleeding none spotting, requiring 
< 2 pads per day 
requiring  2 pads 
per day, but not 
requiring 
transfusion 
requiring transfusion catastrophic 
bleeding, 
requiring major 
non-elective 
intervention 
Hemorrhage-Other  
(Specify site, 
___________) 
none mild without 
transfusion 
- requiring transfusion catastrophic 
bleeding, 
requiring major 
non-elective 
intervention 
HEPATIC 
Alkaline phosphatase WNL > ULN - 2.5 x 
ULN 
> 2.5 - 5.0 x ULN > 5.0 - 20.0 x ULN > 20.0 x ULN 
Bilirubin WNL > ULN - 1.5 x 
ULN 
> 1.5 - 3.0 x ULN > 3.0 - 10.0 x ULN > 10.0 x ULN 
Bilirubin- graft versus host disease (GVHD) 
Note: The following criteria are used only for bilirubin associated with graft versus host disease. 
 normal 2 - <3 mg/100 ml 3 - <6 mg/100 ml 6 - <15 mg/100 ml 15 mg/100 ml 
GGT 
( - Glutamyl 
transpeptidase) 
WNL > ULN - 2.5 x 
ULN 
> 2.5 - 5.0 x ULN > 5.0 - 20.0 x ULN > 20.0 x ULN 
Hepatic enlargement absent - - Present - 
Note: Grade Hepatic enlargement only for changes related to VOD or other treatment related toxicity. 
Hypoalbuminemia WNL <LLN - 3 g/dl 2 - <3 g/dl <2 g/dl - 
Liver dysfunction/failure 
(clinical) 
normal - - Asterixis encephalopathy 
or coma 
Note: Documented viral hepatitis is graded in the INFECTION category. 
Portal vein flow normal - decreased portal 
vein flow 
reversal/retrograde 
portal vein flow 
- 
SGOT (AST)  
(serum glutamic 
oxaloacetic transaminase) 
WNL > ULN - 2.5 x 
ULN 
> 2.5 - 5.0 x ULN > 5.0 - 20.0 x ULN > 20.0 x ULN 
SGPT (ALT)  
(serum glutamic pyruvic 
transaminase) 
WNL > ULN - 2.5 x 
ULN 
> 2.5 - 5.0 x ULN > 5.0 - 20.0 x ULN > 20.0 x ULN 
Hepatic-Other  
(Specify, __________) 
none Mild moderate Severe life-threatening 
or disabling 
INFECTION/FEBRILE NEUTROPENIA 
Catheter-related infection none mild, no active 
treatment 
moderate, localized 
infection, requiring 
local or oral 
treatment 
severe, systemic 
infection, requiring IV 
antibiotic or antifungal 
treatment or 
hospitalization 
life-threatening 
sepsis (e.g., 
septic shock) 
Febrile neutropenia  
(fever of unknown origin 
without clinically or 
microbiologically 
documented infection) 
none - - Present Life-
threatening 
sepsis (e.g., 
septic shock) 
(ANC < 1.0 x 109/L, fever 
38.5°C) 
     
Note: Hypothermia instead of fever may be associated with neutropenia and is graded here. 
Infection (documented 
clinically or 
microbiologically) with 
grade 3 or 4 neutropenia 
none - - Present life-threatening 
sepsis (e.g., 
septic shock) 
(ANC < 1.0 x 109/L)      
Note: Hypothermia instead of fever may be associated with neutropenia and is graded here. In the absence of documented infection with 
grade 3 or 4 neutropenia, grade as Febrile neutropenia. 
Infection with unknown 
ANC 
none - - Present life-threatening 
sepsis (e.g., 
septic shock) 
Note: This toxicity criterion is used in the rare case when ANC is unknown. 
Infection without 
neutropenia 
none mild, no active 
treatment 
moderate, localized 
infection, requiring 
local or oral 
treatment 
severe, systemic 
infection, requiring IV 
antibiotic or antifungal 
treatment, or 
hospitalization 
life-threatening 
sepsis (e.g., 
septic shock) 
 53(74)
TEAM-trial                                           Final protocol, including amendment 1 & 2                       November 10, 2004 
 
Grade 
Toxicity 0 1 2 3 4 
Infection/Febrile 
Neutropenia-Other 
(Specify, __________) 
none Mild moderate Severe life-threatening 
or disabling 
Wound-infectious is graded in the DERMATOLOGY/SKIN category. 
LYMPHATICS 
Lymphatics normal mild lymphedema moderate 
lymphedema 
requiring 
compression; 
lymphocyst 
severe lymphedema 
limiting function; 
lymphocyst requiring 
surgery 
severe 
lymphedema 
limiting 
function with 
ulceration 
Lymphatics-Other  
(Specify, __________) 
none Mild moderate Severe life-threatening 
or disabling 
METABOLIC/LABORATORY 
Acidosis  
(metabolic or respiratory) 
normal pH < normal, but 
7.3 
- pH < 7.3 pH < 7.3 with 
life-threatening 
physiologic 
consequences 
Alkalosis  
(metabolic or respiratory) 
normal pH > normal, but 
7.5 
- pH > 7.5 pH > 7.5 with 
life-threatening 
physiologic 
consequences 
Amylase WNL > ULN - 1.5 x 
ULN 
> 1.5 - 2.0 x ULN > 2.0 - 5.0 x ULN >5.0 x ULN 
Bicarbonate WNL < LLN - 16 mEq/dl 11 - 15 mEq/dl 8 - 10 mEq/dl < 8 mEq/dl 
CPK 
(creatine phosphokinase) 
WNL > ULN - 2.5 x 
ULN 
> 2.5 - 5 x ULN > 5 - 10 x ULN > 10 x ULN 
Hypercalcemia WNL > ULN - 11.5 
mg/dl 
> ULN - 2.9 
mmol/L 
>11.5 - 12.5 mg/dl 
> 2.9 - 3.1 mmol/L 
>12.5 - 13.5 mg/dl 
> 3.1 - 3.4 mmol/L 
> 13.5 mg/dl 
> 3.4 mmol/L 
Hypercholesterolemia WNL > ULN - 300 mg/dl
> ULN - 7.75 
mmol/L 
> 300 - 400 mg/dl 
> 7.75 - 10.34 
mmol/L 
> 400 - 500 mg/dl 
>10.34 - 12.92 mmol/L 
> 500 mg/dl 
> 12.92 
mmol/L 
Hyperglycemia WNL > ULN - 160 mg/dl
> ULN - 8.9 
mmol/L 
> 160 - 250 mg/dl 
> 8.9 - 13.9 
mmol/L 
> 250 - 500 mg/dl 
> 13.9 - 27.8 mmol/L 
> 500 mg/dl 
> 27.8 mmol/L 
or ketoacidosis 
Hyperkalemia WNL > ULN - 5.5 
mmol/L 
> 5.5 - 6.0 mmol/L > 6.0 - 7.0 mmol/L > 7.0 mmol/L 
Hypermagnesemia WNL > ULN - 3.0 mg/dl
> ULN - 1.23 
mmol/L 
- > 3.0 - 8.0 mg/dl 
> 1.23 - 3.30 mmol/L 
> 8.0 mg/dl 
> 3.30 mmol/L 
Hypernatremia WNL > ULN - 150 
mmol/L 
>150 - 155 mmol/L >155 - 160 mmol/L >160 mmol/L 
Hypertriglyceridemia WNL > ULN - 2.5 x 
ULN 
> 2.5 - 5.0 x ULN > 5.0 - 10 x ULN > 10 x ULN 
Hyperuricemia WNL > ULN -  10 
mg/dl 
 0.59 mmol/L 
without 
physiologic 
consequences 
- > ULN -  10 mg/dl 
 0.59 mmol/L with 
physiologic 
consequences 
> 10 mg/dl 
> 0.59 mmol/L 
Also consider Tumor lysis syndrome, Renal failure, Creatinine, Potassium. 
Hypocalcemia WNL <LLN - 8.0 mg/dl 
<LLN - 2.0 
mmol/L 
7.0 - < 8.0 mg/dl 
1.75 - < 2.0 
mmol/L 
6.0 - < 7.0 mg/dl 
1.5 - < 1.75 mmol/L 
<6.0 mg/dl 
< 1.5 mmol/L 
Hypoglycemia WNL <LLN - 55 mg/dl 
<LLN - 3.0 
mmol/L 
40 - < 55 mg/dl 
2.2 - < 3.0 mmol/L 
30 - < 40 mg/dl 
1.7 - < 2.2 mmol/L 
< 30 mg/dl 
< 1.7 mmol/L 
Hypokalemia WNL <LLN - 3.0 
mmol/L 
- 2.5 - <3.0 mmol/L <2.5 mmol/L 
Hypomagnesemia WNL <LLN - 1.2 mg/dl 
<LLN - 0.5 
mmol/L 
0.9 - <1.2 mg/dl 
0.4 - < 0.5 mmol/L 
0.7 - < 0.9 mg/dl 
0.3 - < 0.4 mmol/L 
< 0.7 mg/dl 
< 0.3 mmol/L 
Hyponatremia WNL <LLN - 130 
mmol/L 
- 120 - <130 mmol/L <120 mmol/L 
Hypophosphatemia WNL <LLN -2.5 mg/dl 
<LLN - 0.8 
mmol/L 
2.0 - <2.5 mg/dl 
0.6 - <0.8 mmol/L 
1.0 - <2.0 mg/dl 
0.3 - <0.6 mmol/L 
< 1.0 mg/dl 
<0.3 mmol/L 
Hypothyroidism is graded in the ENDOCRINE category. 
Lipase WNL > ULN - 1.5 x 
ULN 
> 1.5 - 2.0 x ULN > 2.0 - 5.0 x ULN > 5.0 x ULN 
Metabolic/Laboratory-
Other (Specify, 
__________) 
none Mild moderate Severe life-threatening 
or disabling 
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Grade 
Toxicity 0 1 2 3 4 
MUSCULOSKELETAL 
Arthralgia is graded in the PAIN category. 
Arthritis none mild pain with 
inflammation, 
erythema or joint 
swelling but not 
interfering with 
function 
moderate pain with 
inflammation, 
erythema, or joint 
swelling interfering 
with function, but 
not interfering with 
activities of daily 
living 
severe pain with 
inflammation, 
erythema, or joint 
swelling and interfering 
with activities of daily 
living 
disabling 
Muscle weakness 
(not due to neuropathy) 
normal asymptomatic with 
weakness on 
physical exam 
symptomatic and 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
symptomatic and 
interfering with 
activities of daily living 
bedridden or 
disabling 
Myalgia is graded in the PAIN category. 
Myositis 
(inflammation/damage of 
muscle) 
none mild pain, not 
interfering with 
function 
pain interfering 
with function, but 
not interfering with 
activities of daily 
living 
pain interfering with 
function and interfering 
with activities of daily 
living 
bedridden or 
disabling 
Also consider CPK. 
Note: Myositis implies muscle damage (i.e., elevated CPK). 
Osteonecrosis  
(avascular necrosis) 
none asymptomatic and 
detected by 
imaging only 
symptomatic and 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
symptomatic and 
interfering with 
activities of daily living 
symptomatic; 
or disabling 
Musculoskeletal-Other 
(Specify, __________) 
none Mild moderate Severe life-threatening 
or disabling 
NEUROLOGY 
Aphasia, receptive and/or expressive, is graded under Speech impairment in the NEUROLOGY category. 
Arachnoiditis/meningismu
s/ 
radiculitis 
absent mild pain not 
interfering with 
function 
moderate pain 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain interfering 
with activities of daily 
living 
unable to 
function or 
perform 
activities of 
daily living; 
bedridden; 
paraplegia 
Also consider Headache, Vomiting, Fever. 
Ataxia (incoordination) normal asymptomatic but 
abnormal on 
physical exam, and 
not interfering with 
function 
mild symptoms 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
moderate symptoms 
interfering with 
activities of daily living 
bedridden or 
disabling 
CNS cerebrovascular 
ischemia 
none - - transient ischemic event 
or attack (TIA) 
permanent 
event (e.g., 
cerebral 
vascular 
accident) 
CNS hemorrhage/bleeding is graded in the HEMORRHAGE category. 
Cognitive disturbance/ 
learning problems 
none cognitive 
disability; not 
interfering with 
work/school 
performance; 
preservation of 
intelligence 
cognitive disability; 
interfering with 
work/school 
performance; 
decline of 1 SD 
(Standard 
Deviation) or loss 
of developmental 
milestones 
cognitive disability; 
resulting in significant 
impairment of 
work/school 
performance; cognitive 
decline > 2 SD 
inability to 
work/frank 
mental 
retardation 
Confusion normal confusion or 
disorientation or 
attention deficit of 
brief duration; 
resolves 
spontaneously with 
no sequelae 
confusion or 
disorientation or 
attention deficit 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
confusion or delirium 
interfering with 
activities of daily living 
harmful to 
others or self; 
requiring 
hospitalization 
Cranial neuropathy is graded in the NEUROLOGY category as Neuropathy-cranial. 
Delusions normal - - Present toxic psychosis 
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Grade 
Toxicity 0 1 2 3 4 
Depressed level of 
consciousness 
normal somnolence or 
sedation not 
interfering with 
function 
somnolence or 
sedation interfering 
with function, but 
not interfering with 
activities of daily 
living 
obtundation or stupor; 
difficult to arouse; 
interfering with 
activities of daily living 
coma 
Note: Syncope (fainting) is graded in the NEUROLOGY category. 
Dizziness/lightheadedness none not interfering with 
function 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
interfering with 
activities of daily living 
bedridden or 
disabling 
Dysphasia, receptive and/or expressive, is graded under Speech impairment in the NEUROLOGY category. 
Extrapyramidal/  
involuntary movement/ 
restlessness 
none mild involuntary 
movements not 
interfering with 
function 
moderate 
involuntary 
movements 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe involuntary 
movements or torticollis 
interfering with 
activities of daily living 
bedridden or 
disabling 
Hallucinations normal - - Present toxic psychosis 
Headache is graded in the PAIN category. 
Insomnia normal occasional 
difficulty sleeping 
not interfering with 
function 
difficulty sleeping 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
frequent difficulty 
sleeping, interfering 
with activities of daily 
living 
- 
Note: This toxicity is graded when insomnia is related to treatment. If pain or other symptoms interfere with sleep do NOT grade as insomnia. 
Irritability 
(children <3 years of age) 
normal mild; easily 
consolable 
moderate; 
requiring increased 
attention 
severe; inconsolable - 
Leukoencephalopathy 
associated radiological 
findings 
none mild increase in 
SAS (subarachnoid 
space) and/or mild 
ventriculomegaly; 
and/or small (+/- 
multiple) focal T2 
hyperintensities, 
involving 
periventricular 
white matter or < 
1/3 of susceptible 
areas of cerebrum 
moderate increase 
in SAS; and/or 
moderate 
ventriculomegaly; 
and/or focal T2 
hyperintensities 
extending into 
centrum ovale; or 
involving 1/3 to 2/3 
of susceptible areas 
of cerebrum 
severe increase in SAS; 
severe 
ventriculomegaly; near 
total white matter T2 
hyperintensities or 
diffuse low attenuation 
(CT); focal white matter 
necrosis (cystic) 
severe increase 
in SAS; severe 
ventriculomega
ly; diffuse low 
attenuation 
with 
calcification 
(CT); diffuse 
white matter 
necrosis (MRI) 
Memory loss normal memory loss not 
interfering with 
function 
memory loss 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
memory loss interfering 
with activities of daily 
living 
amnesia 
Mood alteration- anxiety 
agitation 
normal mild mood 
alteration not 
interfering with 
function 
moderate mood 
alteration 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe mood alteration 
interfering with 
activities of daily living 
suicidal 
ideation or 
danger to self 
Mood alteration- 
depression 
normal mild mood 
alteration not 
interfering with 
function 
moderate mood 
alteration 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe mood alteration 
interfering with 
activities of daily living 
suicidal 
ideation or 
danger to self 
Mood alteration- euphoria normal mild mood 
alteration not 
interfering with 
function 
moderate mood 
alteration 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe mood alteration 
interfering with 
activities of daily living 
danger to self 
Neuropathic pain is graded in the PAIN category. 
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Grade 
Toxicity 0 1 2 3 4 
Neuropathy- cranial absent - present, not 
interfering with 
activities of daily 
living 
present, interfering with 
activities of daily living 
life-
threatening, 
disabling 
Neuropathy- motor normal subjective 
weakness but no 
objective findings 
mild objective 
weakness 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
objective weakness 
interfering with 
activities of daily living 
paralysis 
Neuropathy-sensory normal loss of deep tendon 
reflexes or 
paresthesia 
(including tingling) 
but not interfering 
with function 
objective sensory 
loss or paresthesia 
(including tingling), 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
sensory loss or 
paresthesia interfering 
with activities of daily 
living 
permanent 
sensory loss 
that interferes 
with function 
Nystagmus absent Present - - - 
Also consider Vision-double vision. 
Personality/behavioral normal change, but not 
disruptive to 
patient or family 
disruptive to patient 
or family 
disruptive to patient and 
family; requiring mental 
health intervention 
harmful to 
others or self; 
requiring 
hospitalization 
Pyramidal tract 
dysfunction (e.g.,  tone, 
hyperreflexia, positive 
Babinski,  fine motor 
coordination) 
normal asymptomatic with 
abnormality on 
physical 
examination 
symptomatic or 
interfering with 
function but not 
interfering with 
activities of daily 
living 
interfering with 
activities of daily living 
bedridden or 
disabling; 
paralysis 
Seizure(s) none - seizure(s) self-
limited and 
consciousness is 
preserved 
seizure(s) in which 
consciousness is altered 
seizures of any 
type which are 
prolonged, 
repetitive, or 
difficult to 
control (e.g., 
status 
epilepticus, 
intractable 
epilepsy) 
Speech impairment  
(e.g., dysphasia or 
aphasia) 
normal - awareness of 
receptive or 
expressive 
dysphasia, not 
impairing ability to 
communicate 
receptive or expressive 
dysphasia, impairing 
ability to communicate 
inability to 
communicate 
Syncope (fainting) absent - - Present - 
Also consider CARDIOVASCULAR (ARRHYTHMIA), Vasovagal episode, CNS cerebrovascular ischemia. 
Tremor none mild and brief or 
intermittent but not 
interfering with 
function 
moderate tremor 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe tremor 
interfering with 
activities of daily living 
- 
Vertigo none not interfering with 
function 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
interfering with 
activities of daily living 
bedridden or 
disabling 
Neurology-Other 
(Specify, __________) 
none Mild moderate Severe life-threatening 
or disabling 
OCULAR/VISUAL 
Cataract none Asymptomatic symptomatic, 
partial visual loss 
symptomatic, visual 
loss requiring treatment 
or interfering with 
function 
- 
Conjunctivitis none abnormal 
ophthalmologic 
changes, but 
asymptomatic or 
symptomatic 
without visual 
impairment (i.e., 
pain and irritation) 
symptomatic and 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
symptomatic and 
interfering with 
activities of daily living 
- 
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Grade 
Toxicity 0 1 2 3 4 
Dry eye normal mild, not requiring 
treatment 
moderate or 
requiring artificial 
tears 
- - 
Glaucoma none increase in 
intraocular 
pressure but no 
visual loss 
increase in 
intraocular pressure 
with retinal changes 
visual impairment unilateral or 
bilateral loss of 
vision 
(blindness) 
Keratitis  
(corneal inflammation/ 
corneal ulceration) 
none abnormal 
ophthalmologic 
changes but 
asymptomatic or 
symptomatic 
without visual 
impairment (i.e., 
pain and irritation) 
symptomatic and 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
symptomatic and 
interfering with 
activities of daily living 
unilateral or 
bilateral loss of 
vision 
(blindness) 
Tearing (watery eyes) none mild: not 
interfering with 
function 
moderate: 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
interfering with 
activities of daily living 
- 
Vision- blurred vision normal - symptomatic and 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
symptomatic and 
interfering with 
activities of daily living 
- 
Vision- double vision 
(diplopia) 
normal - symptomatic and 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
symptomatic and 
interfering with 
activities of daily living 
- 
Vision- flashing 
lights/floaters 
normal mild, not 
interfering with 
function 
symptomatic and 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
symptomatic and 
interfering with 
activities of daily living 
- 
Vision- night blindness 
(nyctalopia) 
normal abnormal electro-
retinography but 
asymptomatic 
symptomatic and 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
symptomatic and 
interfering with 
activities of daily living 
- 
Vision- photophobia normal - symptomatic and 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
symptomatic and 
interfering with 
activities of daily living 
- 
Ocular/Visual-Other  
(Specify, __________) 
normal Mild moderate Severe unilateral or 
bilateral loss of 
vision 
(blindness) 
PAIN 
Abdominal pain or 
cramping 
none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Arthralgia  
(joint pain) 
none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Arthritis (joint pain with clinical signs of inflammation) is graded in the MUSCULOSKELETAL category. 
 58(74)
TEAM-trial                                           Final protocol, including amendment 1 & 2                       November 10, 2004 
 
Grade 
Toxicity 0 1 2 3 4 
Bone pain none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Chest pain  
(non-cardiac and non-
pleuritic) 
none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Dysmenorrhea none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Dyspareunia none mild pain not 
interfering with 
function 
moderate pain 
interfering with 
sexual activity 
severe pain preventing 
sexual activity 
- 
Dysuria is graded in the RENAL/GENITOURINARY category. 
Earache (otalgia) none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Headache none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Hepatic pain none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Myalgia  
(muscle pain) 
none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Neuropathic pain  
(e.g., jaw pain, neurologic 
pain, phantom limb pain, 
post-infectious neuralgia, 
or painful neuropathies) 
none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Pain due to radiation none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Pelvic pain none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
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Grade 
Toxicity 0 1 2 3 4 
Pleuritic pain none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Rectal or perirectal pain 
(proctalgia) 
none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Tumor pain  
(onset or exacerbation of 
tumor pain due to 
treatment) 
none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily living 
disabling 
Tumor flair is graded in the SYNDROME category. 
Pain-Other 
(Specify, __________) 
none Mild moderate Severe disabling 
PULMONARY 
Adult Respiratory Distress 
Syndrome (ARDS) 
absent - - - present 
Apnea none - - Present requiring 
intubation 
Carbon monoxide 
diffusion capacity (DLCO) 
 90% of 
pretreatment or 
normal value 
75 - <90% of 
pretreatment or 
normal value 
50 - <75% of 
pretreatment or 
normal value 
25 - <50% of 
pretreatment or normal 
value 
< 25% of 
pretreatment or 
normal value 
Cough absent mild, relieved by 
non-prescription 
medication 
requiring narcotic 
antitussive 
severe cough or 
coughing spasms, 
poorly controlled or 
unresponsive to 
treatment 
- 
Dyspnea  
(shortness of breath) 
normal - dyspnea on exertion dyspnea at normal level 
of activity 
dyspnea at rest 
or requiring 
ventilator 
support 
FEV1  90% of 
pretreatment or 
normal value 
75 - <90% of 
pretreatment or 
normal value 
50 - <75% of 
pretreatment or 
normal value 
25 - <50% of 
pretreatment or normal 
value 
< 25% of 
pretreatment or 
normal value 
Hiccoughs (hiccups, 
singultus) 
none mild, not requiring 
treatment 
moderate, requiring 
treatment 
severe, prolonged, and 
refractory to treatment 
- 
Hypoxia normal - decreased O2 
saturation with 
exercise 
decreased O2 saturation 
at rest, requiring 
supplemental oxygen 
decreased O2 
saturation, 
requiring 
pressure 
support 
(CPAP) or 
assisted 
ventilation 
Pleural effusion  
(non-malignant) 
none asymptomatic and 
not requiring 
treatment 
symptomatic, 
requiring diuretics 
symptomatic, requiring 
O2 or therapeutic 
thoracentesis 
life-threatening 
(e.g., requiring 
intubation) 
Pleuritic pain is graded in the PAIN category. 
Pneumonitis/pulmonary 
infiltrates 
none radiographic 
changes but 
asymptomatic or 
symptoms not 
requiring steroids 
radiographic 
changes and 
requiring steroids or 
diuretics 
radiographic changes 
and requiring oxygen 
radiographic 
changes and 
requiring 
assisted 
ventilation 
Pneumothorax none no intervention 
required 
chest tube required sclerosis or surgery 
required 
life-threatening 
Pulmonary embolism is graded as Thrombosis/embolism in the CARDIOVASCULAR (GENERAL) category. 
Pulmonary fibrosis none radiographic 
changes, but 
asymptomatic or 
symptoms not 
requiring steroids 
requiring steroids or 
diuretics 
requiring oxygen requiring 
assisted 
ventilation 
Note: Radiation-related pulmonary fibrosis is graded in the RTOG/EORTC Late Radiation Morbidity Scoring Scheme- Lung. (See Appendix 
IV) 
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Grade 
Toxicity 0 1 2 3 4 
Voice 
changes/stridor/larynx 
(e.g., hoarseness, loss of 
voice, laryngitis) 
normal mild or intermittent 
hoarseness 
persistent 
hoarseness, but able 
to vocalize; may 
have mild to 
moderate edema 
whispered speech, not 
able to vocalize; may 
have marked edema 
marked 
dyspnea/stridor 
requiring 
tracheostomy 
or intubation 
Note: Cough from radiation is graded as cough in the PULMONARY category. 
Radiation-related hemoptysis from larynx/pharynx is graded as Grade 4 Mucositis due to radiation in the GASTROINTESTINAL category.  
Radiation-related hemoptysis from the thoracic cavity is graded as Grade 4 Hemoptysis in the HEMORRHAGE category. 
Pulmonary-Other 
(Specify, __________) 
none Mild moderate Severe life-threatening 
or disabling 
RENAL/GENITOURINARY 
Bladder spasms absent mild symptoms, 
not requiring 
intervention 
symptoms requiring 
antispasmotic 
severe symptoms 
requiring narcotic 
- 
      
Creatinine WNL > ULN - 1.5 x 
ULN 
> 1.5 - 3.0 x ULN > 3.0 - 6.0 x ULN > 6.0 x ULN 
Note: Adjust to age-appropriate levels for pediatric patients. 
Dysuria  
(painful urination) 
none mild symptoms 
requiring no 
intervention 
symptoms relieved 
with therapy 
symptoms not relieved 
despite therapy 
- 
Fistula or GU fistula  
(e.g., vaginal, 
vesicovaginal) 
none - - requiring intervention requiring 
surgery 
Hemoglobinuria - Present - - - 
Hematuria (in the absence of vaginal bleeding) is graded in the HEMORRHAGE category. 
Incontinence none with coughing, 
sneezing, etc. 
spontaneous, some 
control 
no control (in the 
absence of fistula) 
- 
Operative injury to 
bladder and/or ureter 
none - injury of bladder 
with primary repair 
sepsis, fistula, or 
obstruction requiring 
secondary surgery; loss 
of one kidney; injury 
requiring anastomosis 
or re-implantation 
septic 
obstruction of 
both kidneys or 
vesicovaginal 
fistula 
requiring 
diversion 
Proteinuria normal or < 0.15 
g/24 hours 
1+ or 0.15 - 1.0 
g/24 hours 
2+ to 3+ or 1.0 - 3.5 
g/24 hours 
4+ or > 3.5 g/24 hours nephrotic 
syndrome 
Note: If there is an inconsistency between absolute value and uristix reading, use the absolute value for grading. 
Renal failure none - - requiring dialysis, but 
reversible 
requiring 
dialysis and 
irreversible 
Ureteral obstruction none unilateral, not 
requiring surgery 
- bilateral, not requiring 
surgery 
stent, 
nephrostomy 
tube, or surgery 
Urinary electrolyte 
wasting (e.g., Fanconi’s 
syndrome, renal tubular 
acidosis) 
none asymptomatic, not 
requiring treatment 
mild, reversible and 
manageable with 
oral replacement 
reversible but requiring 
IV replacement 
irreversible, 
requiring 
continued 
replacement 
Also consider Acidosis, Bicarbonate, Hypocalcemia, Hypophosphatemia. 
Urinary 
frequency/urgency 
normal increase in 
frequency or 
nocturia up to 2 x 
normal 
increase > 2 x 
normal but < hourly 
hourly or more with 
urgency, or requiring 
catheter 
- 
Urinary retention normal hesitancy or 
dribbling, but no 
significant residual 
urine; retention 
occurring during 
the immediate 
postoperative 
period 
hesitancy requiring 
medication or 
occasional in/out 
catheterization (<4 
x per week), or 
operative bladder 
atony requiring 
indwelling catheter 
beyond immediate 
postoperative 
period but for < 6 
weeks 
requiring frequent in/out 
catheterization  
( 4 x per week) or 
urological intervention 
(e.g., TURP, suprapubic 
tube, urethrotomy) 
bladder rupture 
Urine color change  
(not related to other 
dietary or physiologic 
cause e.g., bilirubin, 
concentrated urine, 
hematuria) 
normal asymptomatic, 
change in urine 
color 
- - - 
Vaginal bleeding is graded in the HEMORRHAGE category. 
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Grade 
Toxicity 0 1 2 3 4 
Vaginitis  
(not due to infection) 
none mild, not requiring 
treatment 
moderate, relieved 
with treatment 
severe, not relieved with 
treatment, or ulceration 
not requiring surgery 
ulceration 
requiring 
surgery 
Renal/Genitourinary-
Other (Specify, 
__________) 
none Mild moderate Severe life-threatening 
or disabling 
SECONDARY MALIGNANCY 
Secondary Malignancy-
Other  
(Specify type, 
__________) excludes 
metastastic tumors 
none - - - present 
SEXUAL/REPRODUCTIVE FUNCTION 
Dyspareunia is graded in the PAIN category. 
Dysmenorrhea is graded in the PAIN category. 
Erectile impotence normal mild (erections 
impaired but 
satisfactory) 
moderate (erections 
impaired, 
unsatisfactory for 
intercourse) 
no erections - 
Female sterility normal - - Sterile - 
Femininization of male is graded in the ENDOCRINE category. 
Irregular menses  
(change from baseline) 
normal occasionally 
irregular or 
lengthened 
interval, but 
continuing 
menstrual cycles 
very irregular, but 
continuing 
menstrual cycles 
persistent amenorrhea - 
Libido normal decrease in interest severe loss of 
interest 
- - 
Male infertility - - Oligospermia  
(low sperm count) 
Azoospermia  
(no sperm) 
- 
Masculinization of female is graded in the ENDOCRINE category. 
Vaginal dryness normal Mild requiring treatment 
and/or interfering 
with sexual 
function, 
dyspareunia 
- - 
Sexual/Reproductive 
Function-Other 
(Specify, __________) 
none Mild moderate Severe disabling 
SYNDROMES (not included in previous categories) 
Acute vascular leak syndrome is graded in the CARDIOVASCULAR (GENERAL) category. 
ARDS (Adult Respiratory Distress Syndrome) is graded in the PULMONARY category. 
Autoimmune reactions are graded in the ALLERGY/IMMUNOLOGY category. 
DIC (disseminated intravascular coagulation) is graded in the COAGULATION category. 
Fanconi’s syndrome is graded as Urinary electrolyte wasting in the RENAL/GENITOURINARY category. 
Renal tubular acidosis is graded as Urinary electrolyte wasting in the RENAL/GENITOURINARY category. 
Stevens-Johnson syndrome (erythema multiforme) is graded in the DERMATOLOGY/SKIN category. 
SIADH (syndrome of inappropriate antidiuretic hormone) is graded in the ENDOCRINE category. 
Thrombotic microangiopathy (e.g., thromboitic thrombocytopenic purpura/TTP or hemolytic uremic syndrom/HUS) is graded in the 
COAGULATION category. 
Tumor flare none mild pain not 
interfering with 
function 
moderate pain; pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain; pain or 
analgesics interfering 
with function and 
interfering with 
activities of daily living 
Disabling 
Also consider Hypercalcemia. 
Note: Tumor flare is characterized by a constellation of symptoms and signs in direct relation to initiation of therapy (e.g., anti-
estrogens/androgens or additional hormones). The symptoms/signs include tumor pain, inflammation of visible tumor, hypercalcemia, diffuse 
bone pain, and other electrolyte disturbances. 
Tumor lysis syndrome absent - - Present - 
Also consider Hyperkalemia, Creatinine. 
Urinary electrolyte wasting (e.g., Fanconi’s syndrome, renal tubular acidosis) is graded under the RENAL/GENITOURINARY category. 
Syndromes-Other 
(Specify, __________) 
none Mild moderate Severe life-threatening 
or disabling 
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APPENDIX II Eastern Cooperative Oncology Group (ECOG) 
Performance Status Criteria 
 
 
ECOG KARNOFSKY DEFINITIONS 
(Zubrod) 
 
0  100  Asymptomatic 
 
1 80-90  Symptomatic, fully ambulatory 
 
2 60-70  Symptomatic, in bed less than 50% of the day 
 
3 40-50 Symptomatic, in bed more than 50% of the day, 
but not bedridden 
 
4 20-30 Bedridden 
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APPENDIX III Declaration of Helsinki 
 
World Medical Association Recommendations Guiding Physicians in Biomedical Research Involving Human 
Subjects 
 Adopted by the 18th World Medical Assembly 
Helsinki, Finland, June 1964 
 
and amended by the 
29th World Medical Assembly, Tokyo, Japan, October 1975 
35th World Medical Assembly, Venice, Italy, October 1983 
41st World Medical Assembly, Hong Kong, September 1989 
and the  
48th General Assembly,Somerset West, Republic of South Africa, October 1996  
  INTRODUCTION 
 
 
It is the mission of the physician to safeguard the health of the people. His or her knowledge and conscience are 
dedicated to the fulfillment of this mission. 
 
The Declaration of Geneva of the World Medical Association binds the physician with the words, "The Health of my 
patient will be my first consideration," and the International Code of Medical Ethics declares that, "A physician shall 
act only in the patient's interest when providing medical care which might have the effect of weakening the physical 
and mental condition of the patient." 
 
The purpose of biomedical research involving human subjects must be to improve diagnostic, therapeutic and 
prophylactic procedures and the understanding of the aetiology and pathogenesis of disease. 
 
In current medical practice most diagnostic, therapeutic or prophylactic procedures involve hazards. This applies 
especially to biomedical research. 
 
Medical progress is based on research which ultimately must rest in part on experimentation involving human 
subjects. 
 
In the field of biomedical research a fundamental distinction must be recognized between medical research in which 
the aim is essentially diagnostic or therapeutic for a patient, and medical research, the essential object of which is 
purely scientific and without implying direct diagnostic or therapeutic value to the person subjected to the research. 
 
Special caution must be exercised in the conduct of research which may affect the environment, and the welfare of 
animals used for research must be respected. 
 
Because it is essential that the results of laboratory experiments be applied to human beings to further scientific 
knowledge and to help suffering humanity, the World Medical Association has prepared the following 
recommendations as a guide to every physician in biomedical research involving human subjects. They should be 
kept under review in the future. It must be stressed that the standards as drafted are only a guide to physicians all 
over the world. Physicians are not relieved from criminal, civil and ethical responsibilities under the laws of their 
own countries. 
 
 
I. 
 
BASIC PRINCIPLES 
 
 
 
 
1. Biomedical research involving human subjects must conform to generally accepted scientific principles 
and should be based on adequately performed laboratory and animal experimentation and on a thorough 
knowledge of the scientific literature. 
 
 2. The design and performance of each experimental procedure involving human subjects should be clearly 
formulated in an experimental protocol which should be transmitted for consideration, comment and 
guidance to a specially appointed committee independent of the Investigator and the sponsor provided 
that this independent committee is in conformity with the laws and regulations of the country in which 
the research experiment is performed. 
  3. Biomedical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the 
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human subject must always rest with a medically qualified person and never rest on the subject of the 
research, even though the subject has given his or her consent. 
  4. Biomedical research involving human subjects cannot legitimately be carried out unless the importance of the objective is in proportion to the inherent risk to the subject. 
 
 5. Every biomedical research project involving human subjects should be preceded by careful assessment 
of predictable risks in comparison with foreseable benefits to the subject or to others. Concern for the 
interests of the subject must always prevail over the interests of science and society. 
 
 6. The right of the research subject to safeguard his or her integrity must always be respected. Every 
precaution should be taken to respect the privacy of the subject and to minimize the impact of the study 
on the subject's physical and mental integrity and on the personality of the subject. 
 
 7. Physicians should abstain from engaging in research projects involving human subjects unless they are 
satisfied that the hazards involved are believed to be predictable. Physicians should cease any 
investigation if the hazards are found to outweigh the potential benefits. 
 
 8. In publication of the results of his or her research, the physician is obliged to preserve the accuracy of 
the results. Reports of experimentation not in accordance with the principles laid down in this 
Declaration should not be accepted for publication. 
 
 9. In any research on human beings, each potential subject must be adequately informed of the aims, 
methods, anticipated benefits and potential hazards of the study and the discomfort it may entail. He or 
she should be informed that he or she is at liberty to abstain from participation in the study and that he 
or she is free to withdraw his or her consent to participation at any time. The physician should then 
obtain the subject's freely-given informed consent, preferably in writing. 
 
 10. When obtaining informed consent for the research project the physician should be particularly cautious 
if the subject is in a dependent relationship to him or her or may consent under duress. In that case the 
informed consent should be obtained by a physician who is not engaged in the investigation and who is 
completely independent of this official relationship. 
 
 11. In case of legal incompetence, informed consent should be obtained from the legal guardian in 
accordance with national legislation. Where physical or mental incapacity makes it impossible to obtain 
informed consent, or when the subject is a minor, permission from the responsible relative replaces that 
of the subject in accordance with national legislation. 
 
Whenever the minor child is in fact able to give a consent, the minor's consent must be obtained in 
addition to the consent of the minor's legal guardian. 
  12. The research protocol should always contain a statement of the ethical considerations involved and should indicate that the principles enunciated in the present Declaration are complied with. 
 
 
II. 
 
MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE 
(Clinical Research) 
 
 
 1. In the treatment of the sick person, the physician must be free to use a new diagnostic and therapeutic 
measure, if in his or her judgement it offers hope of saving life, reestablishing health or alleviating 
suffering. 
  2. The potential benefits, hazards and discomfort of a new method should be weighed against the advantages of the best current diagnostic and therapeutic methods. 
 
 3. In any medical study, every patient – including those of a control group, if any - should be assured of the 
best proven diagnostic and therapeutic method. This does not exclude the use of inert placebo in studies 
where no proven diagnostic or therapeutic method exists. 
  4. The refusal of the patient to participate in a study must never interfere with the physician-patient relationship. 
 
 5. If the physician considers it essential not to obtain informed consent, the specific reasons for this 
proposal should be stated in the experimental protocol for transmission to the independent committee (I, 
2). 
 
 6. The physician can combine medical research with professional care, the objective being the acquisition 
of new medical knowledge, only to the extent that medical research is justified by its potential 
diagnostic or therapeutic value for the patient. 
 
 
 
 
 
 
 
 
 
III. 
 
 
 
 
 
 
 
 
NON-THERAPEUTIC BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (Non-
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Clinical Biomedical Research) 
 
 
 1. In the purely scientific application of medical research carried out on a human being, it is the duty of the 
physician to remain the protector of the life and health of that person on whom biomedical research is 
being carried out. 
  2. The subject should be volunteers - either healthy persons or patients for whom the experimental design is not related to the patient's illness. 
  3. The Investigator or the investigating team should discontinue the research if in his/her or their judgement it may, if continued, be harmful to the individual. 
  4. In research on man, the interest of science and society should never take precedence over considerations related to the wellbeing of the subject. 
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APPENDIX IV Classifications of Severity and Relationship to Therapy for 
Adverse Events 
 
Relatedness 
 
A determination of relatedness (yes/no) to Pharmacia Corporation investigational or trial medication, concomitant 
trial specific and other medication is required for all SAEs reported in clinical trials. 
 
The criteria applied is a determination of whether there is a reasonable possibility that the event is related to the 
investigational product.  Note that a “reasonable possibility” does not include cases where there is only a remote or 
unlikely possibility that the SAE may have been caused by the product. 
 
All SAEs should be reviewed by a Local Pharmacia Corporation Office (MC) physician before sending to GDS and 
the CPL.  The MC physician is encouraged to comment on the SAE in order to assist the CPL/GDS in reaching the 
final corporate determination of relatedness although the MC physician is not required to provide her/his own 
personal relatedness determination.  When a MC physician is not available during the required timeframe the SAE 
report should be immediately sent to CPL/GDS by designated MC personnel. 
 
Severity 
 
Adverse events will be reviewed using the National Cancer Institute Common Toxicity Criteria (NCI CTC) 
(Appendix I).  Any adverse events incurred but not categorized by the NCI CTC should be graded by the physician 
and be recorded using a scale of (1) mild, (2) moderate, (3) severe, or (4) life threatening on the case report form, as 
defined below: 
 
 MILD     Does not interfere with subject's usual function 
 
 MODERATE   Interferes to some extent with subject's usual function 
 
 SEVERE    Interferes significantly with subject's usual function 
 
 LIFE THREATENING Resulting in risk of death, organ damage or disability 
 
Note the distinction between the gravity and the intensity of an adverse event.  Severe is a measure of intensity; 
thus, a severe reaction is not necessarily a serious reaction.  For example, a headache may be severe in intensity, but 
would not be classified as serious unless it met one of the criteria that define serious events. 
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APPENDIX V Sample Informed Consent Form 
 
 
PATIËNTENINFORMATIE behorend bij het vergelijkend onderzoek naar het effect van 
een aanvullende behandeling met 2½-3 jaar Tamoxifen gevolgd door 2½-2 jaar Exemestaan 
of met 5 jaar Exemestaan bij vrouwen na de overgang die geopereerd zijn voor 
borstkanker  
 
Geachte mevrouw, 
Uw behandelend arts heeft u voorgesteld aan het hierboven genoemde onderzoek deel te nemen 
en heeft u al het een en ander uitgelegd. Uw toestemming of weigering om deel te nemen moet u 
kunnen baseren op goede voorlichting onzerzijds en zorgvuldig overwegen van uw kant. Daarom 
ontvangt u deze schriftelijke informatie die u rustig kunt (her)lezen en in eigen kring bespreken. 
Ook daarna kunt u altijd nog vragen voorleggen aan uw arts of aan de artsen die aan het einde 
van deze informatie genoemd staan.  
 
Uw medische situatie en behandelingsmogelijkheden 
U bent recent geopereerd wegens borstkanker. Op grond van bepaalde tumorkenmerken, het feit 
dat u na de overgang bent en er sprake is van een hormoongevoelige borstkanker, komt u in 
aanmerking voor een aanvullende behandeling met een anti-hormonaal medicament om de kans 
te verkleinen dat de ziekte terugkeert.  
De behandeling van vrouwen met borstkanker die na de overgang zijn bestaat uit een operatie en 
eventueel bestraling en/of chemotherapie. Als aanvullende behandeling hierop was het gebruikelijk 
om Tamoxifen (Nolvadex) te geven gedurende een periode van 5 jaar. Tamoxifen is een anti-
oestrogeen medicijn dat belemmert dat oestrogenen (= vrouwelijke geslachtshormonen) de groei 
van tumorcellen stimuleren. Recent heeft onderzoek uitgewezen dat een behandeling met 
Tamoxifen gedurende 2½-3 jaar gevolgd door 2½-2 jaar Exemestaan de kans op terugkeer van de 
ziekte verder vermindert t.o.v. een behandeling met Tamoxifen gedurende 5 jaar.  
Exemestaan (Aromasin) is een nieuw medicijn voor de behandeling van borstkanker dat werkt 
door remming van het enzym aromatase. Blokkering van het aromatase enzym zorgt ervoor dat er 
minder oestrogeen bij een vrouw na de overgang wordt aangemaakt, waardoor de stimulering van 
tumorcelgroei verhinderd wordt. 
Op grond van de hogere effectiviteit van de sequentiele behandeling van tamoxifen, gevolgd door 
exemestane, is in de Nederlandse richtlijngroep afgesproken dat de sequentie van tamoxifen, 
gevolgd door een aromataseremmer, beschouwd wordt als de standaardbehandeling bij 
hormoongevoelige postmenopauzale borstkanker. Vooralsnog is het niet bekend hoe het effect is 
van de sequentiebehandeling van tamoxifen gevolgd door exemestane in vergelijking met 
exemestaan gedurende 5 jaren. 
 
Doel van het onderzoek 
In dit onderzoek willen we nagaan wat het effect is van de behandeling met 2½-3 jaar Tamoxifen 
gevolgd door 2½-2 jaar Exemestaan in vergelijking met 5 jaar Exemestaan als aanvullende 
behandeling van hormoongevoelige borstkanker bij postmenopauzale vrouwen. Voorts wordt 
onderzocht welke bijwerkingen optreden bij de behandelingen. 
 
Dit onderzoek vindt plaats in het kader van een vergelijkende studie, die uitgevoerd wordt door 
onderzoekers uit verschillende landen. In totaal zullen wereldwijd ongeveer 8700 vrouwen aan 
deze studie deelnemen. Algemene informatie over klinisch onderzoek kunt u nalezen in de folder 
“Wetenschappelijk onderzoek bij patiënten met kanker”. 
 
 
Wijze van onderzoek en behandelingsplan 
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Om het antwoord op de onderzoeksvraag te krijgen worden de patiënten in 2 volledig vergelijkbare 
groepen verdeeld. De ene groep krijgt de behandeling met 2½-3 jaar Tamoxifen (1X per dag 1 
tablet van 20 mg) gevolgd door 2½-2 jaar Exemestaan (1x per dag 1 tablet van 25 mg) De andere 
groep krijgt de behandeling met 1x per dag 1 tablet Exemestaan (25 mg) gedurende 5 jaar. De 
medicatie kan het beste op een vast tijdstip van de dag ingenomen worden. Exemestaan dient bij 
voorkeur na het eten ingenomen te worden. Beide groepen patiënten worden behandeld gedurende 
een totale periode van 5 jaar. 
 
Een dergelijke objectieve vergelijking van effect en bijwerkingen tussen 2 behandelingen 
noemen we een vergelijkend onderzoek. De verdeling van de patiënten in de verschillende 
behandelingsgroepen gebeurt door loting (randomisatie) zodat niemand - d.w.z. noch de patiënt, 
noch de arts - hierop invloed kan uitoefenen (zie folder “Wetenschappelijk onderzoek bij 
patiënten met kanker”).  
 
Bij de start van de behandeling wordt orienterend onderzoek gedaan, bestaand uit: algemeen 
lichamelijk onderzoek, bloedonderzoek, mammografie (borstfoto) en eventueel aanvullend 
onderzoek als uw arts dat nodig acht.  
 
Het eerste jaar wordt u eens in de 3 maanden gecontroleerd, daarna vindt de controle plaats om de 
6 maanden. Na 5 jaar wordt u jaarlijks gecontroleerd. Naast het lichamelijk onderzoek bij de 
controles, wordt er jaarlijks een mammografie (borstfoto) verricht. Deze controles verschillen niet 
van de gebruikelijke controles bij een patiënte met borstkanker.  
 
Bijwerkingen, risico’s en ongemakken 
De bijwerkingen van Exemestaan en Tamoxifen zoals die in eerdere onderzoeken werden 
waargenomen zijn meestal mild en redelijk te verdragen. 
Bij Tamoxifen kunnen optreden: opvliegers, transpireren, milde misselijkheid (tijdelijk), geringe 
gewichtstoename, vaginale afscheiding, jeuk of droog gevoel ter hoogte van de vagina. Zeldzaam 
optredende bijwerkingen zijn: trombose, vocht vasthouden, veranderingen vanhet oog (lens 
[=staar], netvlies, hoornvlies), veranderingen in het baarmoederslijmvlies (verdikking, 
poliepvorming, kanker bij langdurig gebruik). 
De bijwerkingen die bij de behandeling met Exemestaan kunnen optreden zijn: opvliegers, enige 
misselijkheid, transpireren, tijdelijk enige duizeligheid, moeheid en hoofdpijn. Zeldzaam 
optredende bijwerkingen zijn: slapeloosheid, huiduitslag, vocht vasthouden, enige buikpijn. 
 
Door het afnemen van bloed kan wat irritatie ontstaan op de plaats van de prik.  
Als er tijdens het onderzoek nieuwe informatie beschikbaar komt die uw deelname kan 
beinvloeden, wordt u hiervan tijdig op de hoogte gesteld zodat u de gelegenheid krijgt te 
overwegen of u met het onderzoek wilt doorgaan.  
In geval van (onverwachte) klachten van de behandeling dient u te overleggen met uw 
behandelend specalist, zodat hieraan op adequate wijze aandacht kan worden besteed.  
Voorts vragen wij van u de voorschriften van uw behandelend arts goed op te volgen en u niet, 
zonder diens medeweten, elders te laten behandelen. 
 
Voordelen en nadelen  
De informatie die uit dit onderzoek verkregen wordt, kan nuttig zijn voor de wetenschap en kan 
daarmee mogelijk andere vrouwen helpen. 
 
Privacy 
Uw medisch dossier kan slechts door daartoe geautoriseerde en gekwalificeerde medewerkers van 
het onderzoeksteam, medewerkers van de Inspectie voor de Gezondheidszorg of bevoegde 
inspecteurs van een buitenlandse overheid, leden van de Medisch Ethische Toetsings Commissie 
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Erasmus MC worden ingezien met als doel de onderzoeksprocedures en de betrouwbaarheid van 
de verzamelde gegevens te controleren. Onderzoeksgegevens zullen vertrouwelijk worden 
gehanteerd met inachtneming van de Wet Bescherming Persoonsgegevens en het privacyreglement 
van het [naam ziekenhuis]. Alle medische gegevens die tijdens deze studie worden verzameld 
zullen worden voorzien van een codenummer. De persoonsgegevens zullen niet gebruikt worden op 
studiedocumentatie, in rapporten of publicaties van dit onderzoek. De onderzoeksgegevens worden 
gedurende 15 jaar bewaard. Uw huisarts zal, zoals gebruikelijk in Nederland, in kennis worden 
gesteld van uw behandeling en dus ook van uw deelname aan dit onderzoek. U dient hiervoor echter 
wel toestemming te geven. 
Voor dit onderzoek is goedkeuring verkregen van de Raad van Bestuur van uw ziekenhuis na een 
positief oordeel van de Medisch Ethische Toetsings Commissie van het Erasmus MC. De voor dit 
onderzoek geldende internationale richtlijnen zullen nauwkeurig in acht worden genomen.  
 
Schade 
Voor de uitvoering van het onderzoek is een schade verzekering afgesloten (zie bijlage). 
 
Weigeren voor en tijdens het onderzoek 
Als u besluit deel te nemen, kunt u te allen tijde op dit besluit terugkomen en met het onderzoek 
stoppen zonder opgave van redenen. Uw deelname aan dit onderzoek is dus geheel vrijwillig.  
Mocht u besluiten niet aan het onderzoek mee te doen, of met het onderzoek te willen stoppen, dan 
zal dit de houding van uw arts ten aanzien van uw behandeling niet beinvloeden. In overleg met 
uw behandelend arts zal dan uw behandeling worden bepaald. 
 
Nadere informatie 
Mocht u nog aanvullende vragen hebben, dan kunt u die voorleggen aan uw behandelend specialist 
of aan een van de verantwoordelijke onderzoekers of onderzoeksverpleegkundigen:  
 
Dit zijn: 
Erasmus MC, lokatie Daniel den Hoed: dr. C. Seynaeve, internist-oncoloog (bereikbaar via het 
secretariaat Interne Oncologie, tel. 010-4391754), of dr. M. Bontenbal, internist-oncoloog 
(bereikbaar via het secretariaat Interne Oncologie, tel. 010-4391505)    
 
Mocht U besluiten tot deelname aan dit onderzoek dan vragen wij u het toestemming-
formulier te ondertekenen. U ontvangt dan een kopie van het getekende formulier.  
 
Indien u twijfelt over deelname kunt u een onafhankelijk arts raadplegen, die zelf niet is 
betrokken bij dit onderzoek, maar wel deskundig is op het gebied van geneesmiddelen 
onderzoek: Dr. J. Raemakers, Universitair Medisch Centrum St. Radboud te Nijmegen, 
afdeling hematologie, tel. 024-3614762. Ook als u voor of tijdens de studie vragen heeft, die 
u liever niet aan uw behandelend arts stelt, kunt u contact opnemen met de onafhankelijk 
arts. 
 
Als u niet tevreden bent over het onderzoek of de behandeling kunt u terecht bij de onafhankelijke 
klachtencommissie van het Erasmus MC. De klachtencommissie is te bereiken op telefoonnummer 
010-4633198. 
 
 
Bijgesloten: 
- folder Wetenschappelijk Onderzoek bij patiënten met kanker   
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Bijlage: Informatie betreffende de verzekering 
 
In geval van schade kunt u contact op nemen met de verzekeraar: 
De verzekeraar van het onderzoek is: 
Naam:   AIG Europe (Nederland) NV 
Adres:   Postbus 8606 
   3009 AP Rotterdam  
Telefoonnummer:   010-4535455 
Fax nummer:  010-4528502  
 
De volgende passage met betrekking tot de verzekering van het onderzoek is ontleend aan de wet 
‘Medisch-wetenschappelijk onderzoek met mensen’  (WMO): 
Voor de uitvoering van het onderzoek is een verzekering afgesloten. Deze verzekering dekt de 
eventuele schade door letsel als gevolg van uw deelname aan het onderzoek en die zich 
openbaart gedurende deelname aan dit onderzoek of binnen vijf jaar ná deelname aan dit 
onderzoek. Voor aan het onderzoek gerelateerd letsel zal u kosteloze medische behandeling ter 
beschikking worden gesteld. De verzekering biedt dekking voor een schade tot een 
maximumbedrag van 450.000 euro per proefpersoon, met een maximumbedrag van 3.500.000 
euro per verzekeringsjaar per onderzoek. Indien de opdrachtgever van dit onderzoek meerdere 
onderzoeken tegelijk verricht, geldt een maximumbedrag van 5.000.000 euro per 
verzekeringsjaar voor álle onderzoeken. Als u van mening bent dat u door of tijdens het 
onderzoek schade hebt opgelopen, adviseren wij u zo snel mogelijk contact op te nemen met de 
hieronder genoemde verzekeraar. U dient in dit geval de verzekeraar alle benodigde informatie te 
verschaffen. Het niet nakomen van deze verplichtingen kan leiden tot het niet vergoeden van de 
schade. 
Wij willen u erop wijzen dat de verzekering geen dekking biedt voor schade: 
- die zich bij nakomelingen openbaart als gevolg van een nadelige inwerking van het 
onderzoek op het genetisch (=erfelijk) materiaal van de proefpersoon; 
- door aantasting van uw gezondheid, die zich ook zou hebben geopenbaard wanneer u niet 
aan het onderzoek had deelgenomen; 
- waarvan op grond van de aard van het onderzoek (nagenoeg) zeker was dat deze zich zou 
voordoen (zoals bijvoorbeeld de bijwerkingen die in dit informatieformulier beschreven 
worden); 
- die het gevolg is van het niet of niet volledig opvolgen van aanwijzingen en instructies van 
de behandelend arts. 
 
Verzekeraar: AIG Europe (Nederland) NV     Schaderegelaar: AON Nederland 
Postbus 8606      Postbus 518 
3009 AP Rotterdam     3000 AM Rotterdam 
tel: 010-4535455     tel: 010-4488911 
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TOESTEMMING VOOR DEELNAME AAN WETENSCHAPPELIJK ONDERZOEK 
 
Betreft : 
vergelijkend onderzoek naar het effect van een aanvullende behandeling met 2½-3 jaar 
Tamoxifen gevolgd door 2½-2 jaar Exemestaan of met 5 jaar Exemestaan bij vrouwen na de 
overgang die geopereerd zijn voor borstkanker. 
 
Ondergetekende verklaart als volgt: 
 ik heb uitvoerig mondelinge en schriftelijke informatie ontvangen inzake opzet, doel en 
eventuele ongemakken van bovengenoemd onderzoek en heb dit volledig begrepen; 
 ik heb voldoende gelegenheid gehad tot nadenken, overleg en het stellen van vragen aan de 
onderzoeker(s); 
 ik stem geheel vrijwillig in met deelname aan bovengenoemd onderzoek, zolang ik deze 
toestemming niet herroep; 
 ik weet dat de resultaten van het onderzoek, met inbegrip van gegevens betreffende familie, 
geslacht, leeftijd, geboortedatum, screening, diagnose en identificatienummer onder 
codenummer ter beschikking gesteld kunnen worden aan gekwalificeerde mede-onderzoekers. 
De inzage in mijn dossier gebeurt slechts na goedkeuring van mijn arts. 
 Ik weet dat, indien aan de orde, uitwisseling van gegevens plaatsvindt met mijn huisarts, en 
andere betrokken specialisten. 
 ik kan mij op ieder moment uit het onderzoek terugtrekken zonder nadelig effect op de verdere 
controle, behandeling, verzorging en/of begeleiding van mijzelf of mijn verwanten. 
 
Naam patiënt: 
Handtekening  :     Datum: ___ /___ /200. 
 
Naam onderzoeker : 
Handtekening  :              Datum: ___ /___ /200. 
 
(ter informatie arts: patiënt dient een kopie te krijgen van het getekende toestemmingsformulier) 
goedgekeurd Medisch Ethische Toetsingscommissie d.d. [datum] 
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APPENDIX VI NABON / NVMO guidelines for treatment of primary 
breast cancer 2000 (ref. 49) 
 
 
Guideline for adjuvant systemic therapy in patients with a resectable breast carcinoma, divided in the 
presence or lack of metastases in the axillary lymphnodes 
metastases in the axillary lymphnodes (N+ patients) 
receptor menopausal status/age   
 premenopausal postmenopausal  
  < 70 years ≥ 70 years 
ER+ and/or PgR+ chemotherapy and endocrine 
therapy* 
tamoxifen (possibly with 
chemotherapy)  
tamoxifen 
ER- and PgR- chemotherapy chemotherapy no therapy 
no metastases in the axillary lymphnodes (N0 patients) 
tumor size differentiation grade § or mitotic activity index ║¶ 
 BR I/II or MAI < 10 BR III or MAI ≥ 10  
< 1 cm no therapy no therapy  
1-3 cm no therapy as in N+ patients  
> 3 cm as in N+ patients as in N+ patients  
    
ER = estrogen receptor; PgR = progesteron receptor. 
* Endocrine therapy after chemotherapy (sequential approach). 
 Gives limited therapeutic gain in combination with tamoxifen; to be considered in young patients with a 
poor prognosis. 
 The data are insufficient for an advice. 
§ The differentiation grade is expressed in the modified Bloom-Richardson (BR)-grading: ‘moderately to 
well differentiated’ (respectively BR I and BR II); ‘poorly differentiated’ (BR III). 
║ The mitotic activity index (MAI) expresses the number of mitoses visible in the tumor tissue in every 10 
microscopy fields with strong magnification. 
¶ For each institution the choice has to be made which of the two risk factors will be used. 
 
 73(74)
TEAM-trial                Final protocol, including amendment 1&2   November 10, 2004 
 
APPENDIX VII NABON / NVMO richtlijnen behandeling primair 
mammacarinoom 2000 (ref. 49) 
 
 
Richtlijn voor adjuvante systemische therapie bij patiënten met een resectabel mammacarcinoom, uitgesplitst 
naar het al of niet aanwezig zijn van metastasen in de okselklieren 
lymfkliermetastasen in de oksel (N+ patiënten) 
receptor menopauzale status/leeftijd   
 premenopauzaal postmenopauzaal  
  < 70 jaar ≥ 70 jaar 
ER+ en/of PgR+ chemotherapie met endocriene 
therapie* 
tamoxifen (eventueel met 
chemotherapie)  
tamoxifen 
ER- en PgR- chemotherapie chemotherapie geen therapie 
geen lymfkliermetastasen in de oksel (N0 patiënten) 
tumorgrootte differentiatiegraad § of mitoseactiviteitsindex ║¶ 
 BR I/II of MAI < 10 BR III of MAI ≥ 10  
< 1 cm geen therapie geen therapie  
1-3 cm geen therapie zoals bij N+ patiënten  
> 3 cm zoals bij N+ patiënten zoals bij N+ patiënten  
    
ER = oestrogeenreceptor; PgR = progesteronreceptor. 
* Endocriene therapie na de chemotherapie toepassen. 
 Geeft beperkte therapeutische winst in combinatie met tamoxifen; te overwegen bij jonge patiënten met 
een slechte prognose. 
 Hierover zijn onvoldoende gegevens voor een advies. 
§ De differentiatiegraad wordt uitgedrukt met de gemodificeerde Bloom-Richardson (BR)-gradering: ‘matig 
tot goed gedifferentieerd’ (respectievelijk BR I en BR II); ‘slecht gedifferentieerd’ (BR III). 
║ De mitoseactiviteitsindex (MAI) geeft het aantal mitosen zichtbaar in het tumorweefsel per 10 
microscoopvelden met sterke vergroting. 
¶ Per instituut moet men vaststellen welke van beide risicofactoren gebruikt wordt. 
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1. REASONS FOR CHANGING THE PROTOCOL
The Tamoxifen and Exemestane Adjuvant Multicenter (TEAM) study is an open label, randomized, 
multicenter, comparative trial. The trial was originally designed to compare the efficacy and 
tolerability of 5 years adjuvant exemestane versus 5 years adjuvant tamoxifen in post-menopausal 
women with estrogen receptor (ER) and/or progesterone receptor (PgR) positive early breast 
cancer. In amendment 2 (approved December13, 2004), the design was changed to randomization 
for tamoxifen 2½-3 years followed by exemestane for 2-2 ½ years vs 5 years of adjuvant 
exemestane. Subsequently the study objectives and sample size were changed accordingly.
In this amendment, the primary objective is clarified in addition to amendment 2 and standardized 
according to the definitions used in other adjuvant hormone therapy trials. The efficacy analysis 
variable will change from relapse free survival (RFS) to disease free survival (DFS). Furthermore, 
primary endpoints and timing of interim analysis has changed
2. PRIMARY OBJECTIVE
2.1. Old version primary objective
The primary objective of this study is to determine whether up-front adjuvant treatment with 
exemestane compared with adjuvant tamoxifen improves the relapse-free survival (RFS) of 
postmenopausal, receptor positive, early breast cancer patients following 2½ -3 years of treatment.  
RFS will be measured as the time from start of treatment to the date of relapse.  Relapse is defined 
as local or distant recurrence of disease, secondary invasive breast cancer, or death of any cause.  
Patients who have not had any such event at the time of data analysis will be censored at the last 
date they were known to be event-free. RFS analysis will be based on tumour assessments and 
survival follow-up assessments.
2.2. New version primary objective
There are 2 co- primary objectives in this study:
1. To determine whether adjuvant treatment with exemestane 25 mg once daily improves the 
disease free survival (DFS) of postmenopausal, receptor positive, node negative or node positive 
breast cancer patients at 2¾  years compared with adjuvant tamoxifen 20 mg once daily for 2½ – 3 
years, followed by exemestane, 25 mg once daily for 2 – 2½ years. DFS is defined as the time from 
randomization to the earliest recorded documentation of local/regional or distant recurrence of 
breast cancer, new 2nd primary (contra lateral) invasive breast cancer or death from any cause
2. To determine whether adjuvant treatment with exemestane 25 mg once daily improves the 
disease free survival (DFS) of postmenopausal, receptor positive, node negative or node positive 
breast cancer patients at 5 years compared with adjuvant tamoxifen 20 mg once daily for 2½ – 3 
years, followed by exemestane, 25 mg once daily for 2 – 2½ years.
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3. SECONDARY OBJECTIVES
3.1. Old version secondary objectives
3.1.1 Key secondary objective
The key secondary objective of this study will be 5-years RFS as a point estimate obtained from the 
Kaplan-Meier survival estimates of the two treatment arms. The difference in 5-years RFS between 
the treatment arms will be reported, along with its standard error (SE) and an associated 95%-
confidence interval.
3.1.2. Other secondary objectives
Other secondary objectives of this study will include analysis of overall survival, the relative safety 
profiles, and the incidence of new primary breast cancers of the postmenopausal women treated 
with 5 years of exemestane versus tamoxifen therapy for 2½ -3 years followed by 2½ -2 years of 
exemestane (a total of 5 years). 
3.2. New version secondary objectives
Secondary objectives of this study are DFS, overall survival, the relative safety profiles, and time 
from randomization to new primary breast cancer in postmenopausal women treated with 5 years of 
exemestane versus tamoxifen therapy for 2½- 3 years followed by 2½- 2 years of exemestane.  
3.3. Reasons for change secondary objectives
The primary objective will be clarified and standardized according to the definitions used in 
other adjuvant hormone therapy trials. The efficacy analysis variable will change from relapse 
free survival (RFS) to disease free survival (DFS), and a universal changes will be made within 
the protocol from RFS to DFS. As a co-primary endpoint, DFS will be analyzed after 5 years 
of treatment.
4. DETERMINATION OF EFFICACY
4.1. Old version endpoints
4.1.1. Relapse Free Survival (RFS)
Relapse free survival is defined as the time from first drug administration to the earliest recorded 
documentation of relapse, or death due to any cause in the absence of previous documentation of 
relapse. Patients without relapse may be withdrawn from treatment for a variety of reasons (page 
21), and their relapse time will be censored. Where available, patients withdrawn because of a 
specific event  will be censored at the date of the specific event or the date of recorded confirmation 
of event. If such a date is not appropriate or available, the patient will be censored at date of last 
follow-up. 
4.1.2. Overall Survival
Overall survival (OS) is defined as the time from first drug administration to date of death. In the 
absence of confirmation of death, survival time will be censored to last date of follow-up.
TEAM-trial               Protocol amendment 3                                 November 1, 2006
5(9)
4.2. New version endpoints
4.2.1. Disease Free Survival (DFS)
Disease free survival (DFS) is defined as the time from randomization to the earliest recorded 
documentation of local/regional or distant recurrence of breast cancer, new 2nd primary 
(contralateral) invasive breast cancer or death from any cause. Patients who have not had any such 
event (relapse or death) at the time of data analysis will be censored at 2¾ years for the first co-
primary endpoint and at the last date they were known to be event-free for the 2nd co-primary 
endpoint and the secondary endpoints. Kaplan-Meier estimates of the survival curves for each 
treatment arm (including medians and 95% confidence intervals) as well as the result of the log-
rank test will be presented.
4.2.2. Overall Survival
Overall survival (OS), from the time of randomization to death due to any cause, and time from 
randomization to new primary breast cancer are secondary efficacy endpoints
4.3. Reasons for change endpoints
The efficacy analysis variable will change from relapse free survival (RFS) to disease free 
survival (DFS), and a universal changes will be made within the protocol from RFS to DFS.   
DFS will be analyzed at 2¾ years from randomization, with censoring at 2¾ years of all 
subjects in either treatment arm who have not experienced a DFS event at that time. As a co-
primary endpoint, DFS will be analyzed after 5 years of treatment.
5. STATISTICAL CONSIDERATIONS  
5.1. Addition of section Interim Analysis
The entire TEAM trial will accrue a total of 9300 patients in order to observe 723 DFS
events in the first co-primary endpoint at 2¾ years. Safety analyses will be reported to the 
Independent Data Monitoring Committee (IDMC) every 6 months without evaluation of efficacy. 
The number of efficacy events will be monitored centrally every 3 months and reported to the 
IDMB. One interim efficacy analysis is planned for the first co-primary endpoint, to be reviewed by 
the IDMC.  As part of their evaluation of the progress of the trial, they will review an interim 
analysis of the combined TEAM trial at the time 50% of the events are reported for the first co-
primary endpoint, at or before 2¾ years form the time of randomization when half of the required 
number of DFS events for the first co-primary endpoint have occurred. These unblinded data will 
only be reviewed by IDMC members. The primary objective of the interim analysis is the early 
detection of either alarming side effects, intolerability to the treatment regimens, or of large 
differences in treatment effects.
The overall alpha-level for the first co-primary analysis will be maintained at 0.0302
using an O’Brien-Fleming-type alpha-spending function. The levels of significance at the
interim analysis and at the final analysis for the first co-primary endpoint are 0.0012 and
0.0298, respectively.
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6. HYPOTHESIS AND SAMPLE SIZE 
6.1. Old version hypothesis and sample size
The study will evaluate primarily the relapse-free survival among women who receive either 
tamoxifen or exemestane daily for 30 – 36 months , and secondarily the relapse free and overall 
survival for patients who received tamoxifen for 20-26 months followed by 24 – 30 months of 
exemestane vs. exemestane for 5 years. The safety of adjuvant tamoxifen followed by exemestane 
or exemestane for 5 years will also be assessed in these postmenopausal, receptor positive, node 
negative or node positive breast cancer patients. 
Sample size calculation for the therapy switch from exemestane after tamoxifen treatment 
Sample size calculation for 3-yr analysis before patients in tamoxifen group switching to 
Aromasin
As per amendment 7, patients in tamoxifen arm are switched to exemestane after 33 months (range 
from 30 to 36 months) of treatment with tamoxifen. Analysis of comparison tamoxifen and 
exemestane in RFS will be the primary analysis of this protocol. In this analysis, only data from 
patients in both 2 arms prior to 33 months of treatment will be included. Rules of what data should 
be included in this analysis will be described in SAP in detail. 
ATAC (by Aman U. Buzdar ) paper provided updated information comparing tamoxifen and 
Anastrozole (53). The 3-yr DFS rate was estimated approximately 0.9 for tamoxifen arm. If we still 
assume the HR of RFS to be 1.28 between the two treatment groups (tamoxifen arm/exemestane 
arm). At least 720 events are required to detect the statistical significance in RFS with the 
significant level of 0.05 (2-sided) and 90% of power. Assume that patients were uniformly entered 
the study in 3 years and 3-yr RFS rate is 0.9 for the tamoxifen arm, 8740 patients are required in 
order to observe 720 events. It is estimated that 720 events will be observed at 33 months after the 
last patient is randomized.
This country specific study is designed to be a part of a larger group of studies that will be pooled 
in order to test RFS and OS.  The data from all the trials will be collected in a central database 
located at the Leiden University Medical Center, Netherlands periodically throughout the trial. 
Interim analyses and the final analysis for the combined trial will be conducted in this central 
location. The German protocol will accrue 500 additional patients to permit th entire TEAM study 
to reach its accrual goals.
Timing of the primary analysis on RFS: approximately 33 months after the last patient has been 
enrolled.
Based on this, the following hypotheses are stated:
A: under the null-hypothesis (H0) if no difference between the two treatments, assuming the 3 years 
RFS is 90%, then: treatment arm A (tamoxifen) and treatment arm B (Aromasin) will show a 3 
years RFS of 90%. 
B: under the alternative hypothesis (H1) that the HR is 1.28 for the first 33 months and the HR is 
1.20 after treatment switch to Aromasin for patients in the tamoxifen arm favouring Aromasin but 
the further conditions remain the same. 
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This difference in HR of recurrence/death of 1.28 for the first 33 months and 1.20  for the next 27 
months between treatment groups is considered to be clinically relevant.
Based on these assumptions and considering a significance level () of 0.05, a power (1-) of 0.90 
and a two-sided test, approximately 8740 randomised patients will be required.
Sample size calculation for 5-yr analysis
5-yr analysis on RFS becomes a secondary analysis in the amended protocol. It needs to be 
confirmed that there will be no regulatory (EU and US) impact due to this change. Assume the HR 
is still 1.28 for the first 33 months of the RFS curves, the HR will be smaller between the two arms 
after the time of patients switching from tamoxifen to Aromasin. A paper by R. Charles Coombes 
et al provided information on DFS rate for patients on Aromasin after being on tamoxifen for 2-3 
years (NEJM Vol. 350 No 11, March 2004). It was estimated in this paper that 3-yr DFS rate was 
91.5% after switching from tamoxifen to Aromasin. Assume patients switched to Aromasin after 
2½ years of treatment on tamoxifen, it can be calculated that 5-yr (a 2½-year treatment of 
tamoxifen followed by a 2½-year treatment of Aromasin) DFS rate is 83.76%. It can be estimated 
that the HR of the two arms after switch is approximately 1.3. It is even larger than the one 
assumed in the sample size calculation for the 3-yr analysis before the time of switch. To be 
conservative, we assume HR=1.2 after switch. 878 events are required to detect the statistical 
significance at the significance level of 0.05 (2-sided) with 90% of power. With a total of 8740 
patients, it is estimated that 878 events will be observed at 1.92 years after the last patient is 
randomized. 
To demonstrate the ‘switch’ effect, we need to follow patients long enough after switch. Therefore, 
the required number of DFS events was calculated in order to demonstrate the ‘switch’ effect. The 
number of DFS events needed after ‘switch’ for the 5-yr analysis was calculated as if there was a 
pseudo hypothesis test to detect the statistical significance (significance level of 0.05, 2-sided) 
between the two treatment groups with power of 80%, assuming that the hazard ratio was 1.20. In 
the calculation we also assumed that only the data after ‘switch’ would be included in the analysis 
of this pseudo test. 952 DFS events after ‘switch’ were required. Therefore, the 5-yr analysis will 
be performed when 1672 DFS events (720 events from the data before ‘switch’, 952 events from 
the data after ‘switch’) are observed. It is estimated that 1672 DFS events will be observed at 5.46 
years after the last patient is randomized.
Timing of the primary analysis on RFS: approximately 33 months after the last patient has been 
enrolled.
Based on this, the following hypotheses are stated:
A: under the null-hypothesis (H0) if no difference between the two treatments, assuming the 3 years 
RFS is 90%, then: treatment arm A (tamoxifen) and treatment arm B (Aromasin) will show a 3 
years RFS of 90%. 
B: under the alternative hypothesis (H1) that the HR is 1.28 for the first 33 months and the HR is 
1.20 after treatment switch to Aromasin for patients in the tamoxifen arm favouring Aromasin but 
the further conditions remain the same. 
This difference in HR of recurrence/death of 1.28 for the first 33 months and 1.20  for the next 27 
months between treatment groups is considered to be clinically relevant.
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Based on these assumptions and considering a significance level () of 0.05, a power (1-) of 0.90 
and a two-sided test, approximately 8740 randomised patients will be required.
6.2. New version hypothesis and sample size
In the amended protocol (3rd revised protocol, 2005-02-21), patients in the tamoxifen arm will be 
switched to exemestane after 2½- 3 years of treatment with tamoxifen. The primary analysis will 
compare DFS between the treatment arms after patients have received 2¾ years of treatment. 
The 3-yrs DFS probability was estimated to be approximately 0.90 for the Tamoxifen Arm (i.e., 
Arm B before switch). If the hazard ratio of DFS is assumed to be 1.28 between the two treatment 
arms (Arm B / Arm A), 723 events will achieve 87% power to detect the corresponding difference 
in DFS with a two-sided significance level of 0.0298. Assuming constant exponential rates in both 
groups with a hazard ratio of 1.28), 9300 patients (4650 in each group) are sufficient in order to 
observe these 723 events after each subject is followed for 2¾ years. A maximum of 1550 
patients will be enrolled into this study in Germany.
The second co-primary endpoint is DFS after 5 years of treatment. Because of the switch from 
tamoxifen to exemestane after 2½ – 3 years for patients in arm B (switch arm), the assumption of 
proportional hazards is unlikely to be true. Therefore, two distinct hazard ratios, one for the first 2¾
years (before-switch HR), and one for the subsequent years (post-switch HR) are hypothesized.
Based on a pre-switch tamoxifen 3-yrs DFS rate of 0.90, the pre-switch hazard rate is 0.03512 per 
year assuming DFS follows an exponential distribution. Assuming the pre-switch HR is 1.28, it can 
be calculated that the 3-yrs DFS rate for Exemestane Arm is 92.1% and the hazard rate of the 
Exemestane Arm is thus 0.0274 per year. Coombes et al. (2004) estimated 3-yrs DFS of 91.5% 
after switching from tamoxifen to exemestane. This amounts to a post-switch hazard 
rate of 0.02986 per year for the Switch Arm (receiving exemestane after switch). Assuming that 
pre-switch and post-switch hazard rates of the Exemestane Arm remain equal, then compared to the 
post-switch rate of the Switch Arm, this would imply a post-switch HR of 1.08 (0.02986/0.0274). 
Aiming at detecting a post-switch HR of 1.11. Using a sample size calculation procedure due to 
Shih (1995) allowing for piecewise-proportional hazards, 1285 events achieve 88 % power to 
detect a statistically significant difference in DFS with a HR of 1.28 for the first 2¾ years and a HR 
of 1.11 thereafter, at a two-sided nominal significance level of 0.0298. With 9300 patients enrolled 
uniformly in 3 years, it is estimated that 1285 events will be observed 3.5 years after the last patient 
was enrolled. 
The correlation between the two primary endpoints has been assumed to be 0.75 based on the 
number of events for the two endpoint [(723/1285)1/2 =0.75]. 
6.3. Reason for change hypothesis and sample size
Sample size has been re-calculated on the basis of the ATAC study (Buzdar 2004) provided 
updated information comparing tamoxifen and anastrozole.  
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7. RATIONALE FOR TYPE OF ANALYSIS AND TRIAL ORGANIZATION 
7.1. Old version rationale for type of analysis and trial organization
This country specific study is designed to be a part of a larger group of studies that will be pooled 
in order to test RFS and OS. A total of 720 events are needed in order to test for a reduction in the 
RFS between the two treatment arms (tamoxifen vs. exemestane) for the first 2¾ years of treatment 
when the true hazard ratio is 1.28.
7.2. New version rationale for type of analysis and trial organization
This country specific study is designed to be a part of a larger group of studies that will be pooled 
in order to test DFS and OS. The 3-yrs DFS probability was estimated to be approximately 0.90 for 
the Tamoxifen Arm (i.e., Arm B before switch). If the hazard ratio of DFS is assumed to be 1.28 
between the two treatment arms (Arm B / Arm A), 723 events will achieve 87% power to detect the 
corresponding difference in DFS with a two-sided significance level of 0.0298. Assuming constant 
exponential rates in both groups with a hazard ratio of 1.28), 9300 patients (4650 in each group) 
are sufficient in order to observe these 723 events after each subject is followed for 2¾ years.
7.3. Reason for change rationale for type of analysis and trial organization
Sample size has been re-calculated on the basis of the ATAC study (Buzdar 2004)
8. PRIMARY EFFICACY ANALYSIS
8.1. Old version primary efficacy analysis
The primary efficacy endpoint will be the relapse-free survival at 33 months post-treatment start 
(before tamoxifen arm switching to exemestane), as estimated from the Kaplan-Meier curves for 
each treatment arm.
The difference in RFS will be assessed using the log-rank test at the 0.05 significance level. Ninety-
five percent CI on the treatment estimates and the HR will be computed. Cox regression models 
will be used to explore the influence of stratification and prognostic factors on RFS. Each factor 
will be evaluated for inclusion in the multivariate model, and only factors significant at the 10% 
level will be considered.
8.2. New version primary efficacy analysis
The primary efficacy endpoint will be disease free survival (DFS). DFS is defined as the time from 
randomization to the earliest recorded documentation of local/regional or distant recurrence of 
breast cancer, new 2nd primary (contralateral) invasive breast cancer or death from any cause. DFS 
will be analyzed at 2¾ years from randomization, with censoring at 2¾ years of all subjects in 
either treatment arm who have not experienced a DFS event at that time. As a co-primary endpoint, 
DFS will be analyzed after 5 years of treatment. 
8.3. Reason for change primary efficacy analysis
The primary objective is standarized according to the definitions used in other adjuvant hormone 
therapy trials.
CONSORT 2010 checklist  Page 1 
CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 2-3 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 6 
2b Specific objectives or hypotheses 6 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 7 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons 7 
Participants 4a Eligibility criteria for participants 7 
4b Settings and locations where the data were collected 8 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
7 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
8-9 
6b Any changes to trial outcomes after the trial commenced, with reasons 8 
Sample size 7a How sample size was determined 9 and 
reference to 
previous 
report 
7b When applicable, explanation of any interim analyses and stopping guidelines NA 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence  
8b Type of randomisation; details of any restriction (such as blocking and block size) Page 7 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
Page 7  
CONSORT checklist
CONSORT 2010 checklist  Page 2 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
Page 7 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
Page 7 
11b If relevant, description of the similarity of interventions NA 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 9 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 10 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
Figure 1 
13b For each group, losses and exclusions after randomisation, together with reasons Figure 1 
Recruitment 14a Dates defining the periods of recruitment and follow-up 12 
14b Why the trial ended or was stopped 7 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Table 1 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
Table 2 and 
throughout 
the result 
section for 
each analysis  
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
12,13,14  
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 12,13,14  
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
13,14 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 12 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 19, 20 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 19 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 15,16,17,18 
Other information  
Registration 23 Registration number and name of trial registry 10 
Protocol 24 Where the full trial protocol can be accessed, if available Provided as 
CONSORT 2010 checklist  Page 3 
webappendix  
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 10 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
